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Skin cancer 
Skin cancer is the most common cancer amongst Caucasians.1 It can be divided into 
three major types, from least to most aggressive: basal cell carcinoma (BCC), squamous 
cell carcinoma (SCC) and melanoma. BCC and SCC, the  non-melanoma skin cancers, 
are the most common skin cancers and can usually be well cured.2,3 Melanoma is the 
least common, but most severe type that is capable of metastasizing and can lead to 
death.4  
 
BCC accounts for approximately 80% of non-melanoma skin cancers and arises within 
sun-damaged skin.5 This tumor is a slowly growing, malignant neoplasm of keratino-
cytes that resides within the basal layer of the epidermis. It is presumed that it develops 
from epidermal stem cells of the outer root sheath of the hair follicle.6 Nevertheless, the 
precise origin of BCC is yet unknown. Despite its indolent nature and low mortality 
rate, BCC left untreated or inadequately treated can cause substantial morbidity by tis-
sue destruction and cosmetic disfigurement, especially in the chronic sun-exposed head 
and neck region.5  
 
All types of BCC show increasing incidence rates worldwide including The Nether-
lands.7,8 The largest increase has been observed for the histological superficial subtype. 
In 1991, superficial basal cell carcinoma (sBCC) constituted 17.6% of all BCC but this 
proportion increased to 30.7 in 2007.9 During the last decades, the substantial rise in 
incidence of sBCC has been accompanied by increasing use of non-invasive treatment 
options for this subtype. These trends require evaluation of diagnostic and treatment 
strategies for optimal management of sBCC, which will be the focus of this thesis.  
Epidemiology 
BCC incidence rates are difficult to determine as only a few cancer registries collect BCC 
information. In addition, if there is a registration, only the first BCC in a patient is usu-
ally registered.10 Thus, available incidence rates are definitely underestimating the oc-
currence of BCC. The incidence has risen dramatically last decades with 3-10% annual-
ly, without signs of a future plateau phase.7,11 Although the nodular subtype still remains 
the most common variant (~40%), an increase in both superficial (~30%) and aggressive 
(~30%) subtypes has been observed over the last decades.9 Based on the obtainable data, 
there is a marked geographical variation in incidence rates worldwide, with the highest 
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incidence in Australia.7 The closer Caucasians live to the equator, the higher the risk of 
developing a BCC. A decade ago, De Vries et al. predicted that the European Standard-
ized Rate (ESR) for BCC in The Netherlands would increase from 92 per 100,000 per-
son-years for men in 2005 to 122 per 100,000 in 2015.12 The ESR in women was predict-
ed to increase from 79 to 119. However, an unexpected acceleration in the ESR took 
place. In 2009, the ESR was already 164 per 100,000 person-years for men and 157 for 
women.13 More recent predictions for The Netherlands by Flohil et al. expect that the 
ESR will be 234 per 100,000 person-years for men in 2020 and 226 for women.14 
 
BCC was formerly a disease of the elderly but nowadays a larger number of young peo-
ple are also affected as a result of recreational sun exposure.15 This increase is regardless 
of growing public awareness campaigns targeting the harmful effects of ultraviolet (UV) 
exposure. The incidence is higher in males than in females with a ratio of 2:1. However, 
it is remarkable that in the younger population (< 40 years) women are more affected 
than men.16-19 Currently, one in every 5-6 individuals will develop a BCC during their 
life.14 In addition, persons with a history of BCC are at an increased risk of developing 
subsequent lesions.20,21 A meta-analysis found a 29% risk of developing a second BCC 
after the first tumor.22 This finding suggests a genetic predisposition besides the pres-
ence of other risk factors. These alarming incidence trends warrant the optimization and 
development of diagnostic tools and treatment options to reduce the burden on health 
care services. 
Risk factors 
Many Caucasians have a Fitzpatrick skin type I or II (light skin, blond or red hair, light 
colored eyes), frequently caused by single nucleotide polymorphisms in the melano-
cortin 1 receptor (MC1R) gene.17,19 Their light colored skin with low amounts of mela-
nin makes them vulnerable to the carcinogenic effect of ultraviolet (UV) light exposure. 
UV light exposure is regarded as the major risk factor for BCC but the precise relation-
ship remains obscure.23 UVA is less carcinogenic than UVB. UVA (320-400 nm) pene-
trates deep into the dermis where it mainly causes a skin ageing effect. Its carcinogenic 
effect is 10,000 lower compared to UVB and results from photo-oxidative stress leading 
to DNA mutations.24,25 UVB (290-320 nm) is mostly absorbed in the epidermis and 
directly damages both DNA and RNA. By the cumulative effect of every single UV-light 
exposure DNA repair mechanism will eventually fail and skin cancer develops.26 Inter-
mittent recreational sun exposure appears to be important in the development of sBCC, 
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while chronic sun exposure may be an etiologic factor in nodular (nBCC) and aggressive 
BCC (aBCC).27 The recreational sun seeking behavior might explain the increasing inci-
dence rates in younger population and women. UV light exposure can take place 20-50 
years before the development of a BCC. Therefore, it is not surprising that an older age 
is a risk factor for BCC. Further risk factors are male gender, exposure to phototherapy, 
ionizing radiation, arsenic or coal tear, immunosuppressive therapy and genetic predis-
position.5,28 
Pathogenesis 
The pathogenesis of BCC is complex and includes a disruption of the hedgehog (HH) 
signaling pathway and mutations in the tumor suppressor gene p53. The HH-pathway 
was initially discovered in Drosophila melanogaster. This pathway is important in em-
bryonic development as it regulates cell growth, pattering and differentiation.29 In 
adults, the pathway is usually turned off except in hair, skin and stem cells.30 A human 
homologue of the Drosophila is the patched 1 (PTCH1) gene. The PTCH gene product 
is an inhibitor of the HH-pathway. PTCH1 is part of a receptor for the Sonic Hedgehog 
(SHH) protein, a protein involved in the embryonic development. When SHH binds to 
PTCH1, the transmembrane signaling protein smoothened (SMO) is released. SMO is a 
HH-pathway activator. It is responsible for transducing HH-signaling to downstream 
GLI-transcription factors, resulting in cell growth and differentiation of the embryo. In 
adults, the HH-pathway is normally turned off by the inhibited effect of PTCH1. How-
ever, the pathway may be turned on by mutations or deletions in PTCH1 or SMO. Spo-
radic BCC results from inactivating mutations in PTCH1 (90%) or activating mutations 
(10%) in SMO. If PTCH is unable to inhibit SMO or SMO is activated, downstream 
target genes are overexpressed and may result in the development of a sporadic BCC.31 
Germ-line mutations in the PTCH1 gene on chromosome 9q22 are associated with the 
development of the hereditary basal cell nevus syndrome (BCNS).32 
 
UV-light exposure can cause DNA damage and mutations in the tumor-suppressor gene 
p53.33 In sporadic BCC this mutation is found in approximately 50% of cases.34 p53 is 
normally involved in many diverse cellular processes, such as cell-cycle arrest, DNA 
repair and apoptosis. Mutated p53 allows the proliferation of damaged abnormal cells 
by UV-light. Mutations of p53 are not specific for BCC and are found in almost all hu-
man cancers.   
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Fig. 1 The Hedgehog (HH) signaling pathway. Positive and negative regulatory components are depicted in
green and red, respectively. A In the absence of HH ligand, Patched 1 (PTCH1) inhibits smoothened (SMO)
allowing the GLI processing complex containing suppressor of fused (SUFU) to generate transcriptional
repressors (GLIr). B HH ligand binding to PTCH depresses SMO and generates activated GLI factors (GLIa)
that induce the expression of HH target genes. Clinical and preclinical inhibitors of pathway signaling are
listed at their sites of pathway activity.  
Reprinted with permission from the American Association for Cancer Research: McMillan, Molecular path-
ways: the hedgehog signaling pathway in cancer, Clin Cancer Res, 2012 Sep 15;18(18):4883-8. doi: 
10.1158/1078-0432.CCR-11-2509.35 
Clinical and histological presentation 
The majority of BCC develop in the sun-exposed areas with 56% arising on the 
head/neck region, followed by the trunk and extremities.9 However, BCC have also been 
reported in unusual sites like the genitalia and axillae.36,37 BCC have several clinical fea-
tures, corresponding with different histological subtypes. More than 20 histological 
subtypes have been described in the past, which made implications for clinical practice 
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difficult.38 Therefore, a simplified and more practical classification is available in current 
international guidelines.39,40 This classification distinguishes between non-aggressive 
BCC (superficial and nodular subtypes) and aggressive BCC.41,42  
 
Superficial BCC are predominantly located on the trunk and manifest as an erythema-
tous macule or thin plaque that can mimic actinic keratosis, Morbus Bowen, squamous 
cell carcinoma or eczema (Fig. 2a).43 Atrophy, hypopigmentation and ulceration may be 
present. Dermatoscopy may be helpful to identify arborizing blood vessels, blue-grey 
ovoid nests or ulceration.44 sBCC occur at a younger age than other BCC variants, par-
ticularly in women.16,18 sBCC are histologically characterized by nests of basaloid cells 
that are attached to the epidermis and are confined to the papillary dermis (Fig. 3a). 
Tumor nests may be surrounded by fibrous stroma with a lymphocytic infiltrate and an 
increase in thin-walled vessels.42,45 
 
 
Fig. 2 Clinical presentation of BCC subtypes. 2a. Superficial BCC on the back. 2b. Nodular BCC on the nose.
2c. Aggressive BCC on the angle of the eye. 
 
Nodular BCC are predominantly located in the head and neck region.27 nBCC generally 
occur in older people as a raised, translucent papule or nodule with teleangiectasias (Fig. 
2b).43 In large lesions, tissue destruction and ulceration may be present. nBCC are com-
posed of round/oval nests of basaloid cells in the dermis, often with epidermal attach-
ment (Fig. 3b). These nests differ in shape and size but are often large. The peripheral 
cells are in a palisade arrangement and artificial retraction between tumor nests and the 
surrounding stroma is often present.42,45 
 
Aggressive BCC appear as flat, slightly atrophic macules or plaques without well-
demarcated borders (Fig. 2c).43 The actual tumor size is often larger than the clinically 
visual borders. This subtype is mainly located in the face and is red or whitish in color, 
sometimes with overlying telangiectasia.18 The lesion is typically indurated and can be 
difficult to differentiate from a scar. aBCC consist of infiltrative / morpheaform, mi-
1
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cronodular and basosquamous BCC. Infiltrative / morpheaform BCC present as narrow 
elongated basaloid strands of only a few cell layers thick that infiltrate between collagen 
bundles. The micronodular type resembles nBCC, but tumor nests are smaller, periph-
eral palisading is often absent and the subcutis can be infiltrated (Fig. 3c). Basosqua-
mous BCC are composed of both basaloid and squamoid cells, are more aggressive and 
have metastatic potential.42,45 The aggressive subtype is more destructive than the other 
types, because of its tendency to infiltrate more deeply and to grow with subclinical 
extensions. 
 
BCC may consist of more than one histological subtype (mixed subtypes) within the 
same lesion. Mixed subtypes are present in 18% to 54% of BCC.46,47  
 
 
Fig. 3 Histological presentation of BCC subtypes. 3a. Superficial BCC. 3b. Nodular BCC. 3c. Aggressive (mi-
cronodular) BCC. 
Diagnosis 
Clinical 
BCC are clinically well identifiable by dermatologists because of the typical clinical tu-
mor features. Clinical aspects associated with a BCC diagnosis are the presence of pig-
mentation in 81%, telangiectasias in 65% and a pearly border in 67%.48 Previous studies 
demonstrated that physicians were able to differentiate a BCC clinically from other skin 
diseases with a sensitivity of 64-89%.49-51 The use of a dermatoscope improves the clini-
cal diagnosis of BCC with a sensitivity of 97%, although significant differences in speci-
ficity and positive predictive values were found.52,53 Dermatoscopy even enables the 
detection in an early stage, when the BCC is clinically still unremarkable. Several der-
matoscopic criteria of BCC correspond with the histological subtype.44,54 A new non-
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invasive imaging technique called reflectance confocal microscopy is still thoroughly 
investigated as a diagnostic tool for BCC and its subtypes.55 
Biopsy 
Currently, international guidelines recommend a biopsy for all clinically suspected BCC 
in order to confirm the diagnosis and to identify the histopathological subtype.39,40 Four 
types of skin biopsies are available: punch, shave, excision and incision biopsy.56  
Amongst these, punch biopsies with a diameter of 3 mm are most commonly used in 
The Netherlands. Biopsies should be taken from the clinically most aggressive area in 
order to identify the most aggressive subtype. Several histopathological subtypes can be 
present in one tumor. This so called ‘mixed histological BCC subtype’ is present in 18-
54% of lesions.46,47,57 The majority of mixed subtypes contains an aggressive subtype.58 
Treatment choice will be primarily determined by the most aggressive histopathological 
BCC subtype that is present in the biopsy specimen. Although a punch biopsy is rec-
ommended in clinically suspected BCC, about 7% of BCC are not histologically proven 
prior to treatment.59 These BCC are often suspected for a superficial growth pattern and 
are often located on the trunk. A reason to omit a punch biopsy before treatment might 
be that physicians have got a high confidence in their clinical diagnosis of the BCC sub-
type. Another reason for this trend of omitting punch biopsies might be the disad-
vantages of discomfort for the patient and the associated time and costs.60  
Treatment 
The primary goal of BCC treatment is tumor clearance. Treatment choice depends on 
several factors; patient characteristics (age, previous BCC treatments) and tumor charac-
teristics (location, size and histological subtype seen on prior punch biopsy). In the grow-
ing (young) population with BCC, cosmetic results and health care costs are becoming 
more important. It might be difficult for the treating physician to deal with all these factors 
and the confusing mass of treatment options. There are only a few head-to- head compari-
son studies to guide physicians in the decision making of BCC treatment.2 Many therapies 
are compared with different treatment regimens instead of a different therapy or studies 
have a short follow-up period. Treatment options can be divided into invasive and non-
invasive modalities. Invasive treatments are surgical excision, Mohs’ micrographic surgery 
(MMS), curettage and electrodessication/cautery and cryosurgery.40  
1
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 Surgery remains the gold standard in treatment of BCC. The advantage of surgery is 
the histopathological examination to confirm  tumor clearance. Non-invasive treatment 
modalities are radiotherapy, photodynamic therapy (PDT), imiquimod cream and 5-
fluorouracil (5-FU) cream. These last three therapies are good alternatives for surgery in 
sBCC as the superficial growth pattern makes the tumor well accessible for PDT and 
creams. These treatments are increasingly used and have the advantage of less scarring, 
which is frequently seen after surgery. In addition, they can relieve the busy dermatolo-
gy practice. However, treatment response has to be verified and treatment success rates 
are lower (73-83%) compared to surgery.61-63 BCC rarely metastasizes and any residues 
or recurrences following non-invasive therapy can easily be retreated with surgery. Pa-
tients with metastatic or locally advanced BCC for whom surgery or radiation is not a 
therapeutic option, can be treated with vismodegib (a systemic inhibitor of the HH-
pathway).40  
 Because the focus of this thesis is on surgical excision, PDT, imiquimod and 5-FU, 
these therapies will be further discussed below.  
Surgical excision 
Surgical excision is regarded as the gold standard for all three histological BCC subtypes: 
superficial, nodular and aggressive.2,40,64 In The Netherlands, a clinical excision margin 
of 3 mm is required for primary BCC ≤ 10 mm and a 5 mm margin for BCC >10 mm, 
aggressive subtypes or recurrent tumors.64 Surgical excision permits histologic assess-
ment, although less than 1% of the excised tissue margins is being assessed.65 Excision of 
BCC ≤ 20 mm with a 3 mm margin results in tumor clearance in 85% of cases. This 
percentage increases to 95% when a surgical margin of 4-5 mm is used.66,67 Large BCC 
and aggressive subtypes require larger excision margins in order to obtain tumor clear-
ance.  
Photodynamic therapy 
PDT causes tumor destruction by the use of a photosensitizer, light and oxygen. The 
first step in PDT is application of a photosensitizing cream on the tumor. Most com-
monly used photosensitizers are 5-aminolaevulinic acid (5-ALA) and the more lipo-
philic methylaminolevulinate (MAL). Both agents are normally present in all human 
cells and are a precursor in the haem biosynthesis pathway. 5-ALA and MAL can be 
converted into protoporphyrin IX (PpIX). This conversion occurs more rapidly in neo-
plastic cells compared to normal cells. Porphyrins are photoactive, fluorescing com-
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pounds and, upon light activation of an appropriate wavelength in the presence of oxy-
gen, singlet oxygen is formed which causes damage to cellular compartments, in par-
ticular the mitochondria (Fig. 4). Light activation of accumulated porphyrins leads to a 
photochemical reaction and thereby phototoxicity to the light-exposed target cells.68,69 
 World-wide, MAL is registered for the use of topical PDT in sBCC while 5-ALA is 
registered in the European Union for actinic keratosis only.2,70 In The Netherlands, both 
fractionated 5-ALA 20% and MAL-PDT in 2 sessions are used as treatment for sBCC. 
MAL has the theoretical benefit of being more and faster absorbed in the cell than 5-
ALA 20% and, should therefor generate a higher production of PpIX. In addition, MAL 
has higher selectivity for tumor cells, inducing fewer side-effects in normal tissue.71,72 
 The MAL-PDT protocol recommends application of the cream for 3 hours, after 
which the area is illuminated with a LED light source (wavelength of 570-670 nm and a 
total light dose of 75 J/cm2). After one week, the same procedure is repeated. PDT is a 
hospital administered treatment with a good cosmetic result compared to surgery.63 A 
disadvantage of PDT is the unpredictable burning pain sensation that might influence 
completing the treatment.73  
 
 
Fig. 4 Mechanism of photodynamic therapy (singlet oxygen, 1O2; triplet oxygen, 3O2; PS, photosensitizer).
Reprinted by permission from Macmillan Publishers Ltd: Nat Rev Cancer 68, copyright (2006). 
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Imiquimod 
Imiquimod 5% cream (Aldara®, Meda Pharmaceuticals) is an immune response modifi-
er that is approved since 2004 by the U.S. Food and Drug Administration (FDA) and 
European Medicines Agency (EMA) for the treatment of small, primary sBCC on low 
risk sites in immune competent adults. Although the exact working mechanism is not 
fully understood, previous studies have suggested that imiquimod has antiviral and 
antitumor potentials by activating both the innate and acquired immune system. Bind-
ing of imiquimod to Toll-like receptors 7 and 8 on antigen presenting cells induces 
activation of the central transcription factor nuclear factor-κB. As a result, pro-
inflammatory cytokines, chemokines and other mediators are released. The induction of 
IFN-α is mainly responsible for the innate immune response. In addition, imiquimod 
also stimulates the innate response by stimulation of natural killer cells. The cellular arm 
of the acquired immune response is indirectly activated by production of the Th1 cyto-
kine IFN-γ by naïve T-cells. Imiquimod can suppress the humoral arm of the acquired 
immune response by inhibition of Th2 cytokines (IL-4, IL-5). An additional effect of 
imiquimod is the activation and migration of Langerhans cells from the epidermis to the 
regional lymph nodes, resulting in antigen presentation to T-cells.74,75 A recent study 
revealed that imiquimod also acts as a potent inhibitor of the oncogenic Hedgehog/GLI 
signaling via an unexpected signaling route involving adenosine receptors and protein 
kinase A.76  
 The currently approved imiquimod treatment regimen for sBCC in the EU and USA 
is once daily, five times a week for a period of 6 weeks. The cream has to be applied on 
the tumor and 5-10 mm of the surrounding area. Side effects usually develop in the last 
weeks of treatment and include application side and skin reaction: burning, itching, 
pain, erythema, erosions, ulceration and edema.77 Interestingly, an increase in severity of 
skin reactions is associated with a better tumor clearance.78 As imiquimod is an im-
munomodulator, flu-like symptoms such as fever, fatigue and muscle plain can develop 
during treatment. All side effects are generally mild and resolve after medication is 
withdrawn.  
5-fluorouracil 
5% 5-FU (Efudix® or Efudex®, Meda Pharmaceuticals) cream was the first topical thera-
py approved by the U.S. FDA for the treatment of sBCC. It is a pyrimidine analogue that 
is intracellulary converted into three metabolites: fluorodeoxyuridine monophosphate, 
fluorodeoxyuridine triphosphate and fluorouridine triphosphate.79 These metabolites 
CHAPTER 1 
18 
can interfere with DNA and RNA synthesis. DNA synthesis is also blocked by inhibiting 
thymidylate synthetase (TS), a nucleoside required for DNA replication. TS methylates 
deoxyuridine monophosphate (dUMP) to form the cytotoxic thymidine monophos-
phate (dTMP). The imbalance between dUMP and dTMP causes cell cycle arrest and 
apoptosis. Rapidly proliferating cells are most sensitive to this cytotoxic effect, while 
normal cells are minimally penetrated by 5-FU and are relatively resistant to its effect.80  
 Topical 5-FU should be applied twice daily up to 4 weeks as tolerated. Patients have 
to apply a thin layer of cream on the tumor and 5-10 mm of surrounding tissue. Like 
imiquimod, 5-FU can cause burning, itching, pain, erythema, erosions, ulceration and 
edema. However, the side effects are more predictable as the treatment depends on the 
presence of tumor cells and not on the body’s ability to mount an immune response.81  
Prognosis 
The prognosis of most patients with BCC is excellent as these tumors grow slowly and 
rarely metastasize. However, BCC can cause a significant morbidity due to local tissue 
destruction and cosmetic disfigurement by tumor invasion of skin, nerves, muscles and 
bones. BCC can be divided into ‘low’ and ‘high’ risk tumors based on their ability to 
recur (Table 1). High risk tumors include aggressive subtypes, localization in the H-zone 
of the face, tumor diameter > 2 cm and recurrent BCC.64 These are all risk factors for 
recurrence following surgery. Little is known about possible predictors of treatment 
failure after non-invasive therapies in BCC. Knowledge of treatment effectiveness in 
subgroups of patients and tumors would be of great value in clinical practice as these 
non-invasive treatments are used on a large scale. Defining clinical or histological pre-
dictors for tumor residue or recurrence is of importance to select the most effective 
treatment for an individual patient with BCC. Six non-comparative studies (4 on PDT, 2 
on imiquimod) have investigated patient and tumor characteristics as possible determi-
nants of treatment failure in BCC.78,82-86 The results on possible determinants such as 
gender, age, tumor size, tumor localization and tumor thickness are contradictory.  
 
Table 1. Factors associated with BCC recurrence.64 
 Low risk High risk 
Histological growth pattern Superficial, nodular Aggressive 
Localization Trunk H-zone (eyes, ears, lips, nose) 
Size < 2 cm > 2 cm 
Previous treatment Primary Recurrent 
1
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Follow-up 
Follow-up of patients with BCC are highly considered in order to evaluate treatment 
effects, detect local recurrences and detect new skin cancers.86 Most local recurrences 
occur within two years post treatment, although recurrences have been described after 
10 years.4,86,87 About 30% of patients with one BCC subsequently develop another prima-
ry BCC within 5 years.17 Patients with a BCC also have a higher risk on developing a 
SCC or melanoma, 3 and 2.5 times, respectively.18 
 There is no international consensus on frequency or duration of follow-up of pa-
tients with BCC: regimens range from annual visits for at least 3 years up to life-
long.36,37,88 The Dutch BCC guideline recommends annual follow-up visits of patients 
with high risk BCC or local recurrent BCC in the face.63 The guideline states that for 
some patients a more frequent follow-up scheme might be required. However, exact 
frequencies or total duration of follow-up is unclear. 
Objectives of this thesis 
The aim of this thesis was to contribute to the improvement of diagnosis and treatment 
of BCC. First, the punch biopsy as diagnostic tool for detecting the most aggressive BCC 
subtype will be discussed. Second, treatment modalities for superficial and nodular 
subtypes are evaluated. In addition, determinants of non-invasive treatment failure will 
be discussed. The following questions are answered in this thesis: 
Diagnosis of BCC 
What is the agreement between histological BCC subtype on punch biopsy and the 
subsequent surgical excision of primary BCC? (Chapter 2.1) 
Histological confirmation of a clinically suspected BCC by biopsy is recommended 
before treatment. Treatment choice is among others based on the most aggressive histo-
pathological subtype on punch biopsy. Histological misdiagnosis may result in over- or 
undertreatment. A shave biopsy of the tumor surface can identify the correct subtype in 
76-81% of primary BCC. We hypothesized that the deeper punch biopsy is a better di-
agnostic tool to predict BCC subtype. To confirm this hypothesis, we investigated the 
agreement between histological subtype on punch biopsy and the subsequent surgical 
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excision in primary BCC. In addition, the proportion of BCC in which punch biopsy 
enables identification of the most aggressive subtype was evaluated. 
What is the diagnostic accuracy of clinical assessment of BCC subtype compared to 
histological diagnosis on punch biopsy? (Chapter 2.2) 
Although a punch biopsy is recommended before treatment in European guidelines, 
some experts argue that omitting a biopsy might be acceptable or even preferable in 
some cases. Disadvantages of a punch biopsy are discomfort for the patient and the 
associated time and costs for the physician. In contrast, clinical diagnosis is a painless, 
time- and possibly money-saving procedure. We compared the diagnostic accuracy of 
clinical assessment and histological diagnosis by punch biopsy for subtyping of BCC. 
Furthermore, we evaluated the impact of omitting the punch biopsy on treatment rec-
ommendations. 
Treatment of BCC 
What is the effectiveness of the most frequently used treatments for sBCC? (Chapter 3.1) 
An increase in the superficial BCC subtype has been observed the last decades. Although 
surgical excision is still recommended as first choice treatment in sBCC, non-surgical 
therapies such as PDT, imiquimod and 5-FU are alternatives with a better cosmetic 
outcome and lower costs compared to surgery. However, there is no consensus on the 
treatment of sBCC. We systematically reviewed the literature in order to compare suc-
cess probabilities for primary sBCC treated with frequently used therapies. Results were 
combined in a meta-analysis in order to obtain more reliable results. 
Is the effectiveness of imiquimod and 5-FU comparable to that of MAL-PDT in the 
treatment of primary sBCC? (Chapter 3.2) 
PDT is the most investigated non-invasive treatment for sBCC, with treatment success 
rates ranging between 60-90%. We already know that imiquimod and 5-FU are non-
inferior at one year post treatment. We wonder whether this is still true three years post 
treatment. A non-inferiority, multicenter, randomized controlled trial was performed to 
compare the efficacy of these three therapies. 
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Do patient and tumor characteristics influence treatment response in sBCC treated by 
MAL-PDT or imiquimod? (Chapter 3.3) 
As PDT and imiquimod have a different pharmacological working mechanism, treat-
ment response may depend on certain patient and tumor characteristics. Identification 
of subgroups of patients that differ in treatment response is very valuable in order to 
select the most effective treatment in the individual patient with sBCC. We therefore 
explored whether the relative treatment effect of MAL-PDT and imiquimod is con-
sistent across subgroups defined by patient and tumor characteristics. 
Are tumor thickness and adnexal extension of sBCC determinants of non-invasive 
treatment failure? (Chapter 3.4) 
sBCC grow continuously with the epidermis but tumor nests can reach within the papil-
lary dermis or grow deep along hair follicles. We hypothesized that thick sBCC and 
tumors with adnexal extension fail to respond to the superficial working mechanisms of 
PDT, imiquimod and 5-FU. To support this hypothesis, we compared histopathological 
slides of sBCC with and without treatment failure one year after non-invasive therapies. 
What is the effectiveness of surgical excision in nBCC at the long-term and how is tumor 
thickness related to PDT treatment failure? (Chapter 3.5) 
Although surgical excision has proven to be more effective than PDT in nBCC after five 
years of follow-up, long-term follow-up studies are lacking. However, they could be 
valuable as surgically excised BCC can recur many years after treatment. International 
guidelines recommend surgical excision as first choice treatment in nBCC and PDT as 
alternative in thin nBCC. However, it is still debatable what exact tumor thickness is 
appropriate for PDT treatment. We hypothesized that only extremely thin nBCC are 
suitable for PDT. We performed a prospective, randomized controlled trial with at least 
five year follow-up on fractionated 5-ALA-PDT following partial debulking versus sur-
gical excision in nBCC. 
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Abstract 
 Background: Diagnosis of clinically suspected basal cell carcinoma (BCC) by histo-
logical confirmation by punch biopsy is recommended before treatment. Even shave 
biopsy has been proposed as useful to predict the correct subtype in primary BCC in 76-
81%, whereas the agreement between histological BCC subtype on punch biopsy and 
subsequent excision specimens in recurrent BCC is 67.1%. However, no large studies on 
the agreement between histological BCC subtype seen on punch biopsy and the follow-
ing surgical excision are performed in primary BCC. 
 Objectives: The aims of this study were (1) to establish the agreement between histo-
logical BCC subtype on punch biopsy and the subsequent surgical excision of primary 
BCC and; (2) to investigate the proportion of primary BCC in which punch biopsy ena-
bles identification of the most aggressive growth pattern. 
 Methods: Retrospective analyses of 243 primary BCC with both punch biopsy and 
subsequent surgical excision. Analyses were based on the most aggressive histological 
subtype of the tumor. 
 Results: The agreement between BCC subtype on punch biopsy and the subsequent 
surgical excision of primary BCC was 60.9%. A punch biopsy can predict the most ag-
gressive growth pattern of primary BCC in 84.4%. Seventy-four percent of all primary 
BCC consisted of more than one histological subtype. 
 Conclusions: Dermatologists and other physicians have to be aware of the limited 
diagnostic value of a punch biopsy to determine the histological BCC subtype of the 
whole lesion. Misdiagnosis of the subtype will lead to undertreatment in one out of six 
primary BCC. 
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Introduction 
Basal cell carcinoma (BCC) is a major problem in Caucasians worldwide. Incidence rises 
at an alarming rate by 3-10% annually.1,2 One in six persons will develop a BCC during 
their life and this puts a heavy burden on health care systems.3,4 Treatment of BCC is 
based on the histopathological BCC subtype, its location on the body and whether it 
concerns a primary or recurrent BCC.5,6 
 Three histopathological subtypes can be distinguished for determining treatment: 
superficial (sBCC), nodular (nBCC) and aggressive BCC (aBCC).6 The subgroup aBCC 
contains the infiltrative / morpheaform, micronodular and basosquamous BCC sub-
types.7 The first choice treatment for all BCC is surgical excision.5,6 However, sBCC in 
low-risk areas can also be treated by non-invasive modalities like photodynamic thera-
py, imiquimod or 5-fluorouracil. For nBCC and aBCC surgical excision is the most used 
treatment modality with a 3 mm margin or a 5 mm margin, respectively.8 BCC located 
in cosmetically sensitive areas and recurrent facial BCC, require Mohs’ micrographic 
surgery (MMS).8,9 
 To guide decisions on optimal treatment, accurate diagnosis and treatment of histo-
logical BCC subtype is essential. Prior to treatment, clinically suspected BCC are biop-
sied for histological diagnosis with a punch, shave or incision biopsy.8 The goal of the 
biopsy is twofold; to confirm the diagnosis and to determine the histopathological BCC 
subtype. 
 Prior to treatment, punch and shave biopsies have been proposed to confirm the 
clinical BCC diagnosis and to determine the histopathological BCC subtype.8 The most 
aggressive histological BCC subtype that is identified by biopsy will be an important 
determinant of treatment choice. Detecting the most aggressive subtype can be difficult 
as 18-49% of BCC consist of more than one subtype.7-9 Failure to detect aggressive sub-
types may result in undertreatment. For this reason, it is important to know in what 
proportion of patients a biopsy enables identification of the most aggressive histological 
subtype of BCC. Three previous studies, one on punch biopsies in recurrent BCC and 
two on primary BCC that were mostly biopsied by a shave biopsy, have suggested that 
the agreement between histological subtype on biopsy and the subsequent surgical exci-
sion is limited.10-12 The aim of this study is to evaluate the agreement between punch 
biopsy and excision on the most aggressive histological BCC subtype in primary BCC 
and, thereby, determine the true utility of punch biopsies in the pre-surgical planning.  
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Materials and methods 
In this retrospective study we analyzed the agreement between histological BCC subtype 
and most aggressive component on punch biopsy and the subsequent surgical excision. 
Eligible were patients aged 18 years or older, attending the department of Dermatology 
at the Maastricht University Medical Centre, The Netherlands, between July 1st and 
December 31st 2009, and who underwent both a punch biopsy and a subsequent surgical 
excision of a histological proven primary BCC. Histological data were retrieved from the 
PALGA database, a national pathology registration database. Exclusion criteria were 
shave biopsy, BCC excised without prior punch biopsy, biopsied BCC without following 
excision, patients with genetic skin cancer disorders and recurrent BCC. 
 Punch biopsies were taken in all BCC from the clinically most suspected area for 
thick and infiltrative growth and had a diameter of 3-4 mm. Surgical excision was per-
formed under local anesthesia with a standard clinical safety margin of 3 mm in sBCC 
and nBCC, while aBCC were excised with a 5 mm margin. In case a tumor was located 
in a cosmetically sensitive area, MMS was performed.13 MMS specimens were excluded 
from further analysis because BCC subtype can only be judged at the surgical margins 
and not in the central tumor part. 
 Data were collected and the following characteristics were registered: gender, age, 
tumor location, tumor diameter, histological BCC subtype on punch biopsy and surgery 
specimen, and type of surgery (surgical excision or MMS). Based on the most aggressive 
subtype noted on histology, all BCC were divided into three subgroups, namely sBCC, 
nBCC and aBCC. Infiltrative / morpheaform, micronodular and basosquamous BCC are 
categorized as aBCC.6,7 Histological subtype of BCC was judged by different pathologists 
according to standard defined histopathological features.7,14-16 
 Mixed histological subtypes were defined as tumors with lack of agreement between 
the punch biopsy and the excision specimen on histological subtype or presence of more 
than one subtype on either punch biopsy or excision. A basic assumption underlying the 
analysis is that the most aggressive histological subtype of the tumor, seen on either 
punch biopsy or surgical excision, defines the definite histological subtype of the tumor. 
This means that, on the one hand, if the punch biopsy specimen identifies an aggressive 
subtype that is not observed by excision specimen, we assume that the aggressive com-
ponent of the tumor was removed by biopsy. On the other hand, if the excision speci-
men identifies an aggressive subtype that is not observed on punch biopsy specimen, we 
assume that it was missed by the punch biopsy. 
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Statistical analysis 
Descriptive results are given as number and percentages. BCC tumors are used as unit of 
analysis. Diagnoses of histological subtype by punch biopsy and excision were compared 
separately for all BCC tumors and for tumors composed of more than one subtype on 
histopathological examination (mixed histological subtypes). Proportions with con-
cordant results were calculated as the proportion of tumors with the same diagnosis in 
punch biopsy and excision specimens. Proportions with discordant results were calcu-
lated as the proportion of tumors in which the diagnosis according to punch biopsy 
differed from that by surgical excision. With respect to discordant results, a distinction 
is made between cases where punch biopsy detected a less aggressive subtype than exci-
sion and vice versa. Data analyses were performed with SPSS version 18.0 (SPSS, Chica-
go, IL, USA). 
Results 
Patient characteristics 
We included and analyzed 243 BCC of 191 patients (111 men, 80 women). Twenty-eight 
patients had two BCC, nine had three BCC and two had four BCC. The mean age was 
70.1 years (range 36-93 years). 
Tumor characteristics 
BCC were most frequently located in the head/neck region (n=152, 62.6%). Sixty-one 
tumors (25.1%) were located on the trunk, 20 (8.2%) on the lower extremities and 10 
(4.1%) on the upper extremities. The mean tumor diameter was 8.6 mm (range 2-30 
mm). Seventy-two percent of BCC was 10 mm or smaller. 
Histological subtypes 
On punch biopsy, 61.7% of BCC was histologically nodular (n=150), 34.6% aggressive 
(n=84) and 3.7% (n=9) superficial. Surgical excision specimens demonstrated percent-
ages of 45.7% (n=111), 38.7% (n=94) and 15.6% (n=38) for nodular, aggressive and 
superficial subtypes, respectively. 
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 A total number of 180 BCC (74.1%) was composed of mixed histological subtypes on 
either punch biopsy or the surgical excision. Ten different mixed subtypes were ob-
served. The three most common mixes were ‘superficial/nodular’ (n=65, 36.1%), ‘nodu-
lar/micronodular’ (n=29, 16.1%) and ‘nodular/infiltrative’ (n=23, 12.8%). Tumors with 
a single subtype were seen in 25.9% (63/243) of cases, of which nBCC was the most 
common one (n=53, 84.1%). 
Agreement between punch biopsy and surgical excision of BCC subtype 
The agreement between histological subtype seen on punch biopsy specimen and exci-
sion specimen was 60.9% (148/243 concordance cases, Table 1). The proportion of cases 
where punch biopsy detected a less aggressive subtype than surgical excision was 15.6% 
(38/243) and in 23.5% (57/243) punch biopsy detected a more aggressive subtype. Con-
sidering the assumption that the most aggressive histological subtype of the tumor, seen 
on either punch biopsy or surgical excision, defines the definite histological subtype of 
the tumor, it can be concluded that punch biopsy enables diagnosis of the most aggres-
sive component in 84.4% (205/243). 
 The discrepancy between diagnosis on punch biopsy and excision has important 
consequences. In total, 120 (49.4%) BCC demonstrated an aggressive subtype either on 
punch biopsy or on the subsequent surgical excision. In 36 of the 120 (30%) aggressive 
BCC, aggressive growth was absent in the punch biopsy but present on surgical excision. 
 In the 180 mixed histology tumors, the most aggressive component present in the 
tumor was missed by punch biopsy in 21.1% (38/180) (Table 2). 
 
Table 1. Histological diagnosis of the most aggressive BCC subtype on punch biopsy compared to surgical 
excision. 
Biopsy Surgical excision 
Superficial BCC Nodular BCC Aggressive BCC Total 
Superficial BCC  5 (2.1)   2 (0.8)  2 (0.8)   9 (3.7) 
Nodular BCC 31 (12.8)  85 (35.0) 34 (14.0) 150 (61.7) 
Aggressive BCC  2 (0.8)  24 (9.9) 58 (23.9)  84 (34.6) 
Total 38 (15.6) 111 (45.7) 94 (38.7) 243 (100) 
Data are given as numbers (percentages). Bold numbers indicate concordant cases. BCC; basal cell carcinoma.  
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Table 2. Histology of the mixed BCC (n=180) on punch biopsy compared to surgical excision. 
Biopsy Surgical excision Most aggressive subtype 
missed on biopsy 
Most aggressive subtype 
missed on surgical excision 
Superficial (4) Nodular (1) 100% (4/4)  0% (0/4) 
 Nodular + superficial (1)   
 Mixed with aggressive (2)   
Nodular (54) Superficial (10)  48% (26/54) 19% (10/54) 
 Nodular + superficial (18)   
 Aggressive (4)   
 Mixed with aggressive (22)   
Aggressive (31) Superficial (1)   0% (0/31) 32% (10/31) 
 Nodular (7)   
 Nodular + superficial (2)   
 Aggressive (4)   
 Mixed with aggressive (17)   
Nodular + superficial (43) Superficial (21)  19% (8/43) 49% (21/43) 
 Nodular (3)   
 Nodular + superficial (11)   
 Aggressive (2)   
 Mixed with aggressive (6)   
Mixed with aggressive (48) Superficial (1)   0% (0/31) 35% (17/48) 
 Nodular (10)   
 Nodular + superficial (6)   
 Aggressive (5)   
 Mixed with aggressive (26)   
Total (180)   21% (38/180) 32% (58/180) 
Discussion 
The proportion of punch biopsies that correctly predicts the most aggressive growth 
pattern of the entire BCC is 84.4%. As treatment choice of BCC is based on the most 
aggressive histological subtype seen on punch biopsy, this means that in one out of six 
BCC the most aggressive growth pattern is missed in an adequately taken punch biopsy. 
These tumors might not be properly treated and a higher percentage of re-excision or 
recurrences may occur. 
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 Only three previous studies reported on the agreement between histological BCC 
subtype on biopsy and the subsequent surgical excision in BCC.10-12 These studies in-
cluded mainly shave biopsies in primary BCC or reported on punch biopsy in recurrent 
BCC. However, shave biopsy of the tumor surface might fail to identify BCC subtypes 
located deeper in the dermis. In this study, for the first time the agreement between the 
most aggressive histological subtype seen on punch biopsy and the subsequent surgical 
excision was examined in a large population with 243 primary BCC. 
 We found that a punch biopsy can identify the most aggressive growth pattern of 
primary BCC in 84.4%. A similar percentage (84.2%) was found by Mosterd et al. in 
recurrent BCC judged by one blinded dermatopathologist.12 A slightly higher percentage 
(91.8%) was obtained when histopathological specimens were independently and blind-
ed judged by only two dermatopathologists.11 
 The percentage of concordant cases of BCC subtype on punch biopsy compared to 
surgical excision specimens was 60.9%. This is in contrast to the agreement of 81% Rus-
sell et al. and 89% Haws et al. reported in the subgroup of primary BCC that received a 
punch biopsy (instead of a shave biopsy).10,11 An explanation for our lower agreement 
might be the high percentage of mixed histological subtypes (74.1%) compared to 18-
49% in other studies, that may have influenced results 7,12,17 In case of a mixed histologi-
cal BCC, one subtype might be totally biopsied and is therefore not seen on surgical 
excision. 
 Another explanation might be the fact that verification bias is present due to the 
non-invasively treated sBCC. sBCC are normally treated non-surgically in our clinic. 
This group probably reflects a group were there was doubt about the superficial growth 
and was therefore excised. Furthermore, histological specimens were not judged by one 
or two blinded dermatopathologists. However, our study reflects daily clinical practice 
in which different pathologists, each with a slightly different reference frame of BCC 
subtypes, judge histological specimens. To improve the interobserver agreement be-
tween pathologists that evaluate BCC subtype, it is advisable that histopathological 
slides are judged in a standardized manner by dermatopathologists qualified in evaluat-
ing BCC subtypes. 
 To our knowledge this is to date the first study to determine the agreement between 
punch biopsy and surgical excision to predict the histological BCC subtype in a large 
population with primary BCC. The results of this study indicate that 3 and 4 mm punch 
biopsies are a generally fair diagnostic tool to detect the most aggressive growth pattern 
of the complete tumor. Treatment is based on the most aggressive subtype seen on 
punch biopsies and the chance of undertreatment is still present in one out of six BCC. 
Even when a punch biopsy is taken from the clinically most aggressive part, clinicians 
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have to be aware of this discrepancy. Therefore, we might also have to rely on the clini-
cal diagnosis. In the past, several studies demonstrated that the clinical diagnosis of BCC 
is accurate in 70-89%.18-21 
 However, a correct clinical BCC diagnosis does not imply a correct clinical diagnosis 
of histological subtype. It would be interesting to know whether the clinical BCC sub-
type is as reliable as or even more reliable than the histological BCC subtype determined 
on a punch biopsy. 
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Abstract 
 Background: Basal cell carcinoma (BCC) guidelines recommend a punch biopsy 
prior to treatment to identify the histological subtype for optimal treatment selection. 
However, clinical ability to differentiate between BCC subtypes has not been studied. 
 Objectives: To compare the diagnostic accuracy of clinical assessment and histologi-
cal diagnosis by punch biopsy for subtyping BCC and to evaluate the impact of omitting 
the punch biopsy on treatment recommendations.  
 Methods: Sensitivity, specificity, positive predictive value and negative predictive 
value, with corresponding 95% confidence intervals were calculated for discrimination 
between (i) superficial versus nodular/aggressive BCC and (ii) aggressive versus nodular 
BCC. The gold standard was the histological subtype on the subsequent surgical exci-
sion. 
 Results: 152 histologically confirmed BCC were included. Detection of the most 
aggressive BCC subtype by punch biopsy was better than by clinical diagnosis. Omission 
of punch biopsy may result in overstaging of 1 in 4 superficial BCC and in understaging 
of 1 in 4 aggressive BCC. 
 Conclusions: Punch biopsy is more accurate in BCC subtyping than clinical diagno-
sis. Omitting a punch biopsy may lead to over- and understaging. 
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Introduction 
International guidelines on diagnosis and treatment of basal cell carcinoma (BCC) rec-
ommend a punch biopsy in the majority of clinically suspected BCC prior to treatment. 
This is to confirm diagnosis and to identify the histological subtype (superficial, nodu-
lar, aggressive), which is necessary to know for optimal treatment selection.1,2 A punch 
biopsy can detect the most aggressive subtype in 84-92% of cases, but has the disad-
vantages of discomfort for the patient and costs for the health care system.3-5 In contrast, 
clinical diagnosis is a painless, and possibly money-saving procedure.6 However, the 
difference in diagnostic accuracy of BCC subtyping between punch biopsy and clinical 
diagnosis has never been evaluated. This study compares the diagnostic accuracy of 
clinical assessment and histological diagnosis by punch biopsy for subtyping BCC. Fur-
thermore, we evaluated the impact of omitting the punch biopsy on treatment recom-
mendations. 
Materials and methods 
Eligible patients attending the outpatient department of Dermatology of the Maastricht 
University Medical Centre (MUMC) and the Erasmus Medical Centre Rotterdam 
(Erasmus MC), The Netherlands, were included between August 2011 and August 2012. 
Included were patients aged 18 years or older with a clinically suspected primary BCC 
that was histologically confirmed on surgical excision specimen. Exclusion criteria were: 
genetic skin cancer syndromes and use of immunosuppressive drugs. All patients gave 
written informed consent for participation. The trial was approved by the Medical Eth-
ics and Scientific Committee of the MUMC. 
 Clinical diagnosis of the most aggressive BCC subtype was made by one of the der-
matologists specialized in oncology (three at MUMC, two at Erasmus MC), based on the 
criteria by Crowson et al.7 A distinction was made between superficial, nodular and 
aggressive BCC. Subsequently, a 3 mm punch biopsy was obtained from the clinically 
most aggressive tumor area. Superficial and nodular BCC were surgically excised with a 
3 mm margin, aggressive BCC with 5 mm. Incompletely excised BCC were re-excised 
and Mohs’ micrographic surgery was performed in facial high risk BCC.8 
 All biopsy and excision specimens were haematoxylin and eosin stained. Biopsies 
were (partially) cut in serial sections of 150 μm. Four serial section of 4-5 consecutive 
slices were made. Excision specimens were cut at 2 mm, completely imbedded and once 
slice per section was made. Histopathological slides were evaluated by two dermato-
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pathologists, who were unaware of the diagnosis of the other pathologist and blinded to 
the clinical diagnosis. The most aggressive BCC subtype was recorded following histo-
logical criteria.7,9 Aggressive BCC comprised infiltrative/morpheaform, micronodular 
and basosquamous BCC. 
 This study focused on the ability to discriminate clinically and histologically (by 
punch biopsy) between: i) superficial BCC vs. nodular/aggressive BCC and; ii) aggres-
sive vs. nodular BCC. These distinctions were considered most relevant for optimal 
treatment selection, as superficial BCC can be treated non-invasively and aggressive 
BCC require a larger surgical margin than nodular BCC.10 The primary outcomes were 
sensitivity and specificity of clinical assessment and histological diagnosis by punch 
biopsy. The gold standard for BCC subtyping was the histological subtype on the subse-
quent surgical excision. False positive and false negative results have an impact on 
treatment recommendations. False positive results are associated with overstaging: clini-
cal diagnosis or punch biopsy classified a BCC as more aggressive than the histological 
diagnosis on subsequent surgical excision. False negative results are associated with 
understaging: clinical diagnosis or punch biopsy classified a BCC as less aggressive than 
the gold standard. 
 Diagnostic values with corresponding 95% confidence intervals were calculated for 
discrimination between (i) and (ii). Differences in proportions were tested using the 
McNemar test for paired proportions. P-values ≤ 0.05 were considered to indicate statis-
tical significance. Statistical analyses were performed with SPSS-pc version 20.0 (SPSS, 
Chicago, IL, USA). 
Results 
Biopsies were performed in 285 clinically suspected primary BCC. A total of 191 BCC 
were histologically confirmed, 152 of which were in the 116 patients who agreed to par-
ticipate (64 men, 52 women). Mean age was 68 years (range 33-92 years). Prevalence of 
superficial, nodular and aggressive BCC on surgical excision were 16.4% (25/152), 52.0% 
(79/152) and 31.6% (48/152), respectively (Table 1). 
Superficial versus nodular/aggressive BCC 
Table 2 shows the diagnostic parameters for discrimination between superficial vs. nod-
ular/aggressive BCC. Sensitivity to detect nodular/aggressive BCC was similar for clini-
cal diagnosis and punch biopsy (89.0% vs. 92.1%, p=0.38), but punch biopsy was more 
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specific than clinical diagnosis (88.0% vs. 64.0%, p=0.11); i.e. the percentage of superfi-
cial BCC that was falsely diagnosed as nodular/aggressive decreased from 36% to 12%. 
Thus, omitting a punch biopsy would have resulted in overstaging in an extra 24.0% of 
superficial BCC. 
 
Table 1. Tumor characteristics of 152 basal cell carcinoma. 
Characteristic n (%) 
Tumor localization 
Head/neck 
Trunk 
Upper extremities 
Lower extremities 
 
79 (52) 
53 (35) 
12 (8) 
 8 (5) 
BCC subtype on surgical excision  
Superficial 
Head/neck 
Trunk 
Upper extremities 
Lower extremities 
25 (16) 
 1 (4) 
18 (72) 
 5 (20) 
 1 (4) 
Nodular 
Head/neck 
Trunk 
Upper extremities 
Lower extremities 
79 (52) 
41 (52) 
26 (33) 
 6 (8) 
 6 (8) 
Aggressive 
Head/neck 
Trunk 
Upper extremities 
Lower extremities 
48 (32) 
37 (77) 
 9 (19) 
 1 (2) 
 1 (2) 
Mean tumor diameter in mm (range)  8.6 (3-25) 
Definition of abbreviations: BCC, basal cell carcinoma. 
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Table 2. Diagnostic parameters of clinical diagnosis and histological diagnosis by punch biopsy for detection 
of the most aggressive histological BCC subtype on surgical excision. 
 Sensitivity (%) Specificity (%)  PPV (%) NPV (%)  OR (%) 
Superficial vs. nodular/aggressive BCC 
Clinical diagnosis  89.0 (113/127)  
[0.85-0.92] 
64.0 (16/25)  
[0.45-0.79] 
92.6 (113/122)  
[0.89-0.96] 
53.3 (16/30)  
[0.38-0.66] 
14.4  
[4.8-43.8] 
Punch biopsy 92.1 (117/127)  
[0.89-0.94] 
88.0 (22/25)  
[0.71-0.97] 
97.5 (117/120)  
[0.94-0.99] 
68.8 (22/32)  
[0.56-0.76] 
85.8  
[19.4-442.3] 
Aggressive vs. nodular BCC 
Clinical diagnosis  56.3 (27/48)  
[0.45-0.67] 
77.2 (61/79)  
[0.70-0.84] 
60.0 (27/45)  
[0.47-0.71] 
74.4 (61/82)  
[0.68-0.81] 
4.4  
[1.9-10.12] 
Punch biopsy 85.4 (41/48)  
[0.75-0.93] 
84.8 (67/79)  
[0.78-0.89] 
77.4 (41/53)  
[0.68-0.84] 
90.5 (67/74)  
[0.84-0.95] 
32.7  
[10.8-103.9] 
Data in parentheses are numbers used to calculate the percentage and data in brackets are 95% confidence 
intervals. Definition of abbreviations: BCC, basal cell carcinoma; PPV, positive predictive value; NPV, nega-
tive predictive value; OR, odds ratio. 
Aggressive versus nodular BCC 
Punch biopsy is more sensitive (p=0.002) and more specific (p=0.29) for discrimination 
between aggressive and nodular BCC (Table 2) than clinical diagnosis. The proportion 
of aggressive BCC that was understaged as nodular or superficial was 43.8% (21/48) 
after clinical diagnosis and 14.6% (7/48) after punch biopsy. Thus, omission of a punch 
biopsy would have resulted in understaging of aggressive BCC in an extra 29.2% of cas-
es. 
ROC-curves 
The ROC-curves showed a higher ability for punch biopsy than for clinical diagnosis for 
differentiating between superficial versus nodular/aggressive BCC (Fig. 1) and aggres-
sive versus nodular BCC (Fig. 2). 
 
We repeated the analyses with restriction to BCC on the trunk and extremities. These 
analyses showed similar results. 
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Fig. 1 The ability of clinical diagnosis and the histological diagnosis on punch biopsy to discriminate between
superficial and nodular/aggressive basal cell carcinoma. 
 
 
Fig. 2 The ability of clinical diagnosis and the histological diagnosis on punch biopsy to discriminate between
aggressive and nodular basal cell carcinoma. 
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Discussion 
These findings indicate that a punch biopsy is a better diagnostic tool than the clinical 
diagnosis for detection of the histological BCC subtype, i.e. essentially in line with inter-
national guidelines.1,2 However, some experts argue that omitting a biopsy might be 
acceptable or preferred in some cases.1,2,6 We showed that, when a punch biopsy is omit-
ted, there is a risk of overstaging superficial BCC as more aggressive in an extra 24% of 
cases. In such a case, the physician will probably advise surgical excision and deny the 
patient the choice of less invasive alternatives (photodynamic therapy, imiquimod or 5-
fluorouracil). Superficial BCC comprises approximately 30% of the total BCC popula-
tion.11 Thus, if treatment is based on clinical diagnosis, only a small minority (7%) of all 
patients with BCC would receive a more invasive therapy than strictly required. 
 Another consequence of omitting a punch biopsy is a significantly increased risk of 
understaging an aggressive BCC as nodular BCC in approximately a quarter of cases. 
These patients run the risk of having their tumor excised with too small margins, result-
ing in a re-excision or a recurrence.12 
 Considering these findings, it may be justified that physicians choose to omit the 
punch biopsy if they have high confidence in their diagnosis on the subtype of BCC, 
especially when using a dermatoscope.13 Histological confirmation by punch biopsy 
might then be reserved for diagnoses that are made with less confidence and also for 
BCC in the head/neck region because recurrences in this area are not retreated that 
easily and can cause great morbidity. Nevertheless, the consequences of omitting a 
punch biopsy need to be discussed with the patient. 
 A limitation of the study is that patients with superficial BCC who preferred non-
invasive therapies did not participate. For this reason, the absolute estimates of sensitivi-
ty and specificity (for both clinical diagnosis and punch biopsy) may be subject to verifi-
cation bias, which results in overestimation of sensitivity and underestimation of speci-
ficity.14 Secondly, some results lack statistical significance, probably due to the relatively 
small number of superficial BCC in this study. Thirdly, the level of confidence in the 
clinical diagnosis of BCC subtype was not recorded and, therefore, it was not possible to 
evaluate the level of over- and understaging in case of highly confident diagnoses. 
 In summary, punch biopsy is more accurate in BCC subtyping than clinical diagno-
sis. The impact of over- or understaging on treatment recommendations must be 
weighed against extra time, cost and patient discomfort associated with a punch biopsy. 
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Abstract 
 Background: Several non-invasive treatment modalities are available for superficial 
basal cell carcinoma (sBCC). 
 Objectives: This systematic review aims to determine residue, recurrence and tu-
mor-free survival probabilities of patients with primary sBCC treated with the currently 
most frequently used therapies. 
 Methods: The Pubmed (January 1946 to October 2010), EMBASE (January 1989 to 
October 2010), Cochrane (January 1993 to October 2010) databases, and reference lists 
were searched without date restriction. Inclusion criteria were studies that included 
primary, histologically proven sBCC, that reported on residue and/or recurrence proba-
bilities after treatment, and had a minimum follow-up period of 12 weeks. Both ran-
domized and non-randomized studies were included. The primary and secondary out-
comes were the probability of complete response and tumor-free survival, respectively. 
Two independent reviewers selected 36 studies (14 randomized and 22 non-
randomized), and extracted residue, cumulative recurrence and tumor-free survival 
probabilities. 
 Results: Pooled estimates of percentages of sBCC with complete response at 12 
weeks post treatment, derived from 28 studies, were 86.2% (95% CI 82-90%) for 
imiquimod treatment, and 79.0% (95% CI 71-87%) for photodynamic therapy (PDT). 
With respect to tumor-free survival at one year, the pooled estimates derived from 23 
studies were 87.3% for imiquimod (95% CI 84-91%) and 84.0% for PDT (95% CI 78-
90%). Only a small number of studies reported on results of sBCC treatment with 5-
fluorouracil (two), surgical excision (one) and cryotherapy (two). 
 Conclusions: Pooled estimates from randomized and non-randomized studies 
showed similar tumor-free survival at one year for imiquimod and PDT. The PDT tu-
mor-free survival was higher in studies with repeated treatments. However, these results 
were largely derived from non-randomized studies, and randomized studies with head-
to-head comparison of imiquimod and PDT are lacking. There is a need for head-to-
head comparison studies between PDT, imiquimod and other treatments with long-
term follow-up to enable better recommendations for optimal sBCC treatment. 
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Introduction 
Basal cell carcinoma (BCC) is the most common skin cancer in the white population, 
with a remarkable increase in incidence of 3-10% annually.1-3 Treatment of BCC is be-
coming a major health care problem, causing enormous health care costs and an in-
creased workload for dermatologists and many other physicians. In the past it was a 
disease of elderly patients, but as a consequence of recreational sun exposure and tan-
ning beds, a larger number of young people develop skin cancer as well.4,5 People who 
develop one BCC are at a 10-fold increased risk of developing subsequent BCC at other 
body sites.6,7 A study from The Netherlands in 2005 predicted that the number of pa-
tients with BCC would increase 78% in 2015.1 
 The histopathological diagnosis of BCC can be assessed by punch biopsy.8 There are 
three major histological subtypes corresponding with several clinical manifestations. 
The most common subtype is the nodular BCC (40% of BCC cases). However, a rapid 
rise in the relative proportion of the superficial subtype of BCC has been observed last 
20 years, with an increase from 18% to 31% of total cases.9 Surgical excision remains the 
standard of care in most BCC because histopathological examination ensures tumor 
clearance. However, a good cosmetic outcome is becoming more important with the 
growing affected young population. Superficial BCC (sBCC) is the least aggressive sub-
type, requiring less destructive therapeutic options. Nowadays, sBCC can be treated by a 
variety of non-surgical techniques, such as photodynamic therapy (PDT), immunother-
apy, local chemotherapeutic cream and cryotherapy.8,10 These treatments avoid scarring, 
which is frequently seen after surgical excision. Furthermore, they can relieve the busy 
dermatologist’s practice. However, there is no consensus on the treatment of sBCC. 
Which treatment the patient will receive relies on some tumor characteristics (localiza-
tion and size) and patient characteristics (age, history of previous treatments and gen-
eral health),11 but mostly on the preference of the treating physician.12 In addition, the 
cosmetic outcome, aftercare and costs should be taken into consideration. 
 The objective of this study was to systematically review published studies in order to 
compare the percentage of cases with complete response (primary outcome) and long-
term tumor-free survival (secondary outcome) for patients with primary sBCC between 
the different frequently used treatments. Combined results from a meta-analysis result 
in a more reliable estimate than results from individual studies. Cosmetic outcome, 
aftercare and costs will not be the subject of this review. 
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Materials and methods 
This systematic review was performed according to the PRISMA statement for system-
atic reviews and meta-analyses.13 No online review protocol was made prior to this 
study. 
Search 
A systematic search for papers in the English language was performed in three well-
established databases: Pubmed (January 1946 to October 2010), EMBASE (January 1989 
to October 2010) and Cochrane Library (January 1993 to October 2010). PubMed is a 
free search engine for accessing the MEDLINE database of citations and abstracts of 
biomedical research articles. EMBASE is an abstract and indexing database also special-
ized in the biomedical field. The Cochrane Library is a collection of databases, and con-
tains Cochrane reviews, which represent the highest level of evidence. The following 
search terms (including derivatives and analogues) were used: carcinoma, basal cell, 
superficial in combination with therapy using the following limits randomized controlled 
trial, clinical trial and human. There was no date restriction and the last search was run 
on the 1 October 2010. Further eligible publications were subsequently identified from 
the reference lists and were used for this systematic review. 
Data sources and study selection 
Eligible for review were studies which met the prespecified inclusion criteria. Studies 
had to report on treatment success of a modality for treatment of sBCC and had to in-
clude only patients with primary and histologically proven sBCC. Furthermore, studies 
had to have a follow-up period of at least 12 weeks after treatment. Data on the number 
of patients treated and the number of patients with treatment failure had to be available 
for at least one time point during follow-up. Because there was a limited number of 
randomized controlled trials (RCTs), both randomized and non-randomized studies 
were considered eligible, as well as prospective and retrospective studies, in order to 
include studies with results after long-term follow-up. We excluded case series, case 
reports, reviews, studies in which the recurrence probability of sBCC was not described 
separately from the other histological BCC subtypes, and studies in which results of two 
or more treatments were combined. Different papers by the same author or research 
group were included for review only when it was obvious that a different sample of 
patients was used. Two independent reviewers carefully screened titles and abstracts for 
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relevancy. If necessary, authors were contacted by email or telephone to obtain and 
confirm their data. 
Data extraction 
Two reviewers independently read the full text of the articles that were considered for 
inclusion using structured forms for extraction of relevant data. Any disagreements 
between reviewers were discussed with a third reviewer and further resolved by consen-
sus. From studies which reported results of treatment of different BCC subtypes, only 
the subset of sBCC data was included. The outcomes that were considered of interest in 
this review were: probability of residual tumor/incomplete response, cumulative proba-
bility of recurrence, and probability of tumor-free survival (sustained clearance) at the 
end of follow-up. If any tumor tissue was present at the first control visit after treatment, 
the response to treatment was considered to be incomplete and the lesion was regarded 
as a residual tumor. Recurrence was defined as the presence of tumor tissue that was 
detected during follow-up in patients who had no residual tumor tissue. Tumor-free 
survival was defined as absence of both residual tumor and recurrence. 
 Information was extracted from individual studies regarding (i) treatment modality, 
including type, dose, frequency, duration, margin of cream application, illumination 
source and its tuning; (ii) data required for estimation of probability of residual tu-
mor/incomplete response, cumulative probability of recurrence and probability of tu-
mor-free survival at the end of follow-up; (iii) methodological aspects including sample 
size, selection of study population (such as restriction to tumors ≤ 2 or > 2 cm in diame-
ter), study design (randomized vs. non-randomized), duration of follow-up, verification 
of residual tumor by clinical or a combined clinical and histopathological examination, 
use of time-to-event analysis (yes vs. no) , sponsored by pharmaceutical industry (yes vs. 
no), type of comparison (with placebo, other treatment or no treatment); (iv) distribu-
tion of patients’ characteristics including age, comorbidities and tumor characteristics 
such as localization and size. 
Risk of bias 
To evaluate the methodological quality of the studies we scored eight items that are 
related to (i) representativeness of the study population, (ii) the description of the inter-
vention, (iii) the evaluation of the clinical outcome, (iv) design-specific sources of bias, 
and (v) the analysis of data (Table 1).14 The scores range from 0 to 8 with higher scores 
indicating better methodological quality and less potential for biased estimates. 
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Table 1. Items scored to evaluate methodological quality of non-randomized controlled trials. 
Item Score 
1. Use of a representative study population without restriction to subgroups Yes/no  
2. Use of a well-described and standardized intervention Yes/no  
3. Evaluation of treatment response by histological verification Yes/no  
4. Definition of success as complete response (instead of partial response) Yes/no  
5. Prospective design Yes/no  
6. Inclusion of all treated patients in evaluation of long-term prognosis  Yes/no  
7. Percentage lost to follow up < 10% or ≥ 10% 
8. Use of survival analysis Yes/no  
Non-randomized controlled trials were given a quality score ranging from 0 (poor) to 8 (excellent) points. 
Statistical analysis 
Percentages of patients with complete response to treatment were derived from the 
individual studies. The number of patients with no residual tumor at the first control 
visit after treatment was divided by the number of patients that were included for treat-
ment, irrespective of whether patients were actually treated and/or finished treatment. 
Patients with adverse events (e.g. local skin reactions to imiquimod) were not consid-
ered to be treatment failures. This approach was chosen according to the intention-to-
treat principle to prevent biased estimates due to selective loss to follow-up. 
 Valid estimation of the long-term risk of recurrence and tumor-free survival after 
treatment requires time-to-event analysis. If studies had not performed survival analy-
sis, such as Kaplan-Meier analysis or life table analysis, efforts were made to extract the 
data required for life table analysis. The number of patients at risk at the start of each 1-
year interval, as well as the number lost to follow-up and the number having recurrence 
during each interval, were used to calculate cumulative probabilities of sustained clear-
ance. Only patients with complete response to treatment were considered for these anal-
yses. The probability of tumor-free survival at the end of follow-up was calculated by 
multiplying the probability of complete response by the cumulative probability of sus-
tained clearance. Standard errors were calculated using the Peto formula.15 
 For pooling, a random effects model as proposed by DerSimonian and Leird was 
performed using the inverse of the standard errors of the percentages from the individu-
al studies as weights.16 The I2 index was used to test for heterogeneity between study 
results. The significance of this index indicates that differences between studies cannot 
solely be attributed to sampling variation, and that differences in study population, 
design and analysis are responsible for variation between study results. The I2 index 
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ranges from 0 to 100%. Statistical heterogeneity was defined as a I2 index > 50%.17 Ex-
ploratory subgroup analyses were performed to identify sources of variation between 
study results. These subgroup analyses were not prespecified, but studies were catego-
rized into subgroups according to several study characteristics that can potentially affect 
study results. Publication bias was examined statistically using the Egger’s test.18 All anal-
yses were performed using STATA version 11.0 (STATA Corp, College Station, TX). 
Results 
The literature search identified 903 papers from which 36 studies fulfilled the inclusion 
criteria (Fig. 1). Two papers could not be obtained.19,20 Included studies were conducted 
in the USA, Europe, Australia, New-Zealand and Brazil and were published between 
1994 and 2010. The selected studies often excluded patients with sBCC in the anogenital 
area or areas within 1 cm of the H-zone, or pigmented or morpheaform BCC. Patients 
with dermatologic conditions that interfere with treatment, those who had genetic skin 
disorders, those who were receiving immunosuppressive therapy, or who were pregnant 
or breastfeeding were also often excluded. 
 Fourteen studies were RCTs in which two or more treatment protocols were directly 
compared (Table 2). Eight RCTs were dose-finding studies,21-25 of which three also in-
cluded a placebo study arm.26-28 The other six RCTs compared imiquimod with place-
bo,29 or PDT with another treatment.30-34 The remaining 22 studies were non-RCTs and 
reported results of one treatment modality.11,35-55 One study compared imiquimod with 
methylaminolevulinate (MAL)-PDT in a non-randomized trial.45 
 The majority of studies provided data on the results of treatment with PDT (16)11,30-
34,43,45,47-49,51-55 or imiquimod (15).21-24,27-29,35-37,40,42,44-46 Other treatments that were evaluated 
were pulsed dye laser38,39,50, 5-FU25,41, cryotherapy30,33, surgical excision31 and PEP005.26 
The latter is also known as ingenol mebutate.56 Pooling of results was restricted to PDT 
and imiquimod studies. 
 Probabilities of complete response after treatment could be derived from 34 of 36 
studies,11,21-32,34-42,44-55 and information on recurrence probabilities during follow-up was 
available in 23 of 36 studies.11,21,30-37,39,40,42-45,47-49,51-53,55 Four studies did not use a single 
standardized treatment protocol, but presented study results of combinations of treat-
ment regimens. Subgroup analyses were not performed.11,33,36,44 The follow-up period for 
evaluation of recurrence differed from three months to five years after the first control 
visit. Probability of tumor-free survival at one year follow-up could be derived from 14 
studies,21,30,31,33-37,39,40,42,44,49,55, but estimates at two, three, four and five years of follow-up 
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were only available in six 30,34,35,37,40,44, five 30,35,40,43,44, three 30,35,40 and three 30,35,40 studies, 
respectively. 
 
 
Fig. 1 Flow diagram of study selection in systematic review. 
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-T
2:
 2
 (1
2.
5%
) a
t 1
Y 
Cl
in
ic
al
 v
er
ifi
ca
tio
n.
 
To
ta
l w
ith
dr
aw
al
s n
ot
 m
en
tio
ne
d.
 
Sc
hi
es
sl 
20
07
42
 
A
us
tr
ia
. 
Pr
os
pe
ct
iv
e, 
sin
gl
e-
ar
m
 
stu
dy
. 
N
o 
RC
T 
Q
ua
lit
y 
sc
or
e 5
 
Fu
nd
in
g:
 y
es
. 
 
N
ot
 m
en
tio
ne
d 
41
 p
ar
tic
ip
an
ts
 w
ith
 4
7 
BC
C 
(1
5 
sB
CC
). 
M
ea
n 
su
rfa
ce
 ar
ea
 
0.
5-
24
 cm
2 . 
Lo
ca
liz
at
io
n:
 5
3%
 
tr
un
k,
 4
0%
 h
ea
d/
ne
ck
, 7
%
 ar
m
. 
O
th
er
 p
at
ie
nt
 ch
ar
ac
te
ris
tic
s 
no
t s
pe
ci
fie
d 
fo
r s
BC
C.
 
5x
/w
ee
k 
fo
r 6
 w
ee
ks
 
0 
(0
%
) 
A
t 6
 w
ee
ks
 p
os
t 
tr
ea
tm
en
t, 
co
m
bi
ne
d 
cl
in
ic
al
/h
ist
ol
og
ic
al
 
ve
rif
ic
at
io
n.
 
15
 sB
CC
 en
te
re
d 
lo
ng
-te
rm
 fo
llo
w
-
up
 o
f m
ed
ia
n 
10
 m
on
th
s (
ra
ng
e 2
-
17
). 
1Y
: 0
 (0
%
) 
Cl
in
ic
al
 v
er
ifi
ca
tio
n.
 
To
ta
l w
ith
dr
aw
al
s 8
. 
St
ud
y 
Se
tti
ng
 
Q
ua
lit
y 
as
se
ss
m
en
t 
In
cl
us
io
n 
an
d 
ex
cl
us
io
n 
cr
ite
ria
 P
ar
tic
ip
an
ts 
an
d 
tu
m
or
 
ch
ar
ac
te
ris
tic
s 
Tr
ea
tm
en
t p
ro
to
co
l 
Re
sid
ue
 
Cu
m
ul
at
iv
e r
ec
ur
re
nc
e a
t l
on
g-
te
rm
 
fo
llo
w
-u
p 
 
V
un
 
20
06
44
 * 
A
us
tr
al
ia
. 
Re
tr
os
pe
ct
iv
e, 
sin
gl
e-
ar
m
 
stu
dy
.  
N
o 
RC
T 
Q
ua
lit
y 
sc
or
e 4
 
Fu
nd
in
g:
 y
es
. 
 
In
: s
BC
C 
≤ 
2 
cm
 
in
 d
ia
m
et
er
. 
7 
pa
rt
ic
ip
an
ts 
(1
1 
sB
CC
). 
Lo
ca
tio
n:
 1
00
%
 fa
ce
. O
th
er
 
pa
tie
nt
 an
d 
tu
m
or
 
ch
ar
ac
te
ris
tic
s n
ot
 sp
ec
ifi
ed
 fo
r 
sB
CC
. 
 
7x
/w
ee
k 
fo
r m
ea
n 
6 
w
ee
ks
 
(r
an
ge
 3
-9
) 
1 
(9
.1
%
) 
A
t 1
2 
w
ee
ks
 p
os
t 
tr
ea
tm
en
t, 
cl
in
ic
al
 o
r 
co
m
bi
ne
d 
cl
in
ic
al
/h
ist
ol
og
ic
al
 
ve
rif
ic
at
io
n.
 
10
 sB
CC
 en
te
re
d 
lo
ng
-te
rm
 fo
llo
w
-
up
 o
f m
ea
n 
39
 m
on
th
s (
ra
ng
e 3
3-
51
). 
1Y
: 0
 (0
%
) 
2Y
: 0
 (0
%
) 
Cl
in
ic
al
 o
r c
om
bi
ne
d 
cl
in
ic
al
/h
ist
ol
og
ic
al
 v
er
ifi
ca
tio
n.
 
To
ta
l w
ith
dr
aw
al
s 0
. 
Sc
hu
lz
e 
20
05
29
 
Eu
ro
pe
. P
ha
se
 
3,
 p
ro
sp
ec
tiv
e, 
m
ul
tic
en
te
r, 
ra
nd
om
iz
ed
, 
ve
hi
cl
e-
co
nt
ro
lle
d,
 
do
ub
le
-b
lin
d 
stu
dy
. 
RC
T 
Q
ua
lit
y 
sc
or
e 7
 
Fu
nd
in
g:
 y
es
. 
 
St
an
da
rd
. I
n:
 
sB
CC
 ≥
 0
.5
 cm
2 , 
≤ 
2 
cm
 in
 
di
am
et
er
. 
 
16
6 
pa
rt
ic
ip
an
ts 
(1
66
 sB
CC
), 
ov
er
al
l m
ed
ia
n 
tu
m
or
 si
ze
 1
.0
 
cm
2  (
ra
ng
e 0
.3
-6
.3
). 
-T
1:
 8
4 
pa
rt
ic
ip
an
ts
, 5
0 
M
 an
d 
34
 F
, m
ed
ia
n 
ag
e 6
7 
yr
s (
ra
ng
e 
25
-8
3)
. L
oc
al
iz
at
io
n:
 7
0%
 
tr
un
k,
 2
0%
 ex
tr
em
iti
es
, 1
%
 
fa
ce
, 8
%
 o
th
er
. T
um
or
 si
ze
 n
ot
 
sp
ec
ifi
ed
 to
 tr
ea
tm
en
t g
ro
up
. 
-T
2:
 8
2 
pa
rt
ic
ip
an
ts
, 5
1 
M
 an
d 
31
 F
, m
ed
ia
n 
ag
e 6
8 
yr
s (
ra
ng
e 
31
-8
6)
. L
oc
al
iz
at
io
n:
 6
1%
 
tr
un
k,
 2
9%
 ex
tr
em
iti
es
, 6
%
 
fa
ce
, 4
%
 o
th
er
. T
um
or
 si
ze
 n
ot
 
sp
ec
ifi
ed
 to
 tr
ea
tm
en
t g
ro
up
. 
-T
1:
 7
x/
w
ee
k 
fo
r 6
 w
ee
ks
 
-T
2:
 v
eh
ic
le
 7
x/
w
ee
k 
fo
r 6
 w
ee
ks
 
 
T1
: 1
7 
(2
0.
2%
) 
T2
: 7
7 
(9
3.
9%
) 
A
t 1
2 
w
ee
ks
 p
os
t 
tr
ea
tm
en
t, 
co
m
bi
ne
d 
cl
in
ic
al
/h
ist
ol
og
ic
al
 
ve
rif
ic
at
io
n.
 
N
ot
 p
er
fo
rm
ed
 
3.1
St
ud
y 
Se
tti
ng
 
Q
ua
lit
y 
as
se
ss
m
en
t 
In
cl
us
io
n 
an
d 
ex
cl
us
io
n 
cr
ite
ria
 P
ar
tic
ip
an
ts 
an
d 
tu
m
or
 
ch
ar
ac
te
ris
tic
s 
Tr
ea
tm
en
t p
ro
to
co
l 
Re
sid
ue
 
Cu
m
ul
at
iv
e r
ec
ur
re
nc
e a
t l
on
g-
te
rm
 
fo
llo
w
-u
p 
 
N
ik
ke
ls 
20
05
45
 
 
Be
lg
iu
m
. 
Pr
os
pe
ct
iv
e, 
tw
o-
ar
m
 
stu
dy
. 
N
o 
RC
T 
Q
ua
lit
y 
sc
or
e 5
 
Fu
nd
in
g:
 
un
kn
ow
n.
 
N
ot
 m
en
tio
ne
d 
8 
pa
rt
ic
ip
an
ts 
(3
4 
sB
CC
), 
5 
M
 
an
d 
3 
F,
 m
ea
n 
ag
e 6
3 
yr
s (
ra
ng
e 
41
-7
8)
. L
oc
al
iz
at
io
n:
 7
5%
 
tr
un
k,
 2
5%
 h
ea
d/
ne
ck
. T
um
or
 
siz
e r
an
ge
 1
0-
10
0 
m
m
 in
 
di
am
et
er
.  
3x
/w
ee
k 
fo
r 3
 w
ee
ks
 fo
llo
w
ed
 b
y 
1 
st
op
 w
ee
k.
 R
ep
ea
te
d 
fo
r 3
 
tim
es
. 
2 
(5
.9
%
) 
A
t 1
2 
w
ee
ks
 p
os
t 
tr
ea
tm
en
t, 
co
m
bi
ne
d 
cl
in
ic
al
/h
ist
ol
og
ic
al
 
ve
rif
ic
at
io
n.
 
32
 sB
CC
 en
te
re
d 
lo
ng
-te
rm
 fo
llo
w
-
up
. 
6 
m
on
th
s: 
0 
(0
%
) 
Cl
in
ic
al
 v
er
ifi
ca
tio
n.
 
To
ta
l w
ith
dr
aw
al
s 0
. 
Sh
um
ac
k 
20
04
46
 
A
us
tr
al
ia
 an
d 
N
ew
-Z
ea
la
nd
. 
Ph
as
e 2
, 
pr
os
pe
ct
iv
e, 
m
ul
tic
en
te
r, 
op
en
-la
be
l 
stu
dy
. 
N
o 
RC
T 
Q
ua
lit
y 
sc
or
e 5
 
Fu
nd
in
g:
 y
es
. 
In
: s
BC
C 
≥ 
2 
cm
 
in
 d
ia
m
et
er
. 
66
 p
ar
tic
ip
an
ts
 (6
6 
sB
CC
), 
m
ed
ia
n 
tu
m
or
 si
ze
 4
.3
 cm
2  
(r
an
ge
 2
.0
-4
8.
0)
. O
th
er
 p
at
ie
nt
 
an
d 
tu
m
or
 ch
ar
ac
te
ris
tic
s n
ot
 
sp
ec
ifi
ed
 fo
r s
BC
C 
5x
/w
ee
k 
fo
r 6
 w
ee
ks
 
11
 (1
6.
7%
) a
t 1
2 
w
ee
ks
 p
os
t t
re
at
m
en
t, 
co
m
bi
ne
d 
cl
in
ic
al
/h
ist
ol
og
ic
al
 
ve
rif
ic
at
io
n.
 
N
ot
 p
er
fo
rm
ed
 
M
ar
ks
 
20
04
22
 
A
us
tr
al
ia
. 
Ph
as
e 2
, 
pr
os
pe
ct
iv
e, 
m
ul
tic
en
te
r, 
ra
nd
om
iz
ed
, 
do
ub
le
-b
lin
d 
stu
dy
. 
RC
T 
Q
ua
lit
y 
sc
or
e 5
 
Fu
nd
in
g:
 y
es
. 
N
ot
 m
en
tio
ne
d 
67
 p
ar
tic
ip
an
ts
 (2
08
 sB
CC
). 
-T
1:
 9
7 
sB
CC
, l
oc
al
iz
at
io
n:
 5
2%
 
tr
un
k,
 4
7%
 ex
tr
em
iti
es
, 1
%
 
ne
ck
. 
-T
2:
 1
11
 sB
CC
, l
oc
al
iz
at
io
n:
 
55
%
 tr
un
k,
 4
2%
 ex
tr
em
iti
es
, 3
%
 
ne
ck
. 
Bo
th
 tr
ea
tm
en
ts
 d
ur
in
g 
6 
w
ee
ks
. 
-T
1:
 7
x/
w
ee
k 
-T
2:
 5
x/
w
ee
k 
 
-T
1:
 2
2 
(2
2.
7%
) 
-T
2:
 2
5 
(2
2.
5%
) 
A
t 1
2 
w
ee
ks
 p
os
t 
tr
ea
tm
en
t, 
co
m
bi
ne
d 
cl
in
ic
al
/h
ist
ol
og
ic
al
 
ve
rif
ic
at
io
n.
 
N
ot
 p
er
fo
rm
ed
 
 
St
ud
y 
Se
tti
ng
 
Q
ua
lit
y 
as
se
ss
m
en
t 
In
cl
us
io
n 
an
d 
ex
cl
us
io
n 
cr
ite
ria
 P
ar
tic
ip
an
ts 
an
d 
tu
m
or
 
ch
ar
ac
te
ris
tic
s 
Tr
ea
tm
en
t p
ro
to
co
l 
Re
sid
ue
 
Cu
m
ul
at
iv
e r
ec
ur
re
nc
e a
t l
on
g-
te
rm
 
fo
llo
w
-u
p 
 
G
ei
ss
e 
20
04
27
 
U
SA
. 
Pr
os
pe
ct
iv
e, 
m
ul
tic
en
te
r, 
ra
nd
om
iz
ed
, 
ve
hi
cl
e-
co
nt
ro
lle
d,
 
do
ub
le
 
-b
lin
d 
st
ud
y.
 
RC
T 
Q
ua
lit
y 
sc
or
e 7
 
Fu
nd
in
g:
 
ye
s. 
 
St
an
da
rd
. I
n:
 
sB
CC
 0
.5
-4
.0
 
cm
2 , 
di
am
et
er
 
0.
4-
2.
0 
cm
. 
  
72
4 
pa
rt
ic
ip
an
ts 
(7
24
 sB
CC
), 
ov
er
al
l t
um
or
 si
ze
 0
.2
-5
.8
 cm
2 . 
-T
1:
 1
85
 p
ar
tic
ip
an
ts,
 1
16
 M
 
an
d 
69
 F
, 
m
ed
ia
n 
ag
e 5
9 
yr
s (
31
-8
9)
. 
Lo
ca
liz
at
io
n:
 
49
%
 tr
un
k,
 4
6%
 ex
tr
em
iti
es
, 5
%
 
ot
he
r. 
-T
2:
 1
79
 p
ar
tic
ip
an
ts,
 1
06
 M
 
an
d 
73
 F
, m
ed
ia
n 
ag
e 5
8 
yr
s 
(2
9-
88
). 
Lo
ca
liz
at
io
n:
 4
9%
 
tr
un
k,
 4
4%
 ex
tr
em
iti
es
, 7
%
 
ot
he
r. 
-T
3:
17
9 
pa
rt
ic
ip
an
ts,
 1
20
 M
 
an
d 
59
 F
, m
ed
ia
n 
ag
e 6
1 
yr
s 
(3
5-
85
). 
Lo
ca
liz
at
io
n:
 5
0%
 
tr
un
k,
 4
5%
 ex
tr
em
iti
es
, 5
%
 
ot
he
r. 
-T
4:
 1
81
 p
ar
tic
ip
an
ts,
 1
03
 M
 
an
d 
78
 F
, m
ed
ia
n 
ag
e 5
8 
yr
s 
(3
2-
84
). 
Lo
ca
liz
at
io
n:
 4
3%
 
tr
un
k,
 5
2%
 ex
tr
em
iti
es
, 5
%
 
ot
he
r. 
A
ll 
tr
ea
tm
en
ts
 d
ur
in
g 
6 
w
ee
ks
. 
-T
1:
 5
x/
w
ee
k 
-T
2:
 7
x/
w
ee
k 
-T
3:
 v
eh
ic
le
 5
x/
w
ee
k 
-T
4:
 v
eh
ic
le
 7
x/
w
ee
k 
 
-T
1:
 3
3 
(1
7.
8%
) 
-T
2:
 3
7 
(2
0.
7%
) 
-T
3 
+T
4:
 3
49
 (9
6.
9%
) 
A
t 1
2 
w
ee
ks
 
po
st
 tr
ea
tm
en
t, 
co
m
bi
ne
d 
cl
in
ic
al
/h
ist
ol
og
ic
al
 
ve
rif
ic
at
io
n.
 
N
ot
 p
er
fo
rm
ed
 
    
3.1
St
ud
y 
Se
tti
ng
 
Q
ua
lit
y 
as
se
ss
m
en
t 
In
cl
us
io
n 
an
d 
ex
cl
us
io
n 
cr
ite
ria
 P
ar
tic
ip
an
ts 
an
d 
tu
m
or
 
ch
ar
ac
te
ris
tic
s 
Tr
ea
tm
en
t p
ro
to
co
l 
Re
sid
ue
 
Cu
m
ul
at
iv
e r
ec
ur
re
nc
e a
t l
on
g-
te
rm
 
fo
llo
w
-u
p 
 
St
er
ry
 
20
02
24
 
Eu
ro
pe
. 
Pr
os
pe
ct
iv
e, 
m
ul
tic
en
te
r, 
ra
nd
om
iz
ed
, 
op
en
-la
be
l 
stu
dy
. 
RC
T 
Q
ua
lit
y 
sc
or
e 7
 
Fu
nd
in
g:
 y
es
. 
    
St
an
da
rd
. I
n:
 
sB
CC
 0
.5
-2
.0
 
cm
2 . 
  
93
 p
ar
tic
ip
an
ts
 (9
3 
sB
CC
). 
-T
1:
 2
3 
pa
rt
ic
ip
an
ts
, 1
5 
M
 an
d 
8 
F,
 m
ea
n 
ag
e 6
9 
yr
s. 
Lo
ca
liz
at
io
n:
 7
0%
 tr
un
k,
 3
0%
 
ex
tr
em
iti
es
. M
ed
ia
n 
tu
m
or
 si
ze
 
1.
2 
cm
2 . 
-T
2:
 2
5 
pa
rt
ic
ip
an
ts
, 1
4 
M
 an
d 
11
 F
, m
ea
n 
ag
e 6
1 
yr
s. 
Lo
ca
liz
at
io
n:
 6
8%
 tr
un
k,
 3
2%
 
ex
tr
em
iti
es
. M
ed
ia
n 
tu
m
or
 si
ze
 
1.
0 
cm
2 . 
-T
3:
 2
1 
pa
rt
ic
ip
an
ts
, 1
4 
M
 an
d 
7 
F,
 m
ea
n 
ag
e 6
3 
yr
s. 
Lo
ca
liz
at
io
n:
 6
7%
 tr
un
k,
 2
9%
 
ex
tr
em
iti
es
, 5
%
 o
th
er
. M
ed
ia
n 
tu
m
or
 si
ze
 1
.5
 cm
2 . 
-T
4:
 2
4 
pa
rt
ic
ip
an
ts
, 1
6 
M
 an
d 
8 
F,
 m
ea
n 
ag
e 6
9 
yr
s. 
Lo
ca
liz
at
io
n:
 5
8%
 tr
un
k,
 2
9%
 
ex
tr
em
iti
es
, 1
3%
 o
th
er
. M
ed
ia
n 
tu
m
or
 si
ze
 1
.0
 cm
2 . 
A
ll 
tr
ea
tm
en
ts
 d
ur
in
g 
6 
w
ee
ks
. 
-T
1:
 3
x/
w
ee
k 
w
ith
 o
cc
lu
sio
n 
-T
2:
 3
x/
w
ee
k 
w
ith
ou
t o
cc
lu
sio
n 
-T
3:
 2
x/
w
ee
k 
w
ith
 o
cc
lu
sio
n 
-T
4:
 2
x/
w
ee
k 
w
ith
ou
t o
cc
lu
sio
n 
    
-T
1:
 3
 (1
3.
0%
) 
-T
2:
 6
 (2
4.
0%
) 
-T
3:
 1
2 
(5
7.
1%
) 
-T
4:
 1
2 
(5
0.
0%
) 
A
t 6
 w
ee
ks
 p
os
t 
tr
ea
tm
en
t, 
co
m
bi
ne
d 
cl
in
ic
al
/h
ist
ol
og
ic
al
 
ve
rif
ic
at
io
n.
 
   
N
ot
 p
er
fo
rm
ed
 
 
St
ud
y 
Se
tti
ng
 
Q
ua
lit
y 
as
se
ss
m
en
t 
In
cl
us
io
n 
an
d 
ex
cl
us
io
n 
cr
ite
ria
 P
ar
tic
ip
an
ts 
an
d 
tu
m
or
 
ch
ar
ac
te
ris
tic
s 
Tr
ea
tm
en
t p
ro
to
co
l 
Re
sid
ue
 
Cu
m
ul
at
iv
e r
ec
ur
re
nc
e a
t l
on
g-
te
rm
 
fo
llo
w
-u
p 
 
G
ei
ss
e 
20
02
28
 
U
SA
. P
ha
se
 2
, 
pr
os
pe
ct
iv
e, 
m
ul
tic
en
te
r, 
ra
nd
om
iz
ed
, 
ve
hi
cl
e-
co
nt
ro
lle
d,
 
do
ub
le
-b
lin
d 
stu
dy
. 
RC
T 
Q
ua
lit
y 
sc
or
e 7
 
Fu
nd
in
g:
 y
es
. 
 
St
an
da
rd
. I
n:
 
sB
CC
 0
.5
-2
.0
 
cm
2 . 
12
8 
pa
rt
ic
ip
an
ts 
(1
28
 sB
CC
). 
-T
1:
 1
0 
pa
rt
ic
ip
an
ts
, 8
 M
 an
d 
2 
F,
 m
ea
n 
ag
e 5
9 
yr
s (
ra
ng
e 5
1-
85
). 
Lo
ca
liz
at
io
n:
 4
 tr
un
k,
 5
 
ex
tr
em
iti
es
, 1
 h
ea
d/
ne
ck
. 
M
ed
ia
n 
tu
m
or
 si
ze
 1
.0
 cm
2 . 
-T
2:
 3
1 
pa
rt
ic
ip
an
ts
, 2
0 
M
 an
d 
11
 F
, m
ea
n 
ag
e 5
6 
yr
s (
ra
ng
e 
35
-8
5)
. L
oc
al
iz
at
io
n:
 1
8 
tr
un
k,
 
11
 ex
tr
em
iti
es
, 2
 h
ea
d/
ne
ck
. 
M
ed
ia
n 
tu
m
or
 si
ze
 0
.7
 cm
2 . 
-T
3:
 2
6 
pa
rt
ic
ip
an
ts
, 1
8 
M
 an
d 
8 
F,
 m
ea
n 
ag
e 5
5 
yr
s (
ra
ng
e 3
8-
84
). 
Lo
ca
liz
at
io
n:
 1
6 
tr
un
k,
 9
 
ex
tr
em
iti
es
, 1
 h
ea
d/
ne
ck
. 
M
ed
ia
n 
tu
m
or
 si
ze
 0
.6
 cm
2 . 
-T
4:
 2
9 
pa
rt
ic
ip
an
ts
, 1
6 
M
 an
d 
13
 F
, m
ea
n 
ag
e 6
2 
yr
s (
ra
ng
e 
36
-8
5)
. L
oc
al
iz
at
io
n:
 1
9 
tr
un
k,
 
9 
ex
tr
em
iti
es
, 1
 h
ea
d/
ne
ck
. 
M
ed
ia
n 
tu
m
or
 si
ze
 1
.0
 cm
2 . 
-T
5:
 3
2 
pa
rt
ic
ip
an
ts
, 2
0 
M
 an
d 
12
 F
, m
ea
n 
ag
e 5
8 
yr
s (
ra
ng
e 
38
-8
5)
. L
oc
al
iz
at
io
n:
 1
5 
tr
un
k,
 
14
 ex
tr
em
iti
es
, 3
 h
ea
d/
ne
ck
. 
M
ed
ia
n 
tu
m
or
 si
ze
 0
.8
 cm
2 . 
A
ll 
tr
ea
tm
en
ts
 d
ur
in
g 
12
 w
ee
ks
. 
-T
1:
 tw
ic
e d
ai
ly
 
-T
2:
 o
nc
e d
ai
ly
 
-T
3:
 5
x/
w
ee
k 
-T
4:
 3
x/
w
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 p
ro
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os
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ra
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 p
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, m
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liz
at
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 p
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, m
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, m
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, m
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, m
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 d
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e d
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e d
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e d
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 p
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 p
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ra
nd
om
iz
ed
, 
op
en
 la
be
l 
stu
dy
.  
RC
T 
Q
ua
lit
y 
sc
or
e 4
 
Fu
nd
in
g:
 y
es
. 
 
St
an
da
rd
. I
n:
 
sB
CC
 d
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 p
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 p
ro
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, m
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ra
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at
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 d
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L 
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 m
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ap
pl
ic
at
io
n 
fo
r 3
 h
ou
rs
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at
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 C
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 d
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s r
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ra
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 p
os
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r c
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t p
ro
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e r
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t l
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os
pe
ct
iv
e, 
m
ul
tic
en
te
r, 
ra
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 d
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ge
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liz
at
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ck
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 d
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A
L 
20
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m
 m
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. 
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um
in
at
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e c
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e r
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s r
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ra
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 p
os
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 m
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 b
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 d
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 d
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 m
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ra
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at
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 m
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ra
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at
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 m
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at
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 C
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 p
os
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in
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 m
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 m
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 m
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t p
ro
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e r
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t l
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s. 
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m
 
stu
dy
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 n
o.
 
 
St
an
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rd
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 p
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an
ts 
(8
6 
sB
CC
), 
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M
 
an
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F,
 m
ea
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e 6
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ra
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-8
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. L
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iz
at
io
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4%
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ad
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m
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m
 m
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at
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. 
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at
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ho
ur
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 d
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 p
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w
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ra
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r c
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os
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 p
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at
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 p
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at
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l p
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 m
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at
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 m
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s p
os
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f m
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 m
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t l
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os
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 m
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 m
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ra
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at
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e r
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 m
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A
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s. 
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at
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 p
os
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m
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w
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os
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m
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. 
 
A
LA
 2
0%
, a
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s. 
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at
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 p
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w
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 m
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os
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 p
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m
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 d
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m
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.3
-4
.5
 
cm
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m
 m
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Data are given as number of sBCC and percentages. 
Definition of abbreviations: RCT, randomized controlled trial; sBCC, superficial basal cell carcinoma; M, 
male; F, female; Y, year; T, treatment arm; DMSO, dimetylsulfoxide; EDTA, ethylendiaminetetraacetic acid; 
ITT, intention to treat. 
Standard: inclusion when ≥ 18 yrs, primary histologically confirmed sBCC, not previously treated. Exclusion: 
anogenital area, areas within 1 cm of H-zone, pigmented or morpheaform sBCC, dermatologic conditions that 
interfere with treatment, genetic skin disorders, immunosuppressive therapy, pregnant or breastfeeding women. 
† In number of patients. ‡ Only number of sBCC that actually finished treatment available, not how many 
were included initially. * Not one single standardized treatment protocol. 
 
In most studies, analyses were performed on tumor level. One study on treatment with 
imiquimod reported results from analysis solely on a patient level.21 Ezughah et al. and 
Wennberg et al. calculated residue probability by dividing the number of residues by the 
number of patients who actually finished treatment instead of the number who were 
included at the start of the study.21,52 In all studies, response to treatment was verified by 
clinical verification. An additional histopathological verification was performed in 18 of 34 
studies that reported residue probabilities, of which most were studies on imiquimod.22-
29,37,38,41,42,45-47,50-52 From the 23 studies that reported recurrence probabilities, two studies 
performed an additional histopathological verification of the diagnosis.33,44  
Probability of complete response after treatment with imiquimod or 
photodynamic therapy 
Probabilities of complete response after treatment with imiquimod could be derived 
from 15 studies with a total of 1088 sBCC.21-24,27-29,35-37,40,42,44-46 From six dose-finding 
studies, data were used from only one study arm.21-24,27,28 The preferred arm had a dosing 
regimen most similar to the widely used protocol of imiquimod 5 days a week during 6 
weeks. Schedules differed from three times a week to once daily every day. Treatment 
duration ranged from 4 to 12 weeks and the first control visit to evaluate response to 
treatment was scheduled at 6 and 19 weeks post treatment. Fig. 2a shows a forest plot 
with proportions of patients with complete response and 95% confidence interval (CI) 
for individual imiquimod studies. The pooled estimate was 86.2% (95% CI 82-90%), 
with large heterogeneity (I2 index = 72% and p<0.0001).  
 Probabilities of complete response after treatment with PDT could be derived from 
13 studies with a total of 934 sBCC.11,30-32,34,45,47-49,51-54 From three illumination dose-
finding studies, data were used from only one study arm.47,48,52 The arm most similar to 
the current regimen was preferred; 100 J/cm2, one time 20% aminolevulinic acid (ALA)-
PDT illumination or one cycle (on day 1 and 8) 20% MAL-PDT illumination. Despite 
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this aim, the frequency of illumination ranged from one to four times. Two studies 
compared different light sources and light-sensitive agents.32,34 From each study both 
study arms were used for analysis. 
 
a) 
 
b) 
 
Fig. 2 Forest plots of results from (a) imiquimod and (b) photodynamic therapy studies on complete response
probability at first control visit. 
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The majority of PDT studies used 20% ALA as a light-sensitive agent. The first control 
visit to evaluate response to treatment was scheduled 4 to 26 weeks post treatment. Fig. 
2b shows a forest plot with proportions of sBCC with complete response and 95% CI for 
individual PDT studies. The pooled estimate for the proportion of sBCC with complete 
response to treatment was 79.0% (95% CI 71-87%) with large heterogeneity (I2 index = 
94% and p<0.0001). The difference of 7.2% in pooled estimates of complete response 
probability between imiquimod and PDT did not reach statistical significance 
(p=0.171). This pooled estimate included the complete response probabilities of Szeim-
ies et al. (87.4%) and Basset-Seguin et al. (87.7%) after one or two cycles of MAL-
PDT.30,31 An analysis which excluded patients who received two cycles in these studies 
resulted in a pooled estimate of 75.6%, which was not significantly different from the 
estimate of 86.2% for imiquimod (p=0.057). 
Cumulative probabilities of recurrence and tumor-free survival 
The cumulative probabilities of recurrence and tumor-free survival that could be de-
rived from the studies for one, two and five years post treatment are given in Table 3. 
Fig. 3a and 3b show forest plots with proportions of patients with tumor-free survival 
and 95% CI for individual imiquimod and PDT studies, respectively. The pooled esti-
mate at one year after imiquimod treatment was 87.3% (95% CI 84-91%) without signif-
icant heterogeneity (I2 index = 22% and p=0.263). PDT studies showed a lower pooled 
estimate of 84.0% (95% CI 78-90%) with large heterogeneity (I2 = 73% and p=0.005). 
 The difference of 3.3% in pooled estimates of tumor-free survival at one year be-
tween imiquimod and PDT was not statistically significant (p=0.469). 
Tumor-free survival after other treatments 
There are not enough studies on pulse dye laser, 5-FU, cryotherapy, surgical excision 
and PEP005 in the treatment of sBCC to perform a meta-analysis (Table 
2).25,26,30,31,33,38,39,41,50 Tumor-free survival could be calculated for three individual studies 
(Table 3).30,31,39 The study of Campolmi et al. on treatment with pulsed dye laser resulted 
in 79% tumor-free survival after 1 year.39 Patients treated with one or two double freeze-
thaw cycles of cryotherapy in Basset-Seguin’s study showed a tumor-free survival of 67% 
at 5 years.30 Surgical excision by Szeimies et al. demonstrated a high tumor-free survival 
with 89% (117/135) at 1 year.31 However, in this study 17 of the included sBCC received 
no surgical excision because of patients’ request. Tumor-free survival at one year was 
99% (117/118) for patients actually receiving surgical excision. 
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a) 
 
b) 
 
Fig. 3 Forest plots of results from (a) imiquimod and (b) photodynamic therapy studies on tumor-free surviv-
al at one year. 
Publication bias 
Egger’s test shows that for PDT and imiquimod studies the intercepts were -5.94 
(p=0.012) and -1.92 (p=0.082), respectively. This deviation of the intercept from zero 
indicates that smaller studies showed higher success rates than larger studies and thus 
publication bias is likely to be present.  
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Subgroup analyses 
Subgroup analyses were performed to identify sources of heterogeneity in study results. 
Results are presented in Tables 4 and 5 for imiquimod and PDT studies, respectively. 
For imiquimod studies, the pooled estimates for complete response from randomized 
studies were lower than for non-randomized studies (79.8% vs. 90.7%). For PDT stud-
ies, pooled estimates differed substantially between subgroups of studies with lower and 
higher scores for methodological quality (92.0 % vs. 72.5%) However, these study char-
acteristics do not fully explain the observed heterogeneity between study results, because 
within subgroups of studies the I2-index remained high. 
Sensitivity analyses 
The robustness of the results of this review was evaluated by performing sensitivity 
analyses. 
 With respect to a complete response at the first control visit after treatment, results 
of all imiquimod (15) and PDT (13) study arms were pooled. A first sensitivity analysis 
was performed by including only patients who actually finished treatment. Using these 
percentages, the pooled estimate for complete response of 1065 sBCC treated with 
imiquimod therapy was higher, with 87.6% (95% CI 84-91%, I2 = 67%, p<0.0001) instead 
of 86.2%. A higher pooled estimate of 82.3% (95% CI 75-90%) instead of 79.0% was also 
found for the patients with 914 sBCC, who actually finished treatment with PDT (I2 = 
94%, p<0.0001). 
 Secondly, we pooled the results of five imiquimod studies with a dosing regimen of 5 
days per week during 6 weeks.22,27,40,42,46 A similar pooled estimate for proportion with a 
complete response of 85.8% (95% CI 79-93%, I2 = 82%, p<0.0001) was found compared 
with 86.2% (95% CI 82-90%) for all imiquimod studies. 
 In the third sensitivity analysis, we excluded the PDT study by Haller et al. wherein 
patients were illuminated not once but twice with ALA-PDT.49 The pooled estimate for 
proportion with complete response decreased from 79.0% to 77.3% and for the propor-
tion with tumor-free survival from 84.0% to 81.1%. In that case, the difference of 6.4% 
in pooled estimates of tumor-free survival at one year between imiquimod and PDT was 
statistically significant (p=0.033). 
 Fourth, MAL-PDT studies by Szeimies et al. and Basset-Seguin et al. re-treated pa-
tients who at 3 months had not responded to treatment with one PDT cycle (day 1 and 
8).30,31 When including only results of BCC treated with one PDT cycle in these two 
studies the complete response probabilities were 70.3% (90/128) and 61.4% (70/114) in 
Szeimies et al. and Basset-Seguin et al., respectively.30,31 The pooled estimate of PDT 
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complete response probability decreased from 79.0% to 75.6%, which was not signifi-
cantly lower than that for imiquimod (p=0.057). Restriction of the analysis to PDT stud-
ies with exactly one year follow-up resulted in a decrease of the pooled estimate of tu-
mor-free survival from 84.0% to 76.2% (95% CI 62-90%, I2 = 95%). 
 
Table 4. Imiquimod studies. Pooled estimates of proportion with complete response (with 95% confidence 
intervals) in subgroups of studies according to study and tumor characteristics. 
Imiquimod (n=15 studies) 
RCT Yes No 
 79.8 (76.2 – 83.3), I2 0.0% 90.7 (86.8 – 94.6), I2 58.1% 
 n=7 21-24,27-29 n=8 35-37,40,42,44-46 
Publication year ≤ 2003 > 2003 
 82.5 (75.0 – 89.9), I2 0.0% 86.9 (82.5 – 91.2), I2 75.9% 
 n=3 23,24,28 n=12 21,22,27,29,35-37,40,42,44-46 
Funding Yes No 
 85.6 (80.9 – 90.8), I2 74.8% 88.0 (79.5 – 96.6), I2 67.6% 
 n=12 21-24,27-29,35,40,42,44,46 n=3 36,37,45 
Sample size sBCC ≤ 30 > 30 
 86.7 (76.0 – 97.4), I2 66.0% 85.8 (81.4 – 90.2), I2 76.3% 
 n=5 21,24,28,42,44 n=10 22,23,27,29,35-37,40,45,46 
tumor diameter (inclusion 
criteria) 
≤ 2 cm > 2 cm 
87.4 (83.1 – 91.6), I2 70.9% 80.6 (75.8 – 85.4), I2 0.0% 
n=12 22-24,28,29,35-37,40,42,44,45  n=3 21,27,46 
Fixed treatment protocol Yes No 
86.6 (82.4 – 90.7), I2 74.9% 82.3 (68.4 – 96.2), I2 47.0% 
 n=13 21-24,27-29,35,37,40,42,45,46 n=2 36,44 
Treatment duration ≤ 6 weeks > 6 weeks 
 86.8 (82.2 – 91.4), I2 77.3% 84.1 (75.5 – 92.7), I2 58.2% 
 n=10 21-23,27,29,35,37,40,42,46 n=5 24,28,36,44,45 
Histological residue 
verification  
Yes No 
85.3 (80.2 – 90.3), I2 70.4% 88.7 (83.1 – 94.4), I2 60.9% 
n=10 22-24,27-29,37,42,45,46 n=5 21,35,36,40,44 
Quality score ≤ 5 > 5 
87.2 (81.0 – 93.4), I2 69.3% 85.0 (79.3– 90.7), I2 78.0% 
n= 21,22,36,37,42,44-46 n=7 23,24,27-29,35,40 
RCT, randomized controlled trial; I2, index for heterogeneity; sBCC, superficial basal cell carcinoma. Data are 
given as pooled estimates of proportion with complete response (95% confidence interval). 
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Table 5. Photodynamic therapy studies. Pooled estimates of proportion with complete response (with 95% 
confidence intervals) in subgroups of studies according to study and tumor characteristics. 
PDT (n=13 studies) 
RCT Yes No 
 80.3 (70.8 – 89.8), I2 89.9% 79.4 (65.8 – 93.0), I2 95.4% 
 n=4 30-32,34 n=9 45,47-49,51-54 
Publication year ≤ 2003 > 2003 
 81.5 (69.0 – 94.1), I2 95.9% 77.2(66.0 – 88.4), I2 87.5% 
 n=8 34,47-49,51-54 n=5 11,30-32,45 
Funding Yes No 
 87.6 (83.5 – 91.7), I2 0.0% 78.1 (66.8 – 89.8), I2 954% 
 n=2 30,31 n=11 11,32,34,45,47-49,51-54 
Sample size sBCC ≤ 30 > 30 
 74.9 (50.5 – 99.3), I2 56.4% 83.2 (75.9 – 90.4), I2 94.2% 
 n=4 45,49,53,54 n=9 11,30-32,34,47,48,51,52 
Fixed treatment protocol Yes No 
80.1 (70.7 – 89.5) - 
 n=12 30-32,34,45,47-49,51-54 n=1 11 
Photosensitizer 
 
Aminolaevulinic acid Methylaminolevulinate 
79.0 (67.7 – 90.4), I2 95.5% 78.8 (67.6 – 89.9), I2 80.6% 
n=10 11,32,34,47-49,51-54 n=4 30-32,45 
Light source Standard Special 
 84.8 (75.8 – 93.7), I2 90.5% 72.3 (51.7 – 92.9), I2 97.2% 
 n=8 11,30-32,45,49,51,54 n=5 34,47,48,52,53 
Histological residue 
verification  
Yes No 
81.7 (72.2 – 91.3), I2 26.2% 80.1 (69.8 – 90.4), I2 95.8% 
n=3 45,47,51 n=10 11,30-32,34,48,49,52-54 
Quality score ≤ 4 > 4 
92.0 (84.2 – 99.8), I2 77.7% 72.5 (59.4 – 85.6), I2 95.9% 
n=5 30,47,49,53,54 n=8 11,31,32,34,45,48,51,52 
RCT, randomized controlled trial; I2, index for heterogeneity; sBCC, superficial basal cell carcinoma. Data are 
given as pooled estimates of proportion with complete response (95% confidence interval). 
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Discussion 
This review of the literature on the treatment of sBCC in RCTs and non-RCTs provides 
evidence that treatment with imiquimod or PDT results in nearly equal tumor-free 
survival rates one year after treatment. However, this review reveals that RCTs with 
direct comparisons of imiquimod with PDT are totally lacking and that the number of 
studies with follow-up longer than one year after treatment is very limited. Studies re-
porting on the effect of treatment after pulsed dye laser, 5-FU, cryotherapy, surgical 
excision and PEP005 were scarce. Therefore, reliable evaluation of the results of these 
treatment modalities was not possible. 
 The extensive search of the literature revealed that evidence on the comparative 
effectiveness of treatment modalities of sBCC is not widely available. We experienced 
various difficulties with inclusion of possible relevant studies in this systematic review. 
Many studies used heterogeneous study populations, including patients with genetic 
skin disorders, different BCC subtypes, both histologically and clinically proven sBCC 
prior to treatment, and both primary and recurrent sBCC, whereas subgroup analyses to 
provide results for separate groups were not performed. Therefore, we had to exclude 
these studies. Most of the studies included in the review had limited follow-up. Long-
term follow-up is essential to predict the probability of treatment success after many 
years. Although most recurrences occur within the first two years after treatment, 
treatment failure is also reported after a longer follow-up period.30,31,35 
 This review reveals a lack of head-to-head comparison RCTs, in which the effects of 
treatment with imiquimod and PDT are directly compared.57 Such RCTs provide the 
most rigid and valid evidence on the relative effects of different interventions. The re-
sults from the present review are based on indirect comparison of both treatment mo-
dalities and can be biased by differences in study population and design between 
imiquimod and PDT studies. The literature search points to a need for well-designed 
RCTs comparing one or more treatment modalities with long-term follow-up. Such 
trials guarantee comparability of patients who are assigned to different treatments and 
allow for more valid conclusions on the relative effectiveness of competing treatment 
options. 
 A common problem in meta-analysis is the large heterogeneity of study results. The 
subgroup analyses that were performed to identify the sources of the large variation in 
success rates suggest that several study characteristics may have led to overly optimistic 
estimates. An interesting finding in this respect is that imiquimod studies using histo-
logical verification of tumor clearance reported a higher failure rate than those with only 
a clinical verification.40,42,58 This discrepancy was not found in PDT studies. The most 
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accurate way to determine tumor clearance is complete excision, as in a single biopsy 
sample error is still possible. However, long-term follow-up and evaluation of non-
invasive treatment effects are impossible after surgical excision. In daily practice, clinical 
examination will reveal residues and recurrences as sBCC will eventually develop into a 
visible tumor on long-term follow-up. 
 An interesting finding of this systematic review is that the effectiveness of PDT may 
strongly depend on the number of cycles used. When repetitive PDT treatments are 
used, the pooled estimate increased for both PDT complete tumor response (75.6% to 
79.0%) and tumor-free survival (76.2% to 84.0%). Therefore, PDT illumination might 
result in optimizing clinical outcome of treatments by fractionating ALA-PDT or 
providing two cycles of MAL-PDT.30,31,43,48,49,59 Disadvantages of more frequent illumina-
tions will be higher costs and more frequent treatment appointments. As not all patients 
are capable or willing to visit the hospital multiple times for PDT treatment, and other 
patients are not able or willing to apply imiquimod cream for six weeks, treatment 
choice will also depend on patient preferences and tumor characteristics. 
 Both the subgroup analyses and the Egger’s test indicate that studies with smaller 
sample size showed higher success rates than studies with a larger sample size. This 
finding is suggestive of publication bias. This is a widespread problem and arises from 
the fact that small studies showing favorable results are more likely to be published and 
submitted for publication than small studies showing less favorable results. The pres-
ence of publication bias may imply that the actual benefit from PDT and imiquimod is 
lower than suggested by the studies included in this review.  
 In conclusion, treatment of sBCC with imiquimod or PDT results in similar long-
term tumor-free survival probabilities. Treatment results after PDT might be optimized 
by repetitive treatments. Better designed large RCTs with a head-to-head comparison of 
current treatment modalities for sBCC with long-term follow-up are needed to establish 
the relative effectiveness of the various therapeutic options. Information from such trials 
enable more evidence-based recommendations in treatment of sBCC in the future. 
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Abstract 
 Background: We previously assessed in a randomized controlled trial whether the 
effectiveness of imiquimod and fluorouracil cream were non-inferior to methylami-
nolevulinate (MAL) photodynamic therapy (PDT) in patients with superficial basal cell 
carcinoma (sBCC). The results indicated that imiquimod was superior and fluorouracil 
not inferior to MAL-PDT in terms of one year tumor-free survival. 
 Objectives: Because part of the treatment failure occurs after more than one year 
post treatment, the tumor-free survival of imiquimod and fluorouracil versus MAL-
PDT was evaluated at three years post treatment. 
 Methods: Patients who had participated in a single-blinded, non-inferiority, multi-
center randomized controlled trial and had been tumor-free at one year post treatment, 
were approached for evaluation of treatment success after three years follow-up. Partici-
pants had been randomly assigned to MAL-PDT (two sessions with one week interval), 
imiquimod (once daily, five times a week for a period of 6 weeks), or fluorouracil (twice 
daily for 4 weeks). A research physician who was blinded to the assigned therapy clini-
cally assessed the treated lesion for signs of treatment failure in patients who had been 
tumor-free at one year post treatment. Clinical treatment failures were histologically 
confirmed by a 3 mm punch biopsy. Cox proportional hazard models were used for 
calculation of hazard ratios with 95% confidence intervals. We used a pre-specified non-
inferiority margin of 10% and performed an intention-to-treat as wells as per-protocol 
analysis. Additional subgroup analyses were performed to explore whether the relative 
treatment effect between therapies is consistent across subgroups defined by gender, 
age, tumor location, and tumor size. The trial is registered as ISRCTN 79701845. 
 Results: 601 patients were randomized, of which 442 were tumor-free at one year 
follow-up. Three years post treatment, 66 of 196 patients treated with MAL-PDT, 34 of 
189 treated with imiquimod and 50 of 198 treated with fluorouracil had a treatment 
failure. The probability of tumor-free survival at three years post treatment was 58.0% 
for MAL-PDT (95% CI 47.8-66.9), 79.7% for imiquimod (95% CI 71.6-85.7), and 68.2% 
for fluorouracil (95% CI 58.1-76.3). The hazard ratio (HR) for treatment failure compar-
ing imiquimod with MAL-PDT was 0.50 (95% CI 0.33-0.76, p=0.001). Comparison of 
fluorouracil with MAL-PDT resulted in a HR of 0.73 (95% CI 0.51-1.05, p=0.092), and 
comparison of fluorouracil with imiquimod in a HR of 0.68 (95% CI 0.44-1.06, 
p=0.091). Subgroup analysis showed a higher probability of treatment success for 
imiquimod versus MAL-PDT in all subgroups with an exception of elderly patients with 
a sBCC on the lower extremities. In this latter subgroup, the risk difference in tumor-
free survival was 57.6% in favor of MAL-PDT. 
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 Conclusions: Imiquimod is superior to MAL-PDT in treatment of sBCC. Fluor-
ouracil is not-inferior to MAL-PDT but does not compare favorably with imiquimod. 
Therefore, imiquimod should be considered as first choice non-invasive therapy for 
most primary sBCC. MAL-PDT might be preferred in elderly with sBCC on the lower 
extremities. 
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Introduction 
Basal cell carcinoma (BCC) is the most common type of skin cancer and its increasing 
incidence puts a large burden on health-care services worldwide.1-3 BCC can be catego-
rized into three main histological subtypes: superficial, nodular and aggressive.4 While 
the majority of subtypes require surgery, superficial BCC (sBCC) can also be treated 
topically with alternatives such as photodynamic therapy (PDT), imiquimod cream, 
fluorouracil cream, cryosurgery or electrodessication and curettage.5 The main ad-
vantages of non-invasive therapies like PDT, imiquimod and fluorouracil are a good 
cosmetic outcome, preservation of surrounding tissue and potential for home applica-
tion of both creams.6 However, to date there is a lack of randomized controlled trials 
with a long-term follow-up that compare effectiveness of non-invasive treatment mo-
dalities.7 Therefore, in international BCC guidelines, no consensus has been reached on 
the first choice of non-invasive therapy for sBCC.5 
 To assess the effectiveness of imiquimod and fluorouracil versus methylaminolevul-
inate photodynamic therapy (MAL-PDT) for treatment of sBCC, a randomized con-
trolled trial was conducted. The one year follow-up results of this non-inferiority study 
showed that imiquimod was superior and fluorouracil not inferior to MAL-PDT.8 As 
long-term follow-up studies are lacking and part of sBCC may recur between one and 
three years’ post treatment, a longer follow-up is required to evaluate the sustained 
treatment success.7,9,10 We now report the three year follow-up results of this study. In 
addition, we have performed exploratory (not driven by prior hypotheses) subgroup 
analysis within this non-inferiority trial at three years follow-up. 
Materials and methods 
Study design 
This study compared long-term results between treatment with MAL-PDT and 
imiquimod or fluorouracil cream in patients with sBCC who participated in a non-
inferiority, randomized controlled trial that was conducted in seven hospitals in the 
southern part of The Netherlands.8 Patients were recruited at the departments of Der-
matology between March 2008 and August 2010. Eligible patients had a histologically 
proven, primary sBCC. 
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Randomization and masking 
Participants were randomly assigned to either MAL-PDT, imiquimod, or fluorouracil in 
a 1:1:1 ratio. Randomization was stratified by age (≤ 60 years vs. > 60 years) and tumor 
location (head/neck vs. other). The research physician who assessed the treated lesions 
for signs of treatment failure was blinded to the assigned treatment modality and was 
not involved in the treatment. Patients and treating physicians were not masked for the 
assigned therapy. Statistical analysis was performed by two investigators not blinded to 
allocation. 
Procedures 
Patients randomized to MAL-PDT were treated with one cycle of two treatments with 
one week interval. Imiquimod treatment required a period of 6 weeks in which patients 
applied the cream once daily (evening) for 5 consecutive days a week. Patient random-
ized to fluorouracil had to apply the cream twice daily (morning and evening) for a 
duration of 4 weeks. Additional treatment details have been described previously.8 
Data collection 
The primary outcome was the probability that a patient was free of clinical evidence of 
tumor at all three follow-up visits, which is referred to as the three year probability of 
tumor-free survival. The need for retreatment after histological verification was consid-
ered as treatment failure. During follow-up a physician blinded to treatment assignment 
clinically assessed lesions for signs of treatment failure. Clinically observed treatment 
failures were histologically confirmed by a 3 mm punch biopsy. Relevant baseline pa-
tient and tumor characteristics were used for definition of subgroups. The full study 
design and procedures have been previously described.8,11 
Follow-up information 
Patients who were tumor-free at one year follow-up, were invited for a follow-up visit to 
enable evaluation of a three year probability of tumor-free survival. For logistical rea-
sons, follow-up visits were planned within a window of three months prior or three 
months subsequent to the actual three year follow-up date. 
 The study was performed in accordance with the Declaration of Helsinki. The na-
tional authority and the ethics committees of all participating centers approved the 
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study protocol. All patients gave written, informed consent before participation and the 
trial was registered as International Standard Randomized Controlled Trial (ISRCTN 
79701845). 
Statistical analysis 
Recorded baseline patient and tumor characteristics were summarized per treatment 
with descriptive statistics. The original sample size was estimated at 197 patients per 
treatment group. This sample size enabled detection of an absolute difference in one 
year recurrence-free survival of 10% (non-inferiority margin) with a power of 80% and 
one-sided type I error of 5%. Hereby it was assumed that the proportion with no tumor 
recurrence at one year after treatment with MAL-PDT would be 80%.12,13 
 Time-to-event analyses were performed to account for differences in follow-up be-
tween patients. Data were censored at diagnosis of a treatment failure or when loss-to-
follow-up occurred. Both intention to treat and per protocol analysis was performed. 
The cumulative probability of recurrence free survival at three years’ post treatment was 
estimated using Kaplan Meier survival analysis. Cox proportional hazards models were 
used to calculate hazard ratios (HRs) for treatment failure with 95% confidence intervals 
(95% CI). To facilitate interpretation of HRs, the non-inferiority margin of 10% for 
absolute differences in survival probability was translated to a non-inferiority threshold 
on the relative risk scale based on the observed three year tumor-free survival probabil-
ity (p0) in the MAL-PDT group (log 1-p0/log p0).14 Reported p-values are two-tailed 
corresponding with a one-sided significance level of 2.5% for testing non-inferiority. 
 Subgroup analyses were performed for subgroups defined by patient and tumor 
characteristics such as gender, age, tumor location, and tumor size. Additionally, Cox 
regression models including terms for characteristic by therapy interaction were used to 
test for statistical significance. Therapy was coded by two dummy variables. All data 
were analyzed using SPSS version 22.0 (SPSS, Chicago, IL, USA) and STATA version 
11.0 (STATA Corp, College Station, TX, U.S.A.). 
Results 
A total of 601 patients were randomized to MAL-PDT (n=202), imiquimod (n=198), or 
fluorouracil (n=201). The three study groups had a similar distribution of baseline char-
acteristics, except for tumor size (Table 1). The mean tumor size of tumors treated with 
MAL-PDT was smaller than the mean size in both the imiquimod and fluorouracil 
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group. Of the 601 enrolled patients, 590 started treatment (Fig. 1). Eleven patients did 
not start treatment because they refused, withdrew, died, or were unresponsive on call. 
Following randomization, five cross-overs occurred before the assigned treatment was 
started, due to a strong preference for a different treatment group. One patient did not 
receive the allocated MAL-PDT but was treated with imiquimod, while one patient 
allocated to imiquimod and three patients allocated to fluorouracil received MAL-PDT. 
No treatment failures occurred between the three months and one year follow-up visits. 
During follow-up, protocol deviations occurred in four patients where the treating phy-
sician decided that there was a need for extra treatment due to clinical suspicion of tu-
mor recurrence; surgical excision in two patients and non-invasive treatment in two 
patients. No histological evidence of tumor recurrence was found in the excised speci-
mens and no histological verification was available for the patients treated with MAL-
PDT. As these four patients could not be (further) assessed for recurrence during fol-
low-up the were considered as lost to follow-up (Fig. 1).  
 At the end of follow-up, data were missing for 43 patients (7.4%) who were lost to 
follow-up (7 patients at three months, 19 patients at one year, and 17 patients at three 
years follow-up). 
 Three years post treatment, 66 patients treated with MAL-PDT, 34 patients treated 
with imiquimod, and 50 patients treated with fluorouracil had a treatment failure (Fig. 
1). Twenty-nine treatment failures (15 PDT, 3 imiquimod, 11 fluorouracil) were diag-
nosed after more than one year follow-up. The median follow-up period in the study 
was 35 months (range 1-54). 
 
Table 1. Distribution of patient and tumor characteristics  
Characteristic MAL-PDT  
(n=202) 
Imiquimod cream 
(n=198) 
Fluorouracil cream 
(n=201) 
Sex, M/F 96/106 102/96 106/95 
Median age in years (range)  63 (26-87)  62 (30-91)  64 (35-86) 
Tumor location    
Head/neck  24 (12%)  23 (12%)  31 (15%) 
Trunk 119 (59%) 121 (61%) 120 (60%) 
Upper extremities  32 (16%)  26 (13%)  27 (13%) 
Lower extremities  27 (13%)  28 (14%)  23 (11%) 
Median tumor size in mm2 (range)  52 (5-1382)  63 (5-1413)  63 (9-5472) 
F, female; M, male; MAL-PDT, methylaminolevulinate photodynamic therapy 
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Fig. 1 Flow chart. 
No treatment failures occurred between the three months and one year follow-up visits. 
* Surgical excision was done in two patients due to a strong clinical suspicion of recurrence. Since these pa-
tients could not be assessed for recurrence during follow-up, they were considered lost to follow-up. 
** Non-invasive treatments were given in two patients due to a strong clinical suspicion of recurrence. Since 
these patients could not be assessed for recurrence to the primary non-invasive treatment during follow-up, 
they were considered lost to follow-up. 
911 assessed for eligibility
601 randomised
310 not randomised due to refusal to participate
202 assigned to MAL-PDT 201 assigned to fluorouracil198 assigned to imiquimod
200 received allocated 
intervention
192 received allocated 
intervention
198 received allocated 
intervention
4 lost to follow-up
2 died
1 refused follow-up
1 unable to attend 3-
month appointment due to 
comorbidity
3 lost to follow-up
2 died
1 refused follow-up
196 at 3 months follow-up 198 at 3 months follow-up189 at 3 months follow-up
31 treatment failure 24 treatment failure19 treatment failure
9 lost to follow-up
1 died
5 refused follow-up
1 unable to attend 12-
month appointment due to 
comorbidity
2 surgical excisions (no 
recurrence)*
5 lost to follow-up
1 died
2 refused follow-up
2 unable to attend 12-
month appointment due to 
comorbidity
5 lost to follow-up
2 died
2 refused follow-up
1 unable to attend 12-
month appointment due to 
comorbidity
156 at 1 year follow-up 165 at 1 year follow-up
21 treatment failure 15 treatment failure12 treatment failure
169 at 1 year follow-up
4 treatment failure
5 lost to follow-up
5 died
1 treatment failure
7 lost to follow-up
4 died
2 refused follow-up
1 non-invasive 
treatment**
3 treatment failure
5 lost to follow-up
2 died
2 refused follow-up
1 non-invasive
treatment**
126 at 3 year follow-up 146 at 3 year follow-up145 at 3 year follow-up
10 treatment failure 8 treatment failure2 treatment failure
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Probability of tumor-free survival 
Estimates of the one year and three year cumulative probability of tumor-free survival 
are presented in Table 2. According to the intention-to-treat analysis, probability of 
tumor-free survival at three years was 58.0% for MAL-PDT (95% CI 47.8-66.9), 79.7% 
for imiquimod (95% CI 71.6-85.7), and 68.2% for fluorouracil (95% CI 58.1-76.3). 
 Based on an estimated three year tumor-free survival probability of 58% for the 
MAL-PDT group, the non-inferiority margin of 10% for absolute differences in survival 
probability translates to a non-inferiority threshold for the HR of 1.35 (log 0.48/log 
0.58).14 Consequently, non-inferiority of both creams to MAL-PDT can be concluded if 
the 95% CI of the corresponding HRs are entirely below 1.35. Superiority of both creams 
to MAL-PDT can be concluded if the 95% CI of the corresponding HRs are entirely 
below 1.0. Based on an estimated three year tumor-free survival probability of 79.7% for 
imiquimod, the non-inferiority margin of 10% for absolute differences in survival prob-
ability between imiquimod and fluorouracil translates to a non-inferiority threshold for 
the HR of 1.59 (log 0.697/log 0.797). Superiority of imiquimod to fluorouracil can be 
concluded if the 95% CI of the corresponding HRs are entirely below 1.0.  
 
Table 2. Cumulative probability of tumor-free survival at one and three year post treatment. 
 
One year Three year 
ITT PP  ITT PP 
MAL-PDT 72.8% (66.8-79.4) 72.8% (65.9-78.6) 58.0% (47.8-66.9) 58.3% (48.3-67.1) 
Imiquimod 83.4% (78.2-88.9) 83.4% (78.2-88.9) 79.7% (71.6-85.7) 79.7% (71.6-85.7) 
Fluorouracil 80.1% (74.7-85.9) 79.5% (73.1-84.6) 68.2% (58.1-76.3) 68.1% (57.8-76.4) 
ITT, intention-to-treat; MAL-PDT, methylaminolevulinate photodynamic therapy; PP, per-protocol. 
 
 At three years post treatment, the HR for treatment failure comparing imiquimod 
with MAL-PDT was 0.50 (95% CI 0.33-0.76, p=0.001) (Table 3). Comparison of fluor-
ouracil with MAL-PDT resulted in a HR of 0.73 (95% CI 0.51-1.05, p=0.092), and com-
parison of fluorouracil with imiquimod in a HR of 0.68 (95% CI 0.44-1.06, p=0.091). 
 These results were nearly identical for the per protocol analysis: imiquimod com-
pared with MAL-PDT showed a HR of 0.50 (95% CI 0.33-0.76, p=0.001), fluorouracil 
compared with MAL-PDT a HR of 0.73 (95% CI 0.51-1.06, p=0.095), and fluorouracil 
with imiquimod a HR of 0.69 (95% CI 0.44-1.06, p=0.095) (Table 3). 
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Table 3. Absolute differences and hazard ratios with 95% CI of tumor-free survival at three year follow-up. 
 Intention to treat analysis Per protocol analysis 
 Difference (%) HR (95% CI) p  Difference (%) HR (95% CI) p 
Imiquimod vs. 
MAL-PDT 
21.7 0.50 (0.33 - 0.76) 0.001 21.4 0.50 (0.33 - 0.76) 0.001 
Fluorouracil vs. 
MAL-PDT 
10.2 0.73 (0.51 - 1.05) 0.092 9.8 0.73 (0.51 - 1.06) 0.095 
Fluorouracil vs. 
imiquimod 
-11.5 0.68 (0.44 – 1.06) 0.091 -11.6 0.69 (0.44 – 1.06) 0.095 
CI, confidence interval; HR, hazard ratio; MAL-PDT, methylaminolevulinate photodynamic therapy; p, 
significance; vs., versus. 
Subgroup analysis for treatment success 
The relative effect of imiquimod versus MAL-PDT was dependent on age, sex, localiza-
tion and sBCC size. Imiquimod was superior to MAL-PDT in the subgroups of females, 
patients aged ≤ 60 years, sBCC on the head/neck and trunk, and tumors sized > 60 mm2 
(Table 4). In the other subgroups, imiquimod was also associated with a higher proba-
bility of treatment success (but no superiority). An exception was found for the sub-
group of sBCC localized to the lower extremities, where a significant lower probability 
of treatment success for imiquimod versus MAL-PDT was found with a difference in 
success percentage favoring MAL-PDT of 25.2% (HR 2.07, 95% CI 0.94 - 4.57, p=0.070). 
This finding was further explored by stratifying patients with sBCC on the lower ex-
tremities by age (≤ 60 years vs. > 60 years). Within the subgroup of older patients with 
sBCC on the lower extremities, three year tumor-free survival was lower after 
imiquimod (36.2%) than after MAL-PDT treatment (93.8%). Within the subgroup of 
younger patients, treatment success was observed at 100% subsequent to imiquimod 
compared with 55.6% following MAL-PDT. 
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Table 4. Cumulative probability of tumor-free survival, between group differences and hazard ratios with 95% 
CI at three years post treatment. 
Characteristic Cumulative probabilities of treatment 
success (%, 95% CI) 
Difference (%) HR (95% CI) 
PDT (n=196) Imiquimod (n=189)  Imiquimod vs.  
MAL-PDT 
Imiquimod vs.  
MAL-PDT 
p 
Gender    
Male  57.6 (41.5-7.08) 74.2 (64.0-82.0) 16.6 0.94 (0.58 - 1.52) 0.786 
Female 58.4 (45.1-69.6) 85.4 (70.8-93.1) 27.0 0.30 (0.16 - 0.59) <0.001 
   Interaction p=0.029 
Age    
≤ 60 years 51.0 (35.3-64.7) 86.6 (76.5-92.5) 35.6 0.30 (0.15 - 0.58)  <0.001 
> 60 years 63.8 (50.7-74.3) 75.0 (62.8-83.7) 11.2 0.90 (0.56 - 1.46) 0.677 
    Interaction p=0.049 
Tumor location    
Head/neck  49.7 (28.7-67.6) 79.2 (53.5-91.6) 29.5 0.42 (0.15 - 1.22) 0.112 
Upper extremities 71.5 (48.8-85.5) 75.0 (39.3-91.5) 3.5 0.73 (0.23 - 2.25) 0.578 
Lower extremities  81.2 (56.0-92.8) 56.0 (35.5-72.3) -25.2 2.07 (0.94 - 4.57) 0.070 
Trunk 52.1 (37.8-64.5) 87.6 (79.9-92.4) 35.5 0.38 (0.21 - 0.67) 0.001 
   Interaction p=0.001 
Tumor sizea    
≤ 60 mm2 60.7 (47.1-71.9) 74.4 (60.0-84.3) 13.7 0.77 (0.46 - 1.30) 0.323 
> 60 mm2 54.9 (39.7-67.7) 84.1 (75.1-90.1) 29.2 0.43 (0.24 - 0.77) 0.005 
   Interaction p=0.84 
CI, confidence interval; HR, hazard ratio; MAL-PDT, methylaminolevulinate photodynamic therapy; p, 
significance; vs., versus. P-values in bold did not reach the non-inferiority threshold of the hazard ratio. a Data 
on tumor size were available in 192 of 196 superficial basal cell carcinoma (sBCC) treated with MAL-PDT and 
in 186 of 189 sBCC treated with imiquimod. 
Discussion 
Our results showed that imiquimod is superior and fluorouracil not inferior to MAL-
PDT in treatment of sBCC at three years follow-up. Therefore, imiquimod should be 
considered as a first choice treatment for sBCC in terms of efficacy. 
 The finding that around 80% of patients with sBCC are tumor-free after imiquimod 
treatment at three years follow-up is in accordance with results from previous studies. A 
recent randomized controlled trial by Bath-Hextall et al., that compared surgical exci-
sion with imiquimod, found that imiquimod was successful in 85.1% of sBCC at three 
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years post treatment.15 Two other studies reported a three year cumulative probability of 
tumor-free survival of 82% and 85%.9,16  
 In the present study, the probability of tumor-free survival three years following 
MAL-PDT treatment was 58.0%. To our knowledge, only one other randomized con-
trolled trial on MAL-PDT with at least three years of follow-up has been performed to 
enable comparison of results.17 This study included 114 histologically proven primary 
sBCC that were treated with one or two MAL-PDT cycle. Results showed a higher cu-
mulative probability of tumor-free survival of 70% at three years after MAL-PDT treat-
ment, which may be explained by the fact that incomplete responders received two fur-
ther MAL-PDT sessions (n=20) 3 months subsequent to the first treatment. In our 
study, sBCC were treated with the most current European protocol for MAL-PDT: one 
MAL-PDT cycle consisting of two treatments with one week interval.12 Incomplete or 
non-responders were not retreated. While a second treatment in the case of a non-
responder three months post treatment might increase tumor-free survival, a second 
PDT cycle will further increase the already high treatment costs and requires two addi-
tional patient visits. 7,18 
 Only one previous study by Gross et al. investigated the effectiveness of topical 
fluorouracil twice daily for six to 12 weeks in 31 sBCC.19 The histological clearance rate 
at 3 weeks post treatment was 90%. No long-term follow-up studies have, as yet, been 
reported. 
 A previous systematic review and a network geometry review have shown that there 
is a lack of head-to-head comparison studies for treatment of sBCC.7,20 The present 
study fulfills the need for head-to-head comparison studies by investigating the relative 
treatment effects between non-invasive therapies. Furthermore, it is the first study with 
a long-term follow-up of fluorouracil in treatment of sBCC. Currently, according to the 
European BCC guideline by Trakatelli et al., imiquimod and PDT are both considered 
good treatment options for low-risk sBCC.5 In addition, surgical excision (effectiveness 
of 89-98%) is considered reasonable but not essential.5,15,21 Based on our findings, we 
suggest that imiquimod should be considered as first choice treatment in most primary, 
low-risk sBCC. 
 In order to optimize treatment success, it is of great value to select the most effective 
treatment for an individual patient with a sBCC. We have previously reported subgroup 
analyses showing that imiquimod is more effective than MAL-PDT in most sBCC, with the 
exception of sBCC localized on the lower extremities in older patients.11 At three years of 
follow-up, conclusions remain unaltered: MAL-PDT may be preferable in elderly patients 
with sBCC on the lower extremities. MAL-PDT may also be an alternative therapy in a 
small group of patients for whom cream application is not feasible for practical reasons.  
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 If imiquimod is the treatment of first choice, where stands fluorouracil? Both creams 
have an equal cosmetic outcome and risk of local adverse events.8 Fluorouracil has the 
advantage of lower costs compared to imiquimod. In The Netherlands, the costs for a 
tube fluorouracil (40 grams) are €29.19 and for imiquimod (36 sachets) €170.87.22 At 12 
months follow-up, both creams were cost-effective compared to MAL-PDT although 
the cost-savings were larger for fluorouracil compared to imiquimod.18 However, at 
three years follow-up, the additional cost-savings of fluorouracil compared to 
imiquimod may decrease as the higher number of treatment failures require an increase 
in surgical excisions. Perhaps even more important is the fact that between one and 
three year follow-up, more recurrences were diagnosed in the fluorouracil group com-
pared with the imiquimod group. This higher number of recurrences may necessitate a 
longer yearly follow-up for patients who are treated with fluorouracil. Consequently, the 
additional cost-savings of fluorouracil compared to imiquimod will in all probability 
decrease substantially since the costs of a yearly outpatient visit per patient have to be 
taken into account. Our study showed that the majority of imiquimod treatment failures 
(31/34) already had occurred within one year after therapy. We therefore suggest that 
one follow-up visit at one year post treatment is sufficient in patients with a solitary 
sBCC treated with imiquimod. These patients should be informed and instructed about 
self-examination of the skin after one year because there remains a small risk of a recur-
rence and they have an increased risk of developing multiple BCC. 
 One limitation to a randomized controlled trial is that only patients who are willing 
to participate in a trial, and who have no specific treatment preference, can be random-
ized. In daily practice, not all patients can be motivated or are able to apply a cream 
daily for six weeks. For those patients, a hospital based treatments such as surgical exci-
sion, curettage and electrodessication, or PDT might be preferable. An additional limita-
tion is that post treatment biopsies were not performed to confirm lack of tumor in this 
study. The study was designed to make long-term clinical follow-up possible, in accord-
ance with daily clinical practice, and large biopsies would have interfered with a clinical 
follow-up. However, it is possible that clinical exam missed some subtle recurrences that 
will manifest after the end of the study. Furthermore, as patient preferences are very 
important in choosing an individual treatment, another limitation is that we have not 
evaluated the patient reported outcomes on preference three years post treatment. 
 In summary, our study has shown that imiquimod is superior to MAL-PDT and that 
treatment outcome of fluorouracil compares unfavorably with results after imiquimod 
treatment in patients with sBCC. Imiquimod should be considered as the first choice 
non-invasive treatment in most primary, low-risk sBCC. MAL-PDT might be preferred 
in elderly with sBCC on the lower extremities.  
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Abstract 
 Background: A recent non-inferiority randomized controlled trial (RCT) indicated 
that imiquimod can be considered as superior to methylaminolevulinate photodynamic 
therapy (MAL-PDT) in treatment of superficial basal cell carcinoma (sBCC). 
Knowledge of treatment effectiveness in subgroup of patients is of great value in clinical 
practice to select the most effective treatment for an individual patient with sBCC. 
 Objectives: To explore whether the relative treatment effect of MAL-PDT and 
imiquimod is consistent across subgroups defined by patient and tumor characteristics. 
 Methods: Data were derived from a single-blinded, non-inferiority, multicenter 
RCT comparing MAL-PDT, topical imiquimod and fluorouracil (ISRCTN79701845). 
Treatment success was defined as free of tumor recurrence at 12-months follow-up. 
Subgroup analyses were performed for subgroups defined by sex, age, tumor location 
and tumor size. 
 Results: Two hundred and two patients received MAL-PDT and 198 received 
imiquimod. The superiority of imiquimod vs. MAL-PDT was observed in subgroups of 
females, sBCC on the trunk and large tumors with risk differences in favor of 
imiquimod of 18.4% (95% CI 7.8-29.0%), 21.0% (95% CI 10.9-31.1%), 18.9% (95% CI 
7.1-30.7%), respectively. Higher probability of treatment success for imiquimod vs. 
MAL-PDT was consistently found in all other subgroups with exception of sBCC local-
ized on the lower extremities in older patients. In the latter subgroup, the risk difference 
at the expense of imiquimod was -57.3% (95% CI -81.7 to -32.9%). 
 Conclusions: Imiquimod remains the first choice treatment for sBCC in terms of 
effectiveness. In older patients with sBCC on the lower extremities MAL-PDT might be 
preferred. Results should be interpreted carefully as subgroup analyses were exploratory 
and not driven by prior hypotheses. 
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Introduction 
Worldwide, the incidence rates of non-melanoma skin cancers (NMSC) are growing to 
epidemic proportions. The incidence of NMSC varies worldwide but true rates are esti-
mated to be much higher due to incomplete registration.1 Approximately 80% of these 
NMSC are basal cell carcinoma (BCC) and in The Netherlands, 1 in every 5-6 persons 
will develop a BCC during their life.2 Therefore, BCC puts a large burden on health care 
services.3 
 The gold standard for treatment of BCC is surgery.4,5 However, non-invasive treat-
ment modalities like photodynamic therapy (PDT) and imiquimod have been thor-
oughly investigated and seem good alternatives for surgery in superficial BCC (sBCC).4-7 
We recently published a randomized controlled trial (RCT) showing that imiquimod 
was superior to methylaminolevulinate (MAL)-PDT for treatment of sBCC.7 In addi-
tion, imiquimod is a more cost-effective therapy compared to MAL-PDT in treatment 
of sBCC.8 In this trial, a non-inferiority margin of 10% was used because a between 
group difference in recurrence risk at 1 year after treatment within these limits was 
considered as acceptable. MAL-PDT and imiquimod are both associated with a lower 
success rate (73-83%) compared to surgery (89-100%) but have the benefits of reducing 
the burden on treating physicians, treatment costs and patient discomfort.7,9-11 
 MAL-PDT and imiquimod have a different pharmacological mode of action and 
treatment effects may depend on baseline characteristics, such as sex, age, tumor loca-
tion and tumor size.12,13 Identification of subgroups of patients that differ in response to 
MAL-PDT and imiquimod is of great value in clinical practice to select the most effec-
tive treatment for an individual patient with sBCC. For this reason, the objective of this 
study was to explore whether the relative treatment effect of MAL-PDT and imiquimod 
is consistent across subgroups defined by such baseline characteristics. 
Materials and methods 
Study design 
Data were derived from a single-blinded, non-inferiority, randomized controlled multi-
center trial (ISRCTN 79701845) on treatment success in sBCC of patients who were 
randomly assigned to MAL-PDT or topical imiquimod treatment.7 The study design 
and procedures have been described elsewhere. In summary, the study population con-
sisted of patients attending the dermatology departments of seven participating hospi-
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tals in the southern part of The Netherlands, who had a primary, histologically proven 
sBCC on a 3 mm punch biopsy. A sBCC was defined as a tumor composed of basaloid 
cell nests which are attached intermittently along the epidermis. One sBCC per patient 
was included. Patients were excluded when using immunosuppressive drugs or suffering 
from genetic skin cancer disorders. In addition, breastfeeding or pregnant women were 
excluded. Also, recurrent tumors, pigmented BCC and sBCC located in the H-zone were 
not eligible. The Institutional Review Boards approved the study protocol and all pa-
tients gave written informed consent before participation. The trial was conducted ac-
cording to the Declaration of Helsinki Principles. 
Randomization and masking 
Between March 2008 and August 2010, patients were randomly assigned to MAL-PDT 
and imiquimod in a 1:1 ratio. In order to ensure concealment of allocation, randomiza-
tion was done by phone with a computer-generated numbered list with random per-
muted blocks of six. The list was prepared by an investigator who was not clinically 
involved in the trial. Patients were stratified by age (≤ 60 year and > 60 years) and tumor 
location (head/neck region and other location). An independent investigator, who was 
blinded to the assigned treatment modality and was not involved in the treatment, eval-
uated the tumors for treatment response. Patients and treating physicians were not 
masked for the assigned therapy. Statistical analysis was performed by two investigators 
who were blinded to allocation. 
Follow-up 
Follow-up visits took place 3 and 12 months after last treatment day by an independent 
investigator. Treatment failure was defined as residue or recurrence within 1 year post 
treatment that was histologically confirmed by a 3 mm punch biopsy. 
Procedures 
Prior to PDT treatment, lesions received a non-traumatic surface preparation. MAL 
16% cream (Metvix, Galderma SA, Penn Pharmaceutical Services, Gwent, UK) was 
applied on the sBCC and 5-10 mm of the surrounding skin. The area was covered with 
an occlusive dressing (Tegaderm, 3M, Leiden, The Netherlands) and aluminum foil. 
Three hours after application the area was illuminated for around 7 minutes (630 nm, 
37 J/cm2) with a light emitting diode (LED) light source, Omnilux (Waldmann, Photo-
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therapeutics, London, UK) or Aktilite (Galderma SA, Lausanne, Switzerland). The 
treatment was repeated after 1 week. 
 Participants randomized to 5% imiquimod (Aldara, Meda AB, Solna, Sweden) had 
to apply the cream once daily for five consecutive days during six weeks. Patients were 
instructed to apply the cream on the tumor and 5-10 mm of surrounding healthy skin. 
Data collection 
Baseline data on patient and tumor characteristics such as sex, age, tumor location and 
tumor size, were used for definition of relevant subgroups. Tumor surface area was 
calculated in mm2 by multiplying the short tumor axis by the long axis. 
Statistical analysis 
A pre-specified margin of 10% was used to evaluate non-inferiority for imiquimod to 
MAL-PDT in the treatment of sBCC. This margin was chosen based on a previous study 
in which an increase in recurrence risk by maximally 10% was considered acceptable.11 
sBCC is a non-aggressive slowly growing skin cancer and residue or recurrent tumor is 
easily treated with surgical excision. In order to establish non-inferiority with a power of 
80% and one-sided type I error of 5%, a sample size of 197 participants per group was 
acquired. We presumed that the proportion of treatment success one year after MAL-
PDT is 80%.5,6 The distribution of patient and tumor characteristics was summarized by 
descriptive statistics. Absolute numbers and percentages were used for categorical data 
and median values with range for continuous data. Subgroups were defined by patient 
and tumor characteristics at baseline. Within these subgroups, proportions with treat-
ment success and differences in success percentages between treatment groups with 
corresponding 95% confidence intervals (CIs) were calculated. Subgroup-treatment 
effect interaction was tested for statistical significance using logistic regression analysis 
with treatment outcome as dependent variable and baseline characteristic, treatment 
group and an interaction term as independent variables. Baseline characteristics with 
more than one category were entered as dummy variables. P-values ≤ 0.05 were consid-
ered to indicate statistical significance. All data were analyzed by using SPSS version 
20.0 (SPSS, Chicago, IL, USA) and STATA version 11.0 (STATA Corp, College Station, 
TX, U.S.A.). 
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Results 
Patients and tumors 
A total of 400 patients were randomized to MAL-PDT (n=202) or imiquimod (n=198) 
(Fig. 1). Relevant endpoints were available for 385 patients (MAL-PDT n=196 and 
imiquimod n=189). Table 1 presents the distribution of patient and tumor characteris-
tics according to treatment group. 
 
 
Fig. 1 Flow chart modified from Arits et al.7 MAL-PDT, methylaminolevulinate photodynamic therapy.
*Surgical excision was done in two patients due to a strong clinical suspicion of a recurrence. Because these
patients could not be assessed for recurrence during follow-up, they were considered lost to follow-up. 
200 received allocated  
intervention
192 received allocated 
intervention
21 treatment failure 12 treatment failure
156 at 1 year follow-up 165 at 1 year follow-up
31 treatment failure
9 lost to follow-up
1 died
5 refused follow-up
1 unable to attend 12-month
appointment due to 
comorbidity
2 surgical excisions 
(no recurrence)*
19 treatment failure
5 lost to follow-up
1 died
2 refused follow-up
2 unable to attend 12-month
appointment due to 
comorbidity
196 at 3 month follow-up 189 at 3 month follow-up
4 lost to follow-up 
2 died
1 refused
1 unable to attend 3-month 
appointment due to 
comorbidity 
3 lost to follow-up 
2 died
1 refused follow-up
202 assigned to MAL-PDT 
400 randomised 
198 assigned to imiquimod
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Table 1. Patient and tumor characteristics by treatment group. 
 MAL-PDT (n=202) Imiquimod cream (n=198) 
Mean age; years (range) 63 (26 – 87) 62 (30 – 91) 
Tumor location   
Head/neck 24 (12)  23 (12) 
Trunk 119 (59)  121 (61)  
Upper extremities 32 (16)  26 (13)  
Lower extremities 27 (13)  28 (14)  
Men  96 (48) 101 (51) 
Tumor size; mm2 (range) 52 (5–1382)  63 (5–1413)  
BCC in medical history 102 (50)  96 (48)  
BCC, basal cell carcinoma; MAL-PDT, methylaminolevulinate photodynamic therapy. Continuous variables 
are expressed as median (range) and categorical variables as n (%). 
Subgroup analysis for treatment success 
Superiority of imiquimod versus MAL-PDT was observed in subgroups of females, 
patients aged ≤ 60 years, sBCC on the trunk and tumors with size > 60 mm2 with differ-
ences in success percentages favoring imiquimod of 18.4% (95% CI 7.8-29.0%), 20.5% 
(95% CI 8.3-32.7%), 21.0% (95% CI 10.9-31.1%) and 18.9% (95% CI 7.1-30.7%), respec-
tively (Table 2). A higher probability of treatment success (but no superiority) of 
imiquimod versus MAL-PDT was found for males, patients > 60 years, tumors on the 
head/neck and upper extremities and smaller sBCC. Logistic regression models includ-
ing terms for treatment by subgroup interaction yielded statistically significant p-values 
for sex (p=0.029), age (p=0.032), tumor location (p<0.001) and tumor size (p=0.043) 
 Imiquimod was significantly less effective than MAL-PDT in sBCC localized on the 
lower extremities, with a difference in proportion with treatment success of -35.2% (95% 
CI -56.2. to -14.2%, p=0.003). We therefore performed additional analyses stratifying for 
sBCC location (lower extremities vs. other body sites).  
 Within the subgroup of sBCC on the lower extremities, treatment success after 
imiquimod was lower than after MAL-PDT in patients > 60 years (Table 3); treatment 
success was achieved in only 36.8% for imiquimod and 94.1% for MAL-PDT with a 
difference in success rate of -57.3% (95% CI -81.7 to -32.9%). This higher probability of 
treatment success for MAL-PDT compared to imiquimod was not seen in younger pa-
tients with a sBCC on the lower extremities. 
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Table 2. Proportions with treatment success and between group differences with 95% confidence intervals (CIs). 
Characteristic Probabilities of treatment success (%) Between group differences (95% CI) 
PDT (n=196) Imiquimod (n=189)  Imiquimod vs. PDT p 
Sex   
Male  75.3 (70/93) 77.3 (75/97) 2.0 (-10.1 – 14.1) 0.746 
Female 71.8 (74/103) 90.2 (83/92) 18.4 (7.8 – 29.0) 0.001 
  Interaction p=0.029 
Age   
≤ 60 years 69.1 (56/81) 89.6 (69/77) 20.5 (8.3 – 32.7)  0.002 
> 60 years 76.5 (88/115) 79.5 (89/112) 3.0 (-7.7 – 13.7) 0.586 
   Interaction p=0.032 
Tumor location   
Head/neck  62.5 (15/24) 80.0 (16/20) 17.5 (-9.3 – 43.6) 0.205 
Upper extremities 83.9 (26/31) 88.0 (22/25) 4.1 (-14.1 – 22.2) 0.663 
Lower extremities  92.3 (24/26) 57.1 (16/28) -35.2 (-56.2 – -14.2) 0.003 
Trunk 68.7 (79/115) 89.7 (104/116) 21.0 (10.9 – 31.1) <0.001 
  Interaction p<0.001 
Tumor sizea   
≤ 60 mm2 78.3 (83/106) 80.0 (72/90) 1.7 (-9.7 – 13.1) 0.771 
> 60 mm2 68.6 (59/86) 87.5 (84/96) 18.9 (7.1 – 30.7) 0.002 
  Interaction p=0.043 
PDT, photodynamic therapy. P-values <0.05 were considered to be statistically significant. aData on tumor size 
were available in 192 of 196 superficial basal cell carcinomas (sBCC) treated with PDT and in 186 of 189 sBCC 
treated with imiquimod. 
 
Table 3. Proportions with treatment success and between group differences with 95% confidence intervals for 
superficial basal cell carcinoma on lower extremities. 
Characteristic Probabilities of treatment success (%) Between group differences (95% CI) 
PDT (n=26) Imiquimod (n=28)  Imiquimod vs. PDT p 
Sex   
Male  100.0 (4/4) 46.7 (7/15) -53.3 (-79.0 – -28.1) 0.055 
Female  90.9 (20/22) 69.2 (9/13) -21.7 (-49.5 – 6.1) 0.100 
Age   
≤ 60 years  88.9 (8/9) 100.0 (9/9) 11.1 (-9.4 – 31.6)  0.304 
> 60 years  94.1 (16/17) 36.8 (7/19) -57.3 (-81.7 – -32.9)  <0.001 
Tumor sizea   
≤ 60 mm2  89.5 (17/19) 60.0 (9/15) -29.5 (-57.9 – -1.1) 0.044 
> 60 mm2 100.0 (7/7) 54.5 (6/11) -45.5 (-74.9 – -16.1) 0.036 
CI, confidence interval; PDT, photodynamic therapy. P-values <0.05 were considered to be statistically signifi-
cant. aSome incomplete data as noted in Table 2. 
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For sBCC not localized on the lower extremities, the relative benefits of imiquimod over 
MAL-PDT for males, older patients and small sBCC remained smaller than those for 
females and larger sBCC, but the interaction term for age by treatment was no longer 
statistically significant (p=0.580) (Table 4). 
 
Table 4. Proportions with treatment success and between group differences with 95% confidence intervals 
after exclusion of superficial basal cell carcinoma on lower extremities. 
Characteristic Probabilities of treatment success (%) Between group differences (95% CI) 
PDT (n=170) Imiquimod (n=161)  Imiquimod vs. PDT p 
Sex   
Male  74.2 (66/89) 82.9 (68/82) 8.7 (-3.5 – 20.9) 0.167 
Female 66.7 (54/81) 93.7 (74/79) 27.0 (15.4 – 38.6)  <0.001 
  Interaction p=0.022 
Age   
≤ 60 years 66.7 (48/72) 88.2 (60/68) 21.5 (8.1 – 34.8)  0.002 
> 60 years 73.5 (72/98) 88.2 (82/93) 14.7 (3.8 – 25.6)  0.010 
  Interaction p=0.580 
Tumor sizea   
≤ 60 mm2 75.9 (66/87) 84.0 (63/75) 8.1 (-4.1 – 20.3) 0.202 
> 60 mm2 65.8 (52/79) 91.8 (78/85) 26.0 (14.0 – 38.0) <0.001 
  Interaction p=0.042 
CI, confidence interval; PDT, photodynamic therapy. P-values <0.05 were considered to be statistically signifi-
cant. aSome incomplete data as noted in Table 2. 
Discussion  
Our results consolidate superiority of imiquimod to MAL-PDT in sBCC in females, 
sBCC localized on the trunk and large tumors. In most other subgroups, imiquimod 
also resulted in better treatment results but the differences with MAL-PDT were less 
pronounced. Interestingly, imiquimod was less effective than MAL-PDT in patients > 60 
years with a sBCC on the lower extremities. 
 The higher treatment success of imiquimod in females compared to males might be 
explained by the imiquimod modified immune response. The female estrogen has posi-
tive hormonal effects on cytokines in the immune response.14 Estrogen stimulates the 
secretion of several cytokines, of which certain ones are also induced by the imiquimod 
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induced immune response.15 Differences in adherence to medication regimens between 
men and women were excluded on the basis of the diaries patients completed. 
 The better treatment response of imiquimod in larger tumors is possibly due to the 
imiquimod induced immune response that reaches far into the surrounding tissue, even 
in subclinical tumor cells that may be present at the border. MAL-PDT might be less 
effective in larger sBCC because the light can scatter at the periphery. Therefore, periph-
eral tumor cells may be treated suboptimal by MAL-PDT and can remain. 
 The most remarkable finding of this study is that imiquimod was less effective than 
MAL-PDT in patients > 60 years with a sBCC on the lower extremities. We thought of a 
plausible explanation for this finding. There was no difference in adherence to medica-
tion regimen between young and old patients who applied imiquimod on the lower 
extremities. A hypothesis might be that elderly are less capable of leaning down when 
they apply the cream on their legs and, consequently, imiquimod is applied inadequate-
ly. 
 The results indicate that in patients > 60 years with a sBCC on the lower extremities 
treatment with MAL-PDT might result in more effective treatment than imiquimod 
treatment. Another reason for a preference of MAL-PDT instead of imiquimod in this 
specific subgroup might be the wound healing on the lower legs. It is well known that 
wound healing is often delayed on the lower extremity, especially on the lower legs. A 
result of treatment with imiquimod is erosion and ulceration. In older patients, often 
suffering from venous insufficiency, local wound infections, crural ulceration or erysipe-
las might be expected more frequently. In this trial only one local wound infection in a 
patient with a sBCC on the chest occurred during treatment with imiquimod. 
 Apart from the recently published RCT by Arits et al., there are no head-to-head 
comparison studies on the relative treatment success between MAL-PDT and 
imiquimod cream in sBCC to compare with our results.7,9 However, there are a few non-
comparative studies, four on PDT and two on imiquimod, that investigated possible 
determinants of treatment failure in BCC.  
 Fantini et al. examined possible clinical and pathological determinants of MAL-PDT 
response of BCC and found, in contrast to our results, that tumor location on the limbs 
was associated with higher risk of treatment failure.16 In that study, patient age and sex 
were no determinants of PDT treatment response. Christensen et al. found that male sex 
was associated with treatment failure after 5-aminolaevulinic acid PDT.17 Two other 
studies found that treatment failure occurred more often in large tumors.18,19 These 
studies are different from our study as inclusion was not restricted to sBCC, which is 
likely to have influenced the results. 
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 Two RCTs on imiquimod reported no significant association between age, tumor 
location or tumor size and treatment response.20,21 However, the authors did not report 
whether this lack of significance was due to lack of effect or a small sample size. One of 
these studies reported better treatment response in women (95%) compared to men 
(87%), which is in line with our findings.21 
 We explored the relative treatment effect of MAL-PDT and imiquimod across sub-
groups in a randomized controlled trial. We emphasize that this result should be inter-
preted carefully as the subgroup analyses in this study were not driven by prior hypothe-
ses and should be considered as exploratory. Our findings need to be validated in larger 
studies. 
 In conclusion, treatment success of imiquimod cream versus MAL-PDT was con-
sistently higher across nearly all pre-specified subgroups. This implies that imiquimod 
cream remains the first choice treatment in most patients presenting with sBCC. How-
ever, in the subgroup of patients > 60 years with a sBCC on the lower extremities, MAL-
PDT seems preferable, probably because of application difficulties. 
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Abstract 
 Background: Non-invasive treatments are frequently used in treatment of superfi-
cial basal cell carcinoma (sBCC) because of better cosmetic results, lower costs, and less 
burden on health care services when compared with surgical excision. However, proba-
bility of treatment failure is higher after non-invasive therapies and may depend on 
histological tumor characteristics. 
 Objectives: We sought to investigate whether tumor thickness and adnexal exten-
sion are determinants of treatment failure in sBCC treated with topical methylami-
nolevulinate-photodynamic therapy (MAL-PDT), imiquimod or 5-fluorouracil (5-FU). 
 Methods: Data were derived from a randomized controlled trial on the effectiveness 
of MAL-PDT, imiquimod and 5-FU for treatment of sBCC (ISRCTN79701845). For 
tumors with treatment failure (n=112) and a randomly selected control group of tumors 
without treatment failure (n=224) data on tumor thickness and adnexal extension were 
retrospectively collected. Treatment failure was defined as a clinically and histologically 
persistent or recurrent tumor within one year post treatment. 
 Results: Tumor thickness of included patients ranged from 0.2 to 1.0 mm. Tumor 
thickness and adnexal extension of sBCC were not significantly associated with treat-
ment failure of MAL-PDT, imiquimod or 5-FU. 
 Conclusions: There seems to be no need to determine tumor thickness or adnexal 
extension in sBCC before treatment. 
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Introduction 
Basal cell carcinoma (BCC) is the most common type of skin cancer with a rapidly rising 
incidence worldwide.1 Surgical excision is regarded to be the gold standard for treat-
ment.2,3 To reduce the burden on physicians and decrease health care costs, superficial 
BCC (sBCC) can also be treated with less invasive techniques such as photodynamic 
therapy (PDT), imiquimod, 5-fluorouracil (5-FU), cryosurgery, or electrodessication 
and curettage. In addition, PDT, imiquimod and 5-FU have the benefit of a better cos-
metic outcome compared with surgical excision.4 However, recurrence rates of non-
invasive treatments are higher compared with surgery and range from 13% to 27% at 
one year post treatment.5,6 Little is known about histological characteristics of sBCC that 
may influence treatment response of non-invasive therapies. 
 A sBCC is a basaloid tumor that grows continuously with the epidermis but tumor 
nests can reach within the papillary dermis.7 The tumor sometimes grows deeply along 
hair follicles. We therefore hypothesized that thicker sBCC and tumors with extension 
along the hair follicle might partially fail to respond to the superficially working non-
invasive therapies and lead to residue or recurrence of BCC. A few previous PDT studies 
have reported on tumor thickness as a histological determinant of treatment failure in 
BCC.8-12 However, results were contradictory, possibly because of the fact that inclusion 
was not restricted to sBCC subtypes. Only one study focused solely on sBCC and 
showed that after treatment with imiquimod a tumor with a thickness > 0.4 mm was 
significantly more likely to reoccur than a thinner tumor.13 
 The objective of this study was to investigate whether increased tumor thickness and 
adnexal extension are determinants of treatment failure in sBCC treated with methyla-
minolevulinate (MAL)-PDT, imiquimod or 5-FU. 
Methods 
Patients and tumors 
Data were derived from a recently published non-inferiority, randomized controlled 
trial on treatment success after treatment of sBCC with MAL-PDT, imiquimod or 5-FU 
(ISRCTN79701845). Details of the study design and procedures have previously been 
reported.6 In summary, the study was conducted in 7 hospitals in the southern part of 
The Netherlands. Patients aged 18 years or older attending the department of Derma-
tology with a primary, histologically proven sBCC were eligible to participate in this 
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trial. A sBCC was defined as a tumor with small, islands of basaloid cells attached to the 
epidermis and restricted to the papillary dermis.14 One tumor per patient was included. 
Patient related exclusion criteria were use of immunosuppressive drugs, genetic skin 
cancer disorders, breastfeeding and pregnancy. Recurrent sBCC, pigmented sBCC and 
tumors located in the H-zone of the face were also excluded. In addition, we also ex-
cluded patients who were at risk in terms of precautions, warnings and contraindica-
tions as indicated in the package insert for MAL-PDT, topical imiquimod, and topical 5-
FU. The trial was approved by the Medical Ethics and Scientific Committee of the Maas-
tricht University Medical Centre, The Netherlands. All patients provided written in-
formed consent. 
Follow-up 
Treatment failure was evaluated by an investigator who was blinded to treatment alloca-
tion at 3 and 12 months after the last treatment day. The treatment area was examined 
to detect clinical residue or recurrent tumor. Clinical treatment failure was histologically 
confirmed by a 3 mm punch biopsy specimen. 
Treatments 
Participants randomized to PDT received a non-traumatic tumor surface preparation 
before treatment. MAL 16% cream (Metvix, Galderma SA, Penn Pharmaceutical Ser-
vices, Gwent, United Kingdom) was applied on the tumor and 5-10 mm of the sur-
rounding skin. The area was subsequently covered with an occlusive dressing (Te-
gaderm, 3M, Leiden, The Netherlands) and aluminum foil. After three hours, the area 
was illuminated with a light emitting diode light source, (Omnilux, Waldmann Photo-
therapeutics, London, United Kingdom) or Aktilite (Galderma SA, Lausanne, Switzer-
land), with an optimum wavelength of 630 nm. The same procedure was repeated after 
one week. 
 Patients who were treated with 5% imiquimod (Aldara, Meda AB, Solna, Sweden) 
had to apply the cream during six weeks, once daily (evening) for five following days. 
Patients randomized to 5% 5-FU (Efudix, Meda Pharmaceuticals, Amstelveen, The 
Netherlands) had to apply the cream for four consecutive weeks twice daily (morning 
and evening). Both creams had to be applied on the tumor and 5-10 mm of the sur-
rounding skin. 
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Data collection 
This was designed as a case-control study, where 112 patients with treatment failure 
were selected as cases and 224 patients with treatment success were randomly selected as 
control subjects. Hematoxylin-eosin stained histopathological slides of tumors were 
retrieved to obtain additional data on tumor thickness and adnexal extension. The his-
topathological slides of the initial diagnostic punch biopsy were retrospectively and 
independently judged by two observers who were blinded to case-control status: a resi-
dent in dermatology (M.H.R.) and a sixth-year medical student (L.v.K.). Both observers 
were intensively trained by a dermatopathologist (V.J.L.W.) in judging histological sec-
tions of sBCC. Maximum tumor thickness was measured with a 0.1 mm precise ocular 
micrometer from the top of the stratum granulosum to the deepest located tumor nest. 
The mean tumor thickness measured by the two observers was used for analysis. Ad-
nexal extension of sBCC was recorded as present or absent and was defined as tumor 
cells along hair follicles growing deeper than the deepest located tumor nest (Fig. 1). 
 
 
Fig. 1 Histologic superficial basal cell carcinoma with adnexal extension (Hematoxylin-eosin stain; original 
magnification: x100). 
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Statistical analysis 
Histologic data were available for 112 of 122 tumors with treatment failure. Based on the 
assumption that the proportion of controls with adnexal extension was 10% and a 
case:control ratio of 1:2, a sample of 224 patients without treatment failure was random-
ly selected to enable detection of an odds ratio (OR) ≥ 2.5 with a power of 80% and a 
two-sided alpha of 5%. 
 For each treatment modality, the association between tumor thickness as a continu-
ous variable and treatment failure was visually explored using scatter plots. The associa-
tion between treatment failure with tumor thickness and adnexal extension was estimat-
ed with univariate and multivariate logistic regression models. The multivariate model 
adjusted for potential confounders such as gender, age, type of treatment, tumor surface 
area and tumor location. ORs with 95% confidence intervals (CI) (unadjusted and ad-
justed) were derived by exponentiation of regression coefficients corresponding with 
tumor thickness and adnexal extension. P-values ≤ 0.05 were considered to indicate 
statistical significance. All data were analyzed using SPSS version 20.0 (SPSS, Chicago, 
IL, USA) and STATA version 11.0 (STATA Corp, College Station, TX, U.S.A.). 
Results 
Patients and tumors 
A total of 601 patients were included and randomized between March 2008 and August 
2010. The study population of the present study consisted of 112 tumors with treatment 
failure (cases) and 224 tumors with treatment success (controls). The distribution of 
baseline characteristics was similar among cases and controls, with the exception of 
tumor surface area (Table 1). Among cases with treatment failure, median tumor thick-
ness was 0.35 mm (range 0.20-0.85) and adnexal extension was present in 10% (11/112). 
Among controls with treatment success, median tumor thickness was 0.35 mm (range 
0.20-1.00) and adnexal extension was present in 14% (32/224). sBCC with treatment 
failure showed a larger median tumor surface area (56 mm2) compared to tumors with 
treatment success (47 mm2). Scatter plots show a lack of association between tumor 
thickness as a continuous variable and treatment failure (Fig. 2). A similar distribution 
of thickness for tumors with and without treatment failure is observed for each treat-
ment modality. For this reason, we performed no separate analyses per treatment mo-
dality, but combined all tumors in one dataset. 
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Table 1. Patient and tumor characteristics for cases (treatment failure) and controls (treatment success).  
Characteristics Treatment failure (n=112) Treatment success (n=224) p-value 
Gender, n (%)   0.64 
Male  57 (51) 107 (48)  
Female  55 (49) 117 (52)  
Age, years   0.21 
Mean  60  62  
Median (range)  61 (36-88)  61 (26-87)  
Tumor location, n (%)    
Head/neck, reference  17 (15)  26 (12)  
Upper extremities  11 (10)  37 (16) 0.09 
Lower extremities  19 (17)  26 (12) 0.80 
Trunk  65 (58) 135 (60) 0.38 
Tumor surface area, mm2   0.08 
Median  66  47  
Tumor thickness, mm   0.90 
Mean (range)   0.39 (0.20-0.85)   0.39 (0.20-1.00)  
Median   0.35   0.35  
≤ 0.4 mm, n (%)  61 (54) 115 (51) 0.64 
> 0.4 mm, n (%)  51 (46) 109 (49)  
Adnexal extension, n (%)   0.30 
Absent 101 (90) 192 (86)  
Present  11 (10)  32 (14)  
Treatment, n (%)    
MAL-PDT, reference  49 (44)  72 (32)  
Imiquimod  29 (26)  76 (34) 0.04 
5-FU  34 (30)  76 (34) 0.13 
P-values <0.05 were considered to be statistically significant. 5-FU, 5-fluorouacil; MAL-PDT, methylami-
nolevulinate photodynamic therapy. 
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Fig. 2 Scatter plot for tumor thickness and treatment 
failure per treatment. PDT, photodynamic therapy. 
Tumor thickness 
Tumor thickness of included patients ranged from 0.20 to 1.00 mm. With respect to 
treatment failure, the OR per unit increase of tumor thickness was 1.001 (95% CI 0.985-
1.017). Using a cut-off point of ≤ 0.4 mm versus > 0.4 mm, the association with treat-
ment failure was 0.88 (95% CI 0.56-1.39, p=0.598) (Table 2). After correction for poten-
tial confounders (gender, age, tumor surface area, tumor location and type of treatment) 
in a multivariate logistic regression analysis, the adjusted OR was 0.87 (95% CI 0.54-
1.41, p=0.568). 
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Table 2. Association between treatment failure and tumor thickness and adnexal extension. 
 Unadjusted OR 95% CI p Adjusted OR 95% CI p 
Tumor thickness > 0.4 mm vs. ≤ 0.4 mm 0.88 0.56 – 1.39 0.598 0.87 0.54 – 1.41 0.568 
Adnexal extension 0.65 0.32 – 1.35 0.251 0.66 0.31 – 1.42 0.290 
P-values <0.05 were considered to be statistically significant. The multivariate model adjusted for potential 
confounders: gender, age, type of treatment, tumor surface area and tumor location. CI, confidence interval; 
OR, odds ratio. 
Adnexal extension 
In univariate analysis, the presence of adnexal extension was not significantly associated 
with higher treatment failure (OR 0.65, 95% CI 0.32-1.35, p=0.251) (Table 2). Similar 
results were obtained after correction for potential confounders in a multivariate logistic 
regression analysis; the adjusted OR was 0.66 (95% CI 0.31-1.42, p=0.290). 
Discussion 
The results of this study do not indicate that tumor thickness and adnexal extension are 
predictors of treatment failure in sBCC treated with MAL-PDT, imiquimod, or 5-FU. 
We found no evidence that these histological parameters have to be taken into account 
before deciding whether non-invasive treatment is adequate for a patient presenting 
with sBCC. 
 The Cochrane review on BCC interventions hypothesized that imiquimod response 
depends on tumor thickness.4 This hypothesis was based on a study by Shumack et al., 
who suggests that longer treatment times of imiquimod are needed for nodular BCC 
compared to sBCC.15 A recent study by McKay et al. examined imiquimod response 
rates in 127 sBCC with a mean thickness of 0.30 mm (range 0.09-1.41 mm).13 In contrast 
to our study, a tumor thickness > 0.4 mm was found to be a predictor of treatment fail-
ure. McKay et al. also recommended that adnexal extension should be measured in 
pathology reports, but no statistical analyses were reported to support this finding. 
Based on our analyses we found no evidence that adnexal extension is a determinant of 
non-invasive treatment failure in sBCC. However, our results were obtained in a popu-
lation of sBCC with a mean size of 47-66 mm2. It is unclear whether these results are 
applicable for larger sBCC. 
 Previous PDT studies have shown that BCC do not respond with tumor thickness 
beyond 1.3-2.2 mm.9,16 These studies included superficial, nodular and aggressive BCC 
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subtypes. The maximum tumor thickness of sBCC in the current study was 1.0 mm and 
therefore the data do not allow conclusions about tumors thicker than 1.0 mm. Howev-
er, previous findings of McKay et al. indicate that thickness of the majority of sBCC 
does not exceed 1.0 mm.13 
 Currently, the main indication for non-invasive treatment is a histological superfi-
cial growth pattern on punch biopsy specimen.2,3 The histologic definition of a sBCC is 
multiple lobules of basaloid cells attached to the epidermis and restricted to the papillary 
dermis, while maintaining their attachment to the epidermis, irrespective of how deep 
the deepest tumor nest is located.17 If this definition is maintained, measurement of 
sBCC thickness and adnexal extension seems redundant. 
 Tumor thickness was measured on 3 mm punch biopsy specimens. As a punch biop-
sy represents only a part of the total tumor, the tumor thickness on punch biopsy might 
not represent the thickest part of the entire tumor. However, our study reflects daily 
clinical practice in which a biopsy is taken from the clinically thickest part of the tumor. 
Furthermore, a previous study showed that if sBCC measure ≤ 1.0 mm in depth on 
punch biopsy specimen, the discrepancy between tumor thickness on punch biopsy 
specimen and the subsequent surgical excision is small.18 
 The analysis was restricted to a one year follow-up period, and patients in the con-
trol group may still be at risk of developing a recurrence during later follow-up. Howev-
er, we believe that the majority of treatment failures was captured, because 73-78% of 
failures after non-invasive treatment are known to occur within one year post treat-
ment.19-21 Furthermore, it is unlikely that late recurrences in the control group would 
selectively occur in thicker tumors. 
 In conclusion, in this study with sBCC with a maximum tumor thickness of 1.0 mm, 
we found no evidence that the histological characteristics tumor thickness and adnexal 
extension are associated with treatment failure in sBCC treated with MAL-PDT, 
imiquimod, or 5-FU. Therefore, there seems to be no need to determine tumor thick-
ness or adnexal extension in sBCC before treatment. 
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Abstract 
 Background: Although effective in superficial basal cell carcinoma (BCC), the 
treatment effect of photodynamic therapy (PDT) in nodular BCC (nBCC) is still ques-
tionable. The relation between tumor thickness and PDT failure is unclear. 
 Objectives: We sought to compare long-term effectiveness of fractionated 20% 5-
aminolaevulinic acid (ALA)-PDT with prior partial debulking versus surgical excision 
in nBCC. The effect of tumor thickness on ALA-PDT failure was analyzed. 
 Methods: 173 primary, histologically proven nBCC in 151 patients were randomized 
to fractionated ALA-PDT (n=85) or surgical excision (n=88). Two PDT illuminations 
were performed with a 1-hour interval. Follow-up was at least 5 years post treatment. 
Clinical recurrences were confirmed histologically. 
 Results: A total of 171 nBCC were treated and had a median follow-up of 67 months 
(range 0-106). At 60 months, 23 tumors had recurred in the ALA-PDT group and 2 
tumors in the surgical excision group. Cumulative recurrence probabilities 5 year post 
treatment were 30.7% (95% CI 21.5%–42.6%) for ALA-PDT and 2.3% (95% CI 0.6%–
8.8%) for surgical excision (p<0.0001). Two tumors in the ALA-PDT group recurred at 
72 and 91 months post treatment. Cumulative probability of recurrence-free survival 
following ALA-PDT was 65.0% (95% CI 51%-76%) for nBCC measuring  
> 0.7 mm in thickness and 94.4% (95% CI 67%–99%, p=0.018) for tumors ≤ 0.7 mm. 
 Conclusions: In nBCC, 5-year cumulative probability of recurrence after surgical 
excision is lower than after fractionated ALA-PDT with prior debulking. Although sur-
gical excision remains golden standard of treatment, fractionated ALA-PDT might be 
an alternative for inoperable patients with thin (≤ 0.7 mm) nBCC. 
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Introduction 
The incidence of basal cell carcinoma (BCC) is rapidly increasing worldwide.1-3 There-
fore, effective treatment of this major health problem is essential. 
 Surgical excision is the gold standard for treatment of all three major histological 
BCC subtypes; superficial, nodular and aggressive.4-6 However, the increasing BCC inci-
dence results in a demand for alternative treatments to reduce the workload for physi-
cians and health care costs. Currently, superficial BCC are therefore frequently treated 
with non-invasive treatment modalities such as photodynamic therapy (PDT), 
imiquimod and 5-fluorouracil.6,7 Among these treatments, most experience has been 
gained with PDT. The treatment effect of PDT in nodular BCC (nBCC) is still question-
able as studies on the long-term efficacy are scarce and the effect of tumor thickness on 
treatment failure has not been well established.4,6 
 According to the guidelines by Braathen et al., PDT is suggested as a treatment op-
tion for thin nBCC.7 This recommendation is based on a study by Soler et al. in which 
PDT failure was evaluated 35 months post treatment.8 However, in this study distinction 
between thin (< 2 mm) and thick (> 2 mm) nBCC lesions was based on a clinical evalua-
tion instead of a histological evaluation. We therefore investigated the relation between 
PDT treatment failure and the histological nBCC thickness on punch biopsy specimen. 
We previously described the results of this randomized controlled trial (RCT) on PDT 
and surgical excision in nBCC.9 Our interim analysis with a three year follow-up period 
showed that: (1) tumor thickness was not significantly related to treatment failure after 
PDT; and (2) surgical excision is more effective than PDT. Because it is known from 
literature that BCC treated with PDT can recur years after treatment, long-term results 
are of great importance for conclusive recommendations on nBCC thickness and 
PDT.10-12 
 Here, we report the results of a prospective RCT with at least 5 years of follow-up 
and address the relation between tumor thickness and PDT treatment failure. 
Materials and methods 
Patients and tumor characteristics 
Patients with nBCC were recruited from the outpatient department of Dermatology of 
the Maastricht University Medical Center, The Netherlands. The study design and the 
procedures have been described in a prior report.9 In summary, included were patients 
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aged 18 years or older with a primary, histologically proven tumor on a 3 mm diagnostic 
punch biopsy specimen of the clinically thickest tumor part. BCC had to be exclusively 
of the nodular subtype. Patient related exclusion criteria comprised pregnancy, a life 
expectancy of less than 5 years, any known skin cancer diseases, the use of phototox-
ic/photosensitive drugs, and hypersensitivity to light or 5-aminolaevulinic acid (5-ALA) 
cream. Tumor related exclusion criteria comprised recurrent or pigmented BCC, histo-
logical subtypes other than nodular (e.g. micronodular) and mixed nodular/aggressive 
histological subtypes. Tumors located on extremely concave areas (e.g. alar-facial junc-
tion, ear) or hairy skin were also excluded in order to guarantee an equal light distribu-
tion and a good light absorption in non-pigmented areas, respectively.13,14 Tumors of 
patients who gave written informed consent were randomly assigned in a 1:1 ratio to 
either ALA-PDT or surgical excision using a computer-generated random allocation 
scheme. Blinding of patient or physicians to treatment allocation was not possible be-
cause the practical execution of both treatments extremely differs. The trial was ap-
proved by the Medical Ethics and Scientific Committee of the Maastricht University 
Medical Center. 
Photodynamic therapy 
Before PDT, tumors were partially debulked by removing all tumor tissue above the skin 
level with a 4 mm ring curette (Stiefel Laboratories LTD, Sligo, Ireland). The intention 
was to remove any protuberant tumor and to remove the surface skin barrier. More 
deeply located tumor tissue was not removed in order to prohibit converting the lesion 
into a tumor more suitable for PDT. A pressure bandage was applied in case of bleeding. 
Three weeks after debulking, tumors were treated with fractionated 20% 5-ALA-PDT 
under occlusion. The entire treatment protocol was based on previously reported pre-
clinical in-vivo studies.15-17 The tumor was illuminated with a broadband metal-halogen 
light source (585-720 nm) twice for 15 minutes with an interval of 60 minutes (Photo-
demarcation System 1, Prototype 5 Medeikonos AB®, Götenborg, Sweden; or Wald-
mann PDT 1200®, Waldmann Medizintechnik, Villingen-Schwenningen, Germany). 
This single fractionated treatment on the same day had a total light dose of 150 J/cm2. 
Incomplete response or recurrent tumor was registered as treatment failure and re-
treated surgically. 
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Surgical excision 
nBCC were excised including a 3 mm clinically tumor-free margin with local anesthesia. 
In case of a histologically proven residual tumor, it was registered as treatment failure 
and one or more re-excisions were performed until all margins were free of tumor. 
Tumor thickness 
In the PDT group, tumor thickness was retrospectively measured by an independent 
investigator on the initial diagnostic punch biopsy specimen, by using a microscope and 
a 0.1 mm precise liner. A total of 30 biopsies specimens (35%) was randomly re-
examined by a pathologist whose measurements were compared with those of the inves-
tigator to confirm the accuracy. 
Follow-up 
Follow-up visits took place 1-2 weeks after surgical excision because of removal of 
stitches. At 3, 6, 12, and 18 months post treatment, and after 2, 3, 4, and 5 years all pa-
tients were subsequently examined for recurrence of the tumors. Some patients even 
had a follow-up of 6, 7, or 8 years. If recurrent tumor was suspected at clinical examina-
tion, a 3 mm punch biopsy specimen was obtained for histological confirmation. All 
lesions within 5 mm of the scar were considered suspicious for recurrent tumor.18 Pa-
tients who were lost to follow-up or died during the trial were censored at the date of 
last examination. 
Statistical analysis 
We aimed at including 175 tumors, based on our previously reported sample size calcu-
lation.9 The analysis was performed on tumor level and according to the intention-to-
treat principle. The primary outcome was 5-year cumulative probability of recurrence-
free survival after ALA-PDT and surgical excision. Between-group comparisons were 
performed using Kaplan Meier survival analysis. Recurrence-free survival was defined as 
the absence of any local recurrence during follow-up. Follow-up time was calculated 
from the date of treatment to the date of recurrence or the date of last follow-up (cen-
soring date). An exploratory subgroup analysis was performed to calculate the probabil-
ity of recurrence-free survival according to tumor thickness within the group of patients 
who were treated by PDT. The log rank test was used to test for differences in recur-
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rence-free survival between groups. In all analyses, a p-value <0.05 was considered sta-
tistically significant. Data were analyzed using SPSS-pc version 18.0 (SPSS, Chicago, IL, 
U.S.A.) and STATA version 11.0 (STATA Corp, College Station, TX). 
Results 
Patient and tumor characteristics 
Between August 2002 and February 2006, 151 patients with 173 nBCC were recruited. 
In this study, 171 nBCC in 149 patients were treated, 88 with surgical excision and 83 
with ALA-PDT. Baseline characteristics of patients and tumors were similar in both 
groups (Table 1). 
 
Table 1. Distribution of patient and tumor characteristics. 
Characteristic ALA-PDT (n=83) SE (n=88) Total (n=171) 
Sex, M/F 43/40 44/44 87/84 
Mean age, years (range) 64.0 (24-83) 65.1 (21-91) 64.6 (21-91) 
Tumor localization in the face, n* (%) 
Tumor localization rest of the body, n* (%) 
44 (53) 
39 (47) 
45 (51) 
43 (49) 
89 (52) 
82 (48) 
No. of nBCC (in no. of patients) 
1 
> 1  
 
- 
- 
 
- 
- 
 
132 
17  
Mean tumor size (mm) ± SD 8.9 ± 4.0 9.3 ± 4.3 9.1 ± 4.1 
Mean tumor size of the largest diameter is measured before the diagnostic punch biopsy. ALA-PDT, ami-
nolaevulinic acid photodynamic therapy; F, female; M, male; nBCC, nodular basal cell carcinoma; SE, surgical 
excision. *No. of lesions. 
Follow-up 
The median follow-up of the total study population was 67 months (range 0-106). Be-
fore the start of PDT treatment two patients, each with one tumor, dropped out. One 
patient died before the treatment and one patient turned out to have a recurrent BCC. 
After randomization, three tumors randomized to ALA-PDT were treated with surgical 
excision and two tumors randomized to surgical excision were treated with ALA-PDT 
because the patients preferred the opposite treatment. The tumors in these patients were 
analyzed according to the intention-to-treat principle. After a median follow-up period 
of 67 months, 33 patients with 40 tumors were lost to follow-up (Fig. 1). In all, 25 of 
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these patients with 32 tumors died due to causes unrelated to the tumor or treatment. Of 
the other patients who were lost to follow-up 6 refused further participation in the study 
and 4 were untraceable. A total of 106 tumors (62.0%) had a follow-up period equal to 
or longer than 60 months. Of those, 48 tumors (28.1%) had a follow-up period equal to 
or longer than 84 months and 18 tumors (10.5%) had a follow-up period exceeding 96 
months. 
 
 
Fig. 1 Flow chart. ALA, aminolaevulinic acid; cum, cumulative; FU, follow-up; nBCC, nodular basal cell 
carcinoma; PDT, photodynamic therapy; SE, surgical excision. 
Treatment failure 
During the long-term follow-up, treatment failure occurred in 2 tumors in the surgical 
excision group and 25 tumors in the ALA-PDT group. Cumulative probabilities of 
treatment failure, based on Kaplan-Meier survival analysis, are summarized in Fig. 2. 
After 60 months post treatment, 23 tumors (30.7%) showed treatment failure in the 
1 deceased
1 recurrence
2 failures 2 fai lures
3 months: 86 3 months: 79
12 months: 83 12 months: 69
9 failures (cum. 11)
2 deceased
24 months: 77 24 months: 56
6 deceased 5 failures (cum. 16)
1 deceased
36 months: 72 36 months: 50
Randomized 173 nBCC
Allocated:
88 SE
Allocated:
85 ALA-PDT
60 months: 64 60 months: 42
96 months: 12 96 months: 6
5 failures (cum. 21)
2 failures (cum. 23)
3 deceased
2 failures (cum. 25)
5 deceased
2 refused
1 untraceable
4 deceased
2 untraceable
1 deceased
4 deceased
1 untraceable
1 refused FU
5 deceased
3 refused
1 deceased
Treated: 88 Treated: 83
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ALA-PDT group (95% CI 21.5% – 42.6%) whereas the treatment failure in the surgical 
excision group still was 2.3% (95% CI 0.6% – 8.8%, p<0.0001) (Table 2). Two more tu-
mors in the ALA-PDT group recurred after a longer period than the 60 months follow-
up period, at 72 and 91 months post treatment, and were not included in our analyses. 
The two failures in the surgical excision group were both caused by incomplete excision 
of the tumors. The first tumor remained incompletely excised after two more excisions 
and finally was completely removed as nBCC after Mohs’ micrographic surgery. The 
other tumor remained incompletely excised because the patient refused further treat-
ment. However, in this patient no clinical residual tumor was present at the last follow-
up visit 22 months post treatment. 
 
 
Patients in follow-up (n) 
SE   88        83        77       72        69        64        41        30        12         0 
PDT  83        69        56       50        48        42        33        18          6         0 
Fig. 2 Kaplan–Meier graph: survival analysis in the aminolevulinic acid photodynamic therapy (PDT) and in
the surgical excision (SE) groups. 
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Table 2. Cumulative probabilities of treatment failure after fractionated aminolevulinic acid photodynamic 
therapy with prior curettage versus surgical excision. 
 Cumulative recurrence probability (95% CI) 
Follow-up, months ALA-PDT Surgical excision 
12 13.6 (7.8 – 23.2) 2.3 (0.6 – 8.8) 
24 20.4 (13.0 – 31.2) 2.3 (0.6 – 8.8) 
36 27.6 (18.9 – 39.2) 2.3 (0.6 – 8.8) 
48 27.6 (18.9 – 39.2) 2.3 (0.6 – 8.8) 
60 30.7 (21.5 – 42.6) 2.3 (0.6 – 8.8) 
ALA-PDT, aminolaevulinic acid photodynamic therapy; CI, confidence interval. 
Recurrence-free survival according to tumor thickness 
The effect of tumor thickness on treatment failure was analyzed for nBCC treated with 
ALA-PDT. In 78 (94%) initial punch biopsy specimens tumor thickness was retrospec-
tively measured without interobserver discrepancy. Median tumor thickness was 1.3 
mm (range 0.3 – 3.1 mm). Use of this median value of 1.3 mm as cut-off point resulted 
in probabilities of recurrence-free survival of 77.4% (95% CI 60% - 88%) and 66.8% 
(95% CI 49% - 80%, p=0.14) for tumor thickness < 1.3 mm and ≥ 1.3 mm, respectively. 
We also used the lowest quartile of 0.7 mm as cut-off point and found a significant low-
er probability of recurrence-free survival for nBCC measuring > 0.7 mm in thickness 
(65.0%, 95% CI 51% - 76%) compared with tumors growing ≤ 0.7 mm deep (94.4%, 95% 
CI 67% - 99%, p=0.018) (Table 3). 
 
Table 3. Relationship between tumor thickness on diagnostic punch biopsy specimen an cumulative probabil-
ity of recurrence-free survival 60 months after photodynamic therapy treatment. 
Tumor thickness, mm Cumulative percentage Cumulative recurrence-free survival (95% CI) 
≤ 0.7  23.1  94.4 (67 - 99) 
0.8 – 1.2 48.7  61.9 (36 - 80) 
1.3 – 1.7 75.6  69.0 (43 - 85) 
> 1.7 100  64.3 (37 - 85) 
Data are given in percentages unless indicated otherwise. CI, confidence interval. 
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Discussion 
The results of this RCT showed a significant difference in cumulative probability of 
treatment failure of 2.3% in the surgical excision group compared to 30.7% in the ALA-
PDT group at 60 months of follow-up. Furthermore, success of treatment of nBCC with 
ALA-PDT depends on tumor thickness. Probability of recurrence-free survival is signif-
icantly lower for nBCC growing deeper than 0.7 mm compared with tumors with an 
infiltration depth ≤ 0.7 mm deep (65.0% vs. 94.4%, p=0.018). Notably, we found that 
nBCC treated with ALA-PDT can even recur after 91 months. 
 Our results indicated that ALA-PDT treatment success of nBCC depends on tumor 
thickness corroborate the previous findings by Morton et al.19 For the future this implies 
that: (1) diagnostic punch biopsies should be performed in the clinically thickest tumor 
part; and (2) pathologists should measure nBCC thickness on request when PDT is 
considered as treatment option. However, we realize that the agreement between corre-
sponding tumor thickness measurement in punch biopsy and surgical excision speci-
mens varies and discrepancy increases with increasing tumor thickness.20 
 The position of PDT as a treatment option for nBCC in today’s practice is debatable. 
Although surgical excision is a more effective treatment than PDT, a non-invasive ap-
proach with PDT might be more appropriate for some patients.4,6 PDT may be consid-
ered as an acceptable treatment option in a selected population with nBCC, for example 
elderly, inoperable patients or patients with a tumor thickness ≤ 0.7 mm. Notably, 
nBCC growing deeper than 0.7 mm, BCC with mixed nodular/aggressive histological 
subtypes and aggressive subtypes (e.g. micronodular) should not be treated with PDT. 
 We found that in primary thin nBCC (≤ 0.7 mm thick), the ALA-PDT cure rate of 
94.4% is almost comparable to the 5-year cure rates of nBCC treated with surgical exci-
sion (97.7%). Those cure rates are even among the higher cure rates found in most stud-
ies on treatment of BCC. In a study investigating the effect of Mohs’ micrographic sur-
gery 5-year cure rates of 98% are found21,22 and in a different study in electrodessication 
and curettage cure rates are 79%-99%.23 The efficacy of imiquimod in nBCC is less in-
vestigated and varies between 42-100%.24 Only a small imiquimod study had 5-year 
follow-up and showed a cure rate of 75%.25 In fact, cure rates of different studies may 
not be compared, because of many differences in protocols. However it is important 
information, because, in case of comparable cure rates, other factors such as cosmetic 
outcome and costs will determine treatment choice. The best method to compare cure 
rates of therapies is of course a RCT. 
 A limitation of this study might be that 3 mm punch biopsy specimens may show a 
sample error. It is known from literature that a 3 mm punch biopsy specimen predicts 
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the most aggressive BCC subtype in only 84% of primary BCC.26 As a consequence, 
other BCC subtypes than nodular might have been treated in this trial. However, decid-
ing what treatment should be given on the histological subtype in the punch biopsy 
specimen is representative for daily practice. 
 In 2007 Braathen et al. reviewed the results of both randomized and non-
randomized PDT studies in nBCC. The conclusion of this review was that methylami-
nolaevulinate (MAL)-PDT, as a treatment option for nBCC, is an effective and reliable 
method that is possibly preferable for thin lesions.7 The advice for limits on thickness of 
tumors was based on a retrospective MAL-PDT study by Soler et al. that showed a 7% 
rate of recurrence in thin nBCC (< 2 mm thickness, n=82) compared with 14% in thick 
nBCC (> 2 mm thickness, n=86) after a mean follow-up period of 35 months.8 We did 
not find significant differences in recurrence rate when using this cut-off point; only 
treatment of nBCC with a thickness ≤ 0.7 mm was associated with a low probability of 
treatment failure. Results may differ because Soler et al. determined tumor thickness 
clinically instead of performing a histological measurement via punch biopsy specimen. 
 PDT results depend on treatment protocols. Differences in photosensitizers, prior 
curettage, the use of the tissue penetration enhancer dimethylsulfoxide, or repetitive 
PDT cycles are all protocol variations that may result in different treatment outcomes.27-
30 Some authors claim that MAL-PDT is more effective than ALA-PDT. However, to 
date no study has compared both photosensitizers in a RCT and in the above mentioned 
studies MAL and ALA seem quite similar in treatment results.31-33 
 Fractionated illumination, which has been investigated in ALA-PDT, shows better 
clearance rates than treatment with only one illumination.34,35 When ALA-PDT is used 
in combination with prior dimethylsulfoxide and curettage even lower recurrence prob-
abilities were obtained.36 
 There are some new developments within the PDT field. Recent studies demonstrat-
ed that PDT with BF-200 ALA (Biofrontera Bioscience GmbH, Leverkusen, Germany) is 
a very effective treatment for both BCC and actinic keratosis.37-40 Another new develop-
ment that shows promising results in the treatment of actinic keratosis is patch PDT.41,42 
These developments could offer new insights into possible ways of optimizing PDT as 
therapy for BCC. 
 In conclusion, our study revealed that ALA-PDT is less effective than surgical exci-
sion in treatment of nBCC. Based on our results, ALA-PDT might be a second treat-
ment choice for inoperable patients with nBCC growing ≤ 0.7 mm deep. We therefore 
suggest that when considering PDT as treatment for nBCC, tumor thickness should be 
taken into account. This implies that physicians should take a diagnostic punch biopsy 
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from the clinically thickest tumor part and pathologists should measure thickness of a 
nBCC on request. 
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Despite skin cancer prevention campaigns on sun avoidance, little behavior change is 
seen and the incidence of skin cancer continues to rise. About 80% of skin cancers are 
basal cell carcinoma (BCC). Nowadays, the lifetime risk of developing a BCC before the 
age of 85 years is 1 in 5-6 persons.1 Predictions for the future incidence are even more 
alarming. One should keep in mind that incidence studies are based on data from cancer 
registries which often only register the first, histologically confirmed BCC. Within 5 
years after the first BCC diagnosis, 29% of patients will develop another BCC.2 There-
fore, only the tip of the iceberg is measured and actual incidence rates will be higher. 
BCC may be regarded as a chronic disease which poses a large burden on dermatologic 
health care services. 
 
A century ago, surgery was the only treatment option for BCC and was mostly per-
formed by general surgeons. Surgical excision is a treatment that enables histological 
verification of complete tumor removal. It therefore was (and still is) the most effective 
treatment in BCC. The first non-invasive option that emerged more than 50 years ago 
was 5-fluorouracil (5-FU). This therapy probably became abandoned as more dermatol-
ogists were expanding their surgical skills and a treatment was developed that resulted 
in nearly 100% cure rates (Mohs’ micrographic surgery).3,4 Furthermore, in the 1960-
1980s, incidence of skin tumors was still not that high that alternative treatments were 
in high demand. It is conceivable that in those days patients were glad their tumor was 
removed and were not that concerned about the aesthetic outcome. The situation 
changed in the late 20th century, when the incidence rates of BCC increased rapidly, 
more young patients were affected and patients became more demanding. At that time, 
the second non-invasive treatment was developed: photodynamic therapy (PDT). The 
concept of PDT was already initiated 100 years earlier by Von Tappeiner: an interaction 
between light, a photosensitizer and oxygen.5 It is interesting to observe how PDT sud-
denly gained popularity based on a few small-sized studies with a short follow-up peri-
od. One of the reasons was probably the strong need for non-surgical therapies that 
could be executed by nurses, relieving the busy dermatologic practice. PDT became a 
competitor of surgery with a promised high treatment success and excellent aesthetic 
outcome. PDT was incorporated in (inter)national guidelines on treatment of superficial 
BCC (sBCC). With the introduction of imiquimod in 2004 competition came into play. 
Imiquimod cream is less expensive than the in-hospital PDT. Another advantage of 
imiquimod is that patients can apply the cream themselves at home. Consequently, 
imiquimod became also incorporated in guidelines on BCC treatment. Guidelines agree 
that surgical excision should still be considered as first choice treatment for sBCC but 
excision is not always needed and often considered as overtreatment. Despite the 
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acknowledgement that in some instances non-invasive therapies may be preferred, there 
was no consensus on the best non-invasive treatment choice in sBCC.  
 
In the last decades, the need for consensus has increased due to the observed shift to-
wards sBCC.6 sBCC can be treated non-invasively and this provides the opportunity to 
reduce the workload for dermatologists. As a result, non-invasive therapies such as 
PDT, imiquimod and 5-FU have become increasingly popular. These trends highlight 
the need for evaluation of diagnostic and treatment options for optimal management of 
sBCC. First, the development of these non-invasive therapies demands an accurate di-
agnostic tool with the ability to discriminate between BCC subtypes. Knowledge of sub-
types is important as sBCC can be treated non-invasively while nodular BCC (nBCC) 
and aggressive BCC (aBCC) mostly require a surgical treatment. The need for distinc-
tion between sBCC and other types of BCC asks for diagnostic strategies that can meet 
this requirement. Secondly, the availability of various non-invasive treatment options 
for patients with sBCC asks for comparison of the effectiveness of these treatments and 
other aspects such as cosmetic results, adverse effects and costs. Such results are pivotal 
for reaching consensus on the most effective non-invasive treatment option in patients 
with sBCC. A third issue is whether treatment needs to be tailored based on patient and 
tumor characteristics. It may well be that subgroups of patients benefit more or less 
from specific treatment options.   
Diagnosis  
Optimal management of BCC relies on early and accurate diagnosis in order to optimize 
outcome and minimize morbidity. Current national and international guidelines on 
BCC recommend a punch biopsy of clinically suspected BCC prior to treatment to facil-
itate treatment choice based on the histological BCC subtype.7-9 We performed two 
studies to evaluate the diagnostic accuracy of a punch biopsy. In one study on the 
agreement between the results of punch biopsy and surgical excision, we found that 
punch biopsies can detect the most aggressive subtype in 83.4% of cases when compared 
with surgical excision, resulting in a correct staging in 5 out of 6 primary BCC.10 Our 
findings corroborate results of previous studies that also showed high percentages of 79-
89%.11,12 An explanation for the fact that the most aggressive subtype is not detected in 
all cases is that a punch biopsy, often 3-4 mm, represents only a small sample of the 
tumor. The majority of BCC (74%) consists of a ‘mixed’ histological subtype and the 
most aggressive component can be missed in a small tumor sample.10 However, we can 
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conclude that a punch biopsy has a high sensitivity to identify nBCC and aBCC that 
qualify for surgery instead of a non-invasive treatment.  
 
In another study, the accuracy of punch biopsy was compared with that of a clinical 
diagnosis by a dermatologist. The diagnosis based on the surgical excision specimen was 
used as gold standard. It is assumed that dermatologists can diagnose a BCC fairly well 
by their clinical observation.13 The advantage of clinical diagnosis is that it is a painless, 
time saving and presumably also a cost saving procedure. But a relevant question is: how 
many tumors will be over- or understaged and consequently how many tumors would 
be over- or undertreated when omitting a punch biopsy? We performed a study to com-
pare the diagnostic accuracy of clinical assessment and histological diagnosis by punch 
biopsy for subtyping BCC.14 In this study, a punch biopsy appeared to be a more accu-
rate diagnostic tool than the clinical diagnosis for detection of the histological BCC 
subtype. Omission of a punch biopsy resulted in overstaging of 1 in 4 sBCC as nodular 
or aggressive and in understaging in about 1 in 4 aBCC as nBCC. The question can be 
raised whether these diagnostic errors result in inadequate treatment. In case of over-
staging, the physician will almost certainly advise surgery and the patient will be denied 
the choice between surgery and less invasive alternatives. However, some patients will 
be satisfied with a surgical excision as they are content that their tumor has been re-
moved. In case of understaging, patients are at risk of having their BCC excised with too 
small margins. However, a BCC is a tumor with a low mortality rate and any residue or 
recurrence following therapy can be diagnosed and retreated easily in most cases. Based 
on these findings, it may be justified in a few cases to omit a punch biopsy, especially if 
the tumor is located on a low risk area. It would be interesting to find out whether the 
accuracy of clinical diagnosis approaches that of a punch biopsy when the degree of 
confidence in the diagnosis of BCC subtype is taken into account. In situations where 
physicians are very confident of their clinical diagnosis on BCC subtype, the need for a 
punch biopsy may be less obvious. Furthermore, the subtyping of BCC might further be 
improved by the use of a dermatoscope, which enables detection of certain clinical fea-
tures that are characteristic for BCC subtypes.15 The hypothesis, that a clinical diagnosis 
of BCC subtype made with a dermatoscope and high confidence may exclude the neces-
sity of a punch biopsy prior to treatment, needs to be confirmed in a well-designed pro-
spective study.   
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Treatment 
The equivocal guidelines and the large web of treatment options presented in guidelines 
on sBCC can hamper physicians in making well-informed treatment choices. Due to the 
current lack of evidence on relative effectiveness of therapies, treatment choice is nowa-
days partly based on the doctors’ own experience and education. More evidence on 
relative effectiveness of treatments is needed. We performed a systematic review and 
meta-analysis of published studies to compare the tumor-free survival of patients with 
primary sBCC treated with the most frequently used non-invasive therapies.16 The ma-
jority of the included studies reported on treatment with imiquimod or PDT, which 
enabled a meta-analysis on treatment success of these therapies. The pooled estimates 
for one year tumor-free survival were 87.3% for imiquimod and 84.0% for PDT. Howev-
er, restriction of the analysis to PDT studies with only one PDT cycle resulted in a lower 
pooled estimate of tumor-free survival of 76.2%. These results provided evidence that 
imiquimod and PDT are nearly equally effective in treatment of sBCC at one year post 
treatment. The meta-analysis also revealed that head-to-head comparison studies and 
studies with a long-term follow-up were lacking. Closing this gap in knowledge is essen-
tial to enable better recommendations in guidelines on sBCC treatment.  
 
To fulfill the need for a head-to-head comparison study with long-term follow-up, a 
non-inferiority randomized controlled trial in 601 patients with sBCC treated with me-
thylaminolevulinate (MAL)-PDT, imiquimod or 5-FU has been performed. The one 
year follow-up results indicated that both creams are not inferior to MAL-PDT in terms 
of effectiveness and that imiquimod was even superior to MAL-PDT.17 One year tumor-
free survival for imiquimod was 83.4% versus 72.8% for MAL-PDT with a difference of 
10.6% (95% CI 1.5%-19.5%) favoring imiquimod. Extra data during a three year follow-
up period were collected. At three years post treatment, imiquimod and 5-FU remained 
non-inferior to MAL-PDT, but the gap between imiquimod and MAL-PDT widened 
even more. Imiquimod showed a large advantage in three year tumor-free survival of 
79.7% compared with 68.2% for 5-FU and only 58.0% for MAL-PDT. The conclusion is 
that based on effectiveness, imiquimod should be considered as the first treatment 
choice in primary, low-risk sBCC. 
 The trial was designed as a non-inferiority trial because before the start of the trial it 
was assumed that MAL-PDT was the most effective treatment and that both creams 
might be less effective in terms of tumor-free survival. However, it was expected that the 
creams would have advantages such as lower costs and reduction of workload on der-
matologists, because creams can be applied by the patient at home. Because of these 
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advantages and the possibility to fall back on excision in case of a recurrent BCC, a loss 
in one year tumor-free survival by 10% was deemed acceptable. The choice of MAL-
PDT as reference therapy was based on a review of the Cochrane Collaboration which 
concluded that surgical excision should be the first choice therapy for sBCC but that 
PDT can be considered as a good alternative because of better cosmetic outcomes and a 
greater patient tolerability.18 It was assumed that the one year cumulative probability of 
tumor-free survival after PDT would be about 80%, based on the average of the esti-
mates for PDT from the meta-analysis. However, the trial results seem to contradict the 
correctness of this assumption. This faulty assumption is partly due to the scarcity of 
randomized controlled trials comparing MAL-PDT with surgery. Before the start of the 
trial, only one randomized controlled trial had compared MAL-PDT with surgical exci-
sion at one year post treatment and estimates of treatment success after PDT may have 
been overoptimistic.19 The one trial included 128 histologically proven primary sBCC 
that were treated with one or two MAL-PDT cycles. In this study, 90 of 128 (70.3%) 
sBCC responded to one MAL-PDT cycle, but the non-responders and incomplete re-
sponders received two additional MAL-PDT sessions after a period of three months. 
This increased the overall cumulative probability of sustained clearance to 90% at one 
year post treatment for MAL-PDT. A reason for the observed discrepancy with the ex-
pected 80% treatment success after PDT may be that the most frequently used European 
PDT protocol was applied very strictly in this trial. This protocol for MAL-PDT is ad-
vised by the company producing MAL and prescribes one MAL-PDT cycle consisting of 
two treatments with one week interval.20 Repeating treatments would probably improve 
treatment success but increases the dermatologist’s workload and treatment costs.  
 The trial results indicate that PDT is not the most effective non-invasive treatment 
option. However, PDT has the benefit of being a two-day treatment with less side effects 
and a more rapid recovery compared with imiquimod. In this respect, further research 
to improve PDT and its illumination protocol seems worthwhile.   
 
Now we have concluded that imiquimod should be the first choice therapy in primary 
sBCC, the question raises whether imiquimod is the most effective therapy for every 
patient with a sBCC. Based on data derived from the above mentioned non-inferiority 
trial, subgroup analyses were performed to explore whether the relative treatment effect 
of MAL-PDT and imiquimod is consistent across subgroups of patients and tumors.21 A 
higher probability of treatment success for imiquimod versus MAL-PDT at three year 
follow-up was confirmed in most subgroups. An interesting finding was that in patients 
>60 years with a sBCC on the lower extremities, MAL-PDT was more effective than 
imiquimod (tumor-free survival of 93.8% vs. 36.2%). This finding coming from an ex-
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plorative analysis needs to be confirmed in future studies, but for the time being these 
results suggest that MAL-PDT can be considered as a treatment option for older pa-
tients with sBCC on the lower extremities, in whom the imiquimod induced erosion 
might  cause local wound infections, ulcerations or erysipelas. There are other situations 
wherein imiquimod may not be the optimal choice for an individual patient. Imiquimod 
requires compliance with a treatment regimen which prescribes application once daily, 
five times a week for six weeks. Therefore, this treatment is not indicated when the 
sBCC is situated inconveniently on a body site that is out of reach of a patient or when 
there is another reason why patients are not capable of applying the cream. In these 
cases, PDT may be an option, but surgery may also be considered depending on the 
comparative assessment between effectiveness and cosmetic aspects.  
 
It was also evaluated whether tumor thickness and adnexal extension might influence 
response to non-invasive treatments. The superficial growth pattern is easily accessible 
for topical treatments. We defined a sBCC as a tumor existing of small buds of prolifer-
ating basal cells that grow down from the epidermis into the superficial dermis, whilst 
maintaining their attachment to the base of the epidermis. However, it might be that 
there is a threshold thickness above which sBCC do not respond well to PDT, 
imiquimod and 5-FU. We measured tumor thickness in 336 sBCC with a median thick-
ness of 0.35 mm and a range of  0.2-1.0 mm.22 Our results showed that tumor thickness 
and adnexal extension of sBCC were not significantly associated with treatment failure 
following MAL-PDT, imiquimod or 5-FU.  
 
International guidelines recommend PDT as treatment option for sBCC, but also for 
‘thin’ nBCC that cannot be surgically excised. Thin tumors are likely to respond to the 
superficially working PDT. We analyzed the effect of nBCC thickness on treatment 
failure five years after treatment with fractionated aminolaevulinic acid (ALA)-PDT.23 
The cumulative probability of tumor-free survival after ALA-PDT was 65.0% for tumors 
measuring > 0.7 mm in thickness compared with 94.4% in tumors ≤ 0.7 mm. The find-
ing that thin nBCC in this trial responded more often to PDT than the sBCC in the non-
inferiority trial (treatment success of 94.4% vs. 58.0%) might be explained by the partial 
debulking prior to PDT.  
 Another explanation might be that nBCC were treated with ALA-PDT instead of 
MAL-PDT. According to the literature, the effectiveness in terms of clearance rates of 
sBCC is lower for MAL-PDT in two sessions compared with fractionated ALA-PDT: 
73% vs.88% at five years post treatment.24,25 Based on these results, fractionated ALA-
PDT with partial debulking might be considered as an acceptable non-invasive treat-
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ment option in a selected population of inoperable patients with nBCC measuring ≤ 0.7 
mm in thickness.  
 
Based on the data in this thesis, we can conclude that a punch biopsy is preferred in 
clinically suspected BCC in order to confirm the diagnosis but, even more important, to 
identify the most aggressive subtype. Omission of a punch biopsy may be justified in few 
cases, but the possible consequences should always be discussed carefully with the pa-
tient. First choice treatment for sBCC is imiquimod cream whereas PDT might be a 
treatment option in elderly patients with sBCC on the lower extremities or in patients 
for whom cream application is not feasible for practical reasons. It will remain a goal but 
also a challenge for dermatologist and other physicians to provide clear guidance in 
treatment of an individual patient with sBCC.  
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Summary  
The rapid increase in basal cell carcinoma (BCC) incidence has prompted the need for 
new, non-invasive treatment modalities. These superficial working therapies are good 
alternatives for surgery in superficial BCC. As BCC are categorized in three main sub-
types (superficial, nodular and aggressive, denoted as sBCC, nBCC and aBCC, respec-
tively), it is of great importance to accurately discriminate between histological subtypes 
in order to select an appropriate treatment. sBCC can be treated non-invasively while 
nBCC and aBCC require a surgical treatment. This thesis addresses the results of seven 
studies on the diagnosis and treatment of BCC. 
 
Chapter 1 gives an introduction to the thesis. It provides a short overview of the epide-
miology, risk factors, pathogenesis, diagnosis and treatment of BCC. Furthermore, the 
objectives of the thesis are described in this chapter. 
 
Chapter 2 describes two studies on the diagnosis of BCC. In chapter 2.1 we present the 
results of a retrospective study that established the agreement between the histological 
BCC subtype and the most aggressive component on punch biopsy and diagnosis ac-
cording to the subsequent surgical excision specimen. A total of 243 primary BCC in 
191 patients were analyzed and the histological subtype present on punch biopsy and 
the subsequent surgical excision was recorded. As a substantial percentage of BCC con-
sist of more than one subtype, our analyses were based the most aggressive histological 
subtype. The agreement between histological subtype observed on punch biopsy speci-
mens and excision specimens was 60.9%. The proportion of punch biopsies that correct-
ly identifies the most aggressive growth pattern of the entire BCC was 84.4%. This 
means that in one out of six BCC the most aggressive growth pattern is missed in an 
adequately taken punch biopsy. In addition, we found that 74% of all primary BCC 
consisted of more than one histological subtype. These results indicate that dermatolo-
gists and other physicians treating BCC should be aware of the limited diagnostic value 
of a punch biopsy to determine the histological BCC subtype of the entire lesion. Misdi-
agnosis of the subtype may lead to under- and overtreatment of BCC. 
 Some dermatologists argue that omitting a biopsy might be acceptable or even pref-
erable in some cases. Disadvantages of a punch biopsy are discomfort for the patient and 
the associated time and costs for the physician. In contrast, clinical diagnosis is a pain-
less, time- and possibly cost-saving procedure. In chapter 2.2 we compare the diagnos-
tic accuracy of clinical assessment and histological diagnosis by punch biopsy for sub-
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typing BCC. The gold standard for subtyping BCC was the histological subtype on the 
subsequent surgical excision. In addition, we evaluate the impact of omitting the punch 
biopsy on treatment recommendations. This study was performed at the departments of 
Dermatology of the Maastricht University Medical Centre and the Erasmus Medical 
Centre Rotterdam. A total of 152 histologically confirmed BCC from 116 patients were 
evaluated for the most aggressive subtype by clinical diagnosis, the subsequent punch 
biopsy and surgical excision specimens. A distinction was made between superficial, 
nodular and aggressive BCC. The gold standard for BCC subtyping was the histological 
subtype on the subsequent surgical excision. The results show that omission of a punch 
biopsy may result in overstaging of 1 in 4 sBCC and in understaging of 1 in 4 aBCC. 
Thus, a punch biopsy is a better diagnostic tool than the clinical diagnosis for detection 
of the histological BCC subtype, which is in line with international guidelines. In case a 
physician decides to omit a punch biopsy, the impact of over- or understaging must be 
weighed against extra time, cost and patient discomfort associated with a punch biopsy.  
 
Chapter 3 consists of five sections and presents several studies on the efficacy of differ-
ent treatment modalities for low risk BCC. In addition, we aimed at identifying sub-
groups of patients and tumors that differ in treatment response in order to select the 
most effective treatment for individual patients depending on patient and tumor charac-
teristics. 
 In chapter 3.1 a systematic review and meta-analysis was performed to determine 
the residue-free, recurrence-free and tumor-free survival probabilities of patients with 
primary sBCC treated with the currently most frequently used treatment options. We 
searched for articles in the Pubmed, EMBASE and Cochrane databases, and reference 
lists of selected articles were retraced. Included were studies reporting on residue and/or 
recurrence probabilities after treatment of primary, histologically proven sBCC with a 
minimum follow-up of 12 weeks. Thirty-six studies (14 randomized and 22 non-
randomized trials) were included. The pooled estimates of sBCC with tumor-free sur-
vival at one year post treatment, derived from 23 studies, were 87.3% (95% CI 84-91%) 
for imiquimod and 84.0% (95% CI 78-90%) for photodynamic therapy (PDT). The PDT 
tumor-free survival was lower in studies with a single treatment cycle. To date, only a 
few studies have reported on treatment of sBCC with 5-fluorouracil (5-FU) or surgical 
excision. Based on our meta-analysis, we can conclude that imiquimod and PDT are 
both good non-invasive treatment options for sBCC. However, there is a lack of head-
to-head comparison studies between imiquimod, PDT and other therapies and long-
term follow-up studies are scarce.  
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In chapter 3.2 we present the results of a non-inferiority randomized controlled trial 
with three year follow-up that investigated the tumor-free survival of imiquimod and 5-
FU versus methylaminolevulinate (MAL)-PDT in patients with sBCC. This study fulfills 
the need for head-to-head comparison studies with long-term follow-up and enables 
better treatment recommendations for non-invasive treatment of sBCC. A total of 601 
patients with a primary sBCC were enrolled at seven departments of Dermatology in the 
southern part of The Netherlands. Participants had been randomly assigned to MAL-
PDT (two sessions with one week interval), imiquimod (once daily, five times a week for 
6 weeks), or 5-FU (twice daily for 4 weeks). A follow-up visit took place at three years 
post treatment by a research physician who was blinded to the assigned therapy. Clinical 
treatment failures were histologically confirmed by a 3 mm punch biopsy. A pre-
specified non-inferiority margin of 10% was used. We showed that the probability of 
tumor-free survival at three years post treatment was 58.0% for MAL-PDT, 79.7% for 
imiquimod, and 68.2% for 5-FU. The hazard ratio for treatment failure comparing 
imiquimod with MAL-PDT was 0.50 (95% CI 0.33-0.76, p=0.001). Comparison of 5-FU 
with MAL-PDT resulted in a hazard ratio of 0.73 (95% CI 0.51-1.05, p=0.092), and 
comparison of 5-FU with imiquimod in a hazard ratio of 0.68 (95% CI 0.44-1.06, 
p=0.091). Thus, imiquimod is superior to MAL-PDT and guidelines on sBCC treatment 
should recommend imiquimod as first choice treatment option. 5-FU is not-inferior to 
MAL-PDT, but compares unfavourably with treatment success after imiquimod treat-
ment. Both creams have a comparable cosmetic outcome and risk of local adverse 
events. Although 5-FU is less expensive than imiquimod, the additional cost-savings of 
5-FU compared to imiquimod is small since the higher number of treatment failures 
require more additional treatments. 
 In chapter 3.3 we explore whether this relative treatment effect of MAL-PDT and 
imiquimod is consistent across subgroups defined by certain patient and tumor charac-
teristics. Identification of subgroups of patients that differ in response to MAL-PDT and 
imiquimod is of great value in clinical practice to select the most effective treatment for 
an individual patient with sBCC. Data were derived from the multicenter randomized 
controlled trial described in chapter 3.2. Treatment success was defined as tumor-free 
survival at one year post treatment. Subgroup analyses were performed for subgroups 
defined by sex, age (≤ 60 years vs. > 60 years), tumor location (head/neck, trunk, lower 
extremities or upper extremities) and tumor size (≤ 60 mm2 vs. > 60 mm2). Relevant 
endpoints were available for 196 patients treated with MAL-PDT and 189 patients treat-
ed with imiquimod. Imiquimod was superior to MAL-PDT in subgroups of females, 
sBCC on the trunk and large tumors with differences in success percentages favoring 
imiquimod of 18.4%, 21.0%, 18.9%, respectively. A higher probability of treatment suc-
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cess (but no superiority) of imiquimod vs. MAL-PDT was consistently found for males, 
patients > 60 years, tumors on the head/neck and upper extremities, and smaller sBCC. 
Interestingly, within the subgroup of sBCC on the lower extremities, treatment success 
after imiquimod was much lower (36.8%) than after MAL-PDT (94.1%) in patients > 60 
years. This higher probability of treatment success for MAL-PDT compared to 
imiquimod was not seen for younger patients with a sBCC on the lower extremities. In 
chapter 3.2 we showed that the results of these subgroup analyses remained unaltered at 
three years of follow-up. However, we emphasize that the results should be interpreted 
carefully as the subgroup analyses in this study were exploratory and not driven by prior 
hypotheses. Based on the results, imiquimod should remain the first choice treatment 
for sBCC in terms of effectiveness. However, MAL-PDT might be preferred in elderly 
with sBCC on the lower extremities. 
 In chapter 3.4 we further investigate whether the histological characteristics tumor 
thickness and adnexal extension of sBCC may influence treatment response of non-
invasive therapies. Again, we used the database of the non-inferiority randomized con-
trolled trial described in chapter 3.2. The study was designed as a case-control study, 
where 112 patients with treatment failure were selected as cases and 224 patients with 
treatment success were randomly selected as control subjects to enable detection of an 
odds ratio ≥ 2.5 with a power of 80% (alpha = 5%). Histopathological slides of the initial 
diagnostic punch biopsies were retrieved to obtain additional data on tumor thickness 
and adnexal extension. Scatter plots showed a lack of association between tumor thick-
ness as a continuous variable and treatment failure for all treatment groups. Therefore, 
no separate analyses per treatment modality was performed and all tumors were com-
bined in one dataset. Tumor thickness of included patients ranged from 0.2 to 1.0 mm. 
The results showed that tumor thickness and adnexal extension of sBCC were not sig-
nificantly associated with treatment failure of MAL-PDT, imiquimod or 5-FU. Similar 
results were obtained after correction for potential confounders (sex, age, type of treat-
ment, tumor surface area and tumor location) in a multivariate logistic regression analy-
sis. We therefore conclude that tumor thickness and adnexal extension do not have to 
be taken into account before deciding whether non-invasive treatment is adequate for a 
patient with sBCC. 
 In chapter 3.5 we compare the long-term effectiveness of fractionated 20% 5-
aminolaevulinic acid (ALA)-PDT with prior partial debulking versus surgical excision 
in nBCC. In addition, we analyze the effect of nBCC thickness on ALA-PDT failure. 
Patients presenting at the department of Dermatology at the Maastricht University 
Medical Centre with a primary, histologically proven nBCC were included and random-
ly assigned to treatment with fractionated ALA-PDT (n=85) or surgical excision with a 
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3 mm margin (n=88). Two PDT illuminations were performed with a one hour interval. 
Follow-up was at least 5 years post treatment and clinical treatment failures were histo-
logically confirmed by a 3 mm punch biopsy. In the ALA-PDT group, tumor thickness 
was retrospectively measured by an independent investigator on the initial diagnostic 
punch biopsy specimens. The cumulative recurrence probability at 5 years post treat-
ment was 30.7% for ALA-PDT and 2.3% for surgical excision (p<0.0001). Remarkably, 
two tumors treated with ALA-PDT even recurred after 72 and 91 months post treat-
ment. The tumor thickness of nBCC ranged from 0.3-1.3 mm. We found that the cumu-
lative probability of tumor-free survival after ALA-PDT was 65.0% for tumors measur-
ing > 0.7 mm in thickness compared with 94.4% in tumors ≤ 0.7 mm. These findings 
confirm that surgical excision remains the gold standard for treatment of nBCC. How-
ever, ALA-PDT might be considered as an acceptable treatment option in a selected 
population of  inoperable patients with nBCC measuring ≤ 0.7 mm in thickness. This 
implies that in case of a suspected nBCC, physicians should take a diagnostic punch 
biopsy from the clinically thickest tumor part and pathologists should measure the 
thickness of a nBCC on request.  
 
Finally, chapter 4 describes the discussion and valorization in which the results of this 
thesis are put into perspective. We discuss the position of our results within the current 
knowledge on diagnosis and treatment of BCC.  
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Samenvatting 
De snelle incidentie stijging van het basaal cel carcinoom (BCC) heeft ervoor gezorgd 
dat er nieuwe, niet-invasieve behandelingen op de markt zijn gekomen. Deze opper-
vlakkig werkende therapieën zijn goede alternatieven voor chirurgie in het superficieel 
BCC. Omdat BCC worden onderverdeeld in drie grote subgroepen (superficieel, nodu-
lair en agressief, afgekort als respectievelijk sBCC, nBCC en aBCC) is het van groot 
belang om accurate diagnostiek toe te passen met een goed vermogen om te discrimine-
ren tussen de verschillende histologische subtypes zodat een gepaste behandeling kan 
worden gekozen. sBCC kunnen niet-invasief worden behandeld terwijl nBCC en aBCC 
een chirurgische behandeling vereisen. In dit proefschrift worden de resultaten weerge-
geven van zeven studies naar de diagnostiek en de behandeling van het BCC.  
 
Hoofdstuk 1 geeft een algemene introductie van het proefschrift. Hierin wordt een kort 
overzicht gegeven van de epidemiologie, risicofactoren, pathogenese, diagnostiek en 
behandeling van het BCC. Daarnaast worden in dit hoofdstuk de doelstellingen van het 
proefschrift besproken. 
 
Hoofdstuk 2 beschrijft twee studies naar de diagnostiek van het BCC. In hoofdstuk 2.1 
presenteren we de resultaten van een retrospectieve studie waarin wordt vastgesteld wat 
de overeenkomst is tussen het histologisch BCC subtype en de meest agressieve compo-
nent op het punch biopt in vergelijking met de diagnose op de daaropvolgende chirurgi-
sche excisie. In totaal werden 243 primaire BCC bij 191 patiënten geanalyseerd en werd 
het histologisch subtype op het punch biopt en de daaropvolgende chirurgische excisie 
genoteerd. Omdat bekend is dat een aanzienlijk percentage van BCC uit meer dan één 
subtype bestaat, zijn de analyses gebaseerd op het meest agressieve histologisch subtype. 
De overeenkomst tussen histologisch subtype op het punch biopt en de chirurgische 
excisie was 60.9%. De proportie van punch biopten dat op een correct wijze het meest 
agressieve groeipatroon van het gehele BCC kan identificeren was 84.4%. Dit betekent 
dat in 1 op de 6 BCC het meest agressieve groeipatroon wordt gemist in een juist afge-
nomen punch biopt. Deze resultaten geven aan dat dermatologen en overige artsen die 
BCC behandelen zich bewust moeten zijn van de beperkte diagnostische waarde van een 
punch biopt bij het vaststellen van het histologisch BCC subtype van de gehele laesie. 
Foutieve diagnose van het subtype kan leiden tot onder- en overbehandeling van het 
BCC. 
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 Sommige dermatologen betwisten of het achterwege laten van een biopt acceptabel is 
of zelfs de voorkeur geniet in sommige gevallen. Nadelen van een punch biopt zijn na-
melijk het ongemak voor de patiënt en de gerelateerde tijd en kosten voor de arts. De 
klinische diagnose is daarentegen een pijnloze, tijd- en kostenbesparende procedure. In 
hoofdstuk 2.2 vergelijken we de diagnostische nauwkeurigheid van de klinische blik en 
de histologische diagnose middels punch biopt voor subtypering van het BCC. De gou-
den standaard voor subtypering van het BCC was het histologische subtype aanwezig in 
het chirurgisch excisie preparaat. Daarnaast evalueren we de gevolgen van het achterwe-
ge laten van het punch biopt op de behandelvoorstellen. Deze studie werd uitgevoerd op 
de afdeling dermatologie in het Maastricht Universitair Medisch Centrum en het Eras-
mus Medisch Centrum Rotterdam. In totaal werden 152 histologisch bewezen BCC van 
116 patiënten beoordeeld op het meest agressieve subtype middels klinische blik, het 
daaropvolgende punch biopt en de chirurgische excisie. Er werd een onderscheid ge-
maakt tussen superficieel, nodulair of agressief BCC. De gouden standaard voor BCC 
subtypering was het histologisch subtype aanwezig in de chirurgische excisie. De resul-
taten laten zien dat het achterwege laten van een punch biopt kan resulteren in oversta-
diëring van 1 op de 4 sBCC en onderstadiëring van 1 op de 4 aBCC. Een punch biopt is 
dus een beter diagnostisch middel dan de klinische blik voor het vaststellen van het 
histologisch BCC subtype, hetgeen in overeenstemming is met internationale richtlij-
nen. In het geval dat een arts toch beslist om het punch biopt achterwege te laten, moet 
er een afweging worden gemaakt tussen de impact van over- en onderstadiëring en de 
extra tijd, kosten en ongemak voor de patiënt die gerelateerd zijn aan het nemen van een 
punch biopt.  
 
Hoofdstuk 3 is onderverdeeld in vijf secties en beschrijft studies naar de effectiviteit van 
verschillende behandelopties voor laag-risico BCC. Bovendien streefden wij naar het 
identificeren van subgroepen van patiënten en tumoren die verschillen in behandelreac-
tie om zodoende de meest effectieve behandeling te selecteren voor individuele patiën-
ten gebaseerd op patiënt en tumor karakteristieken. 
 In hoofdstuk 3.1 werd een systematische review en meta-analyse uitgevoerd om vast 
te stellen wat de residuvrije, recidiefvrije en de tumorvrije overlevingskansen zijn van 
patiënten met een primair sBCC behandeld met één van de huidige, meest frequente 
behandelopties. We zochten naar artikelen op de Pubmed, EMBASE en Cochrane data-
base. Daarnaast werden referentielijsten van de geselecteerde artikelen nagetrokken. 
Studies werden geïncludeerd wanneer deze rapporteerden over residu en/of recidief 
kansen na behandeling van primair, histologisch bewezen sBCC met een minimale fol-
low-up van 12 weken. Zesendertig studies (14 gerandomiseerde en 22 niet-gerando-
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miseerde trials) werden geïncludeerd. De gepoolde uitkomst van sBCC met tumorvrije 
overleving één jaar na behandeling , verkregen uit 23 studies, was 87.3% (95% CI 84-
91%) voor imiquimod en 84.0% (95% CI 78-90%) voor fotodynamische therapie (PDT). 
De PDT tumorvrije overleving was lager voor onderzoeken waarin werd behandeld met 
één enkele cyclus. In de literatuur zijn slechts enkele studies voorhanden die rapporte-
ren over de behandeling van sBCC middels 5-fluorouracil (5-FU) of chirurgische exci-
sie. Aan de hand van onze meta-analyse concluderen we dat imiquimod en PDT allebei 
goede niet-invasieve behandelopties zijn voor sBCC. Er is echter wel een gebrek aan 
head-to-head vergelijkende studies tussen imiquimod, PDT en andere behandelingen en 
lange termijn studies zijn schaars. 
 In hoofdstuk 3.2 presenteren we de resultaten van een non-inferioriteit gerandomi-
seerde trial met drie jaar follow-up, waarin de tumorvrije overleving werd onderzocht 
van imiquimod en 5-FU ten opzichte van methylaminolevulaat (MAL)-PDT in patiën-
ten met sBCC. Deze studie voldoet aan de behoefte naar head-to-head vergelijkende 
studies met een lange follow-up en maakt het mogelijk om betere aanbevelingen te doen 
voor niet-invasieve behandelingen van sBCC. In totaal werden 601 patiënten met een 
primair sBCC geïncludeerd op zeven afdelingen dermatologie in het zuiden van Neder-
land. Deelnemers werden gerandomiseerd naar MAL-PDT (twee sessies met één week 
interval), imiquimod (éénmaal daags, vijf dagen per week gedurende 6 weken) of 5-FU 
(tweemaal daags gedurende 4 weken). Een controle afspraak vond plaats drie jaar na 
behandeling door een arts-onderzoeker die geblindeerd was voor de toegewezen behan-
deling. Klinisch behandelfalen werd histologisch bevestigd met een 3 mm punch biopt. 
Een vooraf vastgestelde non-inferioriteits marge van 10% werd gehanteerd. We toonden 
aan dat de kans op tumorvrije overleving drie jaar na behandeling 58.0% was voor 
MAL-PDT, 79.7% voor imiquimod en 68.2% voor 5-FU. De hazard ratio voor behandel-
falen tussen imiquimod en MAL-PDT was 0.50 (95% CI 0.33-0.76, p=0.001). De verge-
lijking tussen 5-FU met MAL-PDT resulteerde in een hazard ratio van 0.73 (95% CI 
0.51-1.05, p=0.092) en de vergelijking tussen 5-FU en imiquimod in een hazard ratio 
van 0.68 (95% CI 0.44-1.06, p=0.091). Imiquimod is dus superieur aan MAL-PDT en 
richtlijnen over sBCC behandeling zouden imiquimod moeten aanbevelen als eerste 
keus behandeling. 5-FU is niet inferieur aan MAL-PDT, maar is ongunstig vergeleken 
met het behandelsucces na imiquimod behandeling. Beide crèmes hebben een vergelijk-
baar cosmetisch resultaat en risico op lokale bijwerkingen. Ondanks het feit dat 5-FU 
minder duur is dan imiquimod, is de kostenbesparing van 5-FU vergeleken met 
imiquimod erg laag gezien het feit dat het hoge aantal behandelfalen meer aanvullende 
behandelingen vereist.  
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 In hoofdstuk 3.3 hebben we onderzocht of het relatieve behandeleffect van MAL-
PDT en imiquimod consistent is binnen subgroepen gedefinieerd door bepaalde patiënt 
en tumor karakteristieken. Het definiëren van subgroepen patiënten die verschillen in 
reactie op MAL-PDT en imiquimod is van grote waarde in de klinische praktijk voor het 
selecteren van de meest effectieve behandeling voor een individuele patiënt met een 
sBCC. De benodigde gegevens werden verkregen uit de gerandomiseerde multicenter 
studie die in hoofdstuk 3.2 is beschreven. De behandeling werd als succesvol gedefini-
eerd bij een tumorvrije overleving één jaar na behandeling. Subgroep analyses werden 
uitgevoerd voor subgroepen gedefinieerd door geslacht, leeftijd (≤ 60 jaar vs. > 60 jaar), 
tumor locatie (hoofd/hals, romp, onderste extremiteiten en bovenste extremiteiten) en 
tumor grootte (≤ 60 mm2 vs. > 60 mm2). Relevante eindpunten waren beschikbaar voor 
196 patiënten behandeld met MAL-PDT en 189 patiënten behandeld met imiquimod. 
Imiquimod was superieur aan MAL-PDT in de subgroepen vrouwen, sBCC op de romp 
en grote tumoren met een verschil in slagingspercentages in het voordeel van 
imiquimod van respectievelijk 18.4%, 21.0% en 18.9%. Een grotere kans op behandelsla-
gen (maar geen superioriteit) van imiquimod versus MAL-PDT werd consequent vast-
gesteld bij mannen, patiënten > 60 jaar, tumoren in het hoofd/hals gebied en de boven-
ste extremiteiten en bij kleinere sBCC. Opmerkelijk is dat binnen de subgroep van sBCC 
op de onderste extremiteiten de kans op een succesvolle behandeling na imiquimod veel 
kleiner was (36.8%) dan na MAL-PDT (94.1%) in patiënten > 60 jaar. Deze hogere kans 
op behandelslagen voor MAL-PDT ten opzichte van imiquimod werd niet waargeno-
men bij jongere patiënten met een sBCC op de onderste extremiteiten. In hoofdstuk 3.2 
hebben we laten zien dat de resultaten van deze subgroep analyses onveranderd blijven 
na 3 jaar follow-up. We willen echter wel benadrukken dat de resultaten voorzichtig 
geïnterpreteerd dienen te worden omdat de subgroep analyses in deze studie exploratief 
waren en niet aangestuurd door vooraf gedefinieerde hypothesen. Op basis van de resul-
taten zou imiquimod de eerste keus behandeling blijven voor sBCC in termen van effec-
tiviteit. MAL-PDT zou echter de voorkeur kunnen hebben in ouderen met een sBCC op 
de onderste extremiteiten. 
 In hoofdstuk 3.4 hebben we verder onderzocht of de histologische karakteristieken 
tumordikte en uitbreiding langs haarfollikels van sBCC invloed hebben op het behan-
delslagen van niet-invasieve therapieën. Wederom hebben we hiervoor gebruik gemaakt 
van de gegevens afkomstig uit de gerandomiseerde multicenter studie die in hoofdstuk 
3.2 is beschreven. De studie werd opgezet als een case-controle onderzoek waarin 112 
patiënten met behandelfalen werden geselecteerd als cases en 224 patiënten met behan-
delslagen willekeurig werden geselecteerd als controle personen. Hierdoor was het mo-
gelijk om een odds ratio ≥ 2.5 te detecteren met een power van 80% (alfa = 5%). Histo-
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pathologische coupes van de initiële diagnostische punch biopten werden opgevraagd 
om aanvullende informatie te verkrijgen over tumordikte en uitbreiding langs haarfolli-
kels. Spreidingsdiagrammen toonden aan dat er geen verband is tussen tumordikte als 
continue variabele en behandelfalen voor alle behandelgroepen. Daarom zijn er geen 
aparte analyses per behandeling uitgevoerd maar zijn alle tumoren gecombineerd in één 
dataset. De tumordikte van alle geïncludeerde patiënten varieerde van 0.2 tot 1.0 mm. 
De resultaten lieten zien dat de tumordikte en uitbreiding langs haarfollikels van sBCC 
niet significant geassocieerd waren met behandelfalen na MAL-PDT, imiquimod of 5-
FU. Vergelijkbare resultaten werden verkregen na correctie voor eventuele confounders 
(geslacht, leeftijd, type behandeling, tumor oppervlakte en tumor locatie) in een meer-
voudige logistische regressie analyse. We concluderen daarom dat tumordikte en uit-
breiding langs haarfollikels niet in acht genomen hoeven te worden bij het besluit of 
niet-invasieve behandeling adequaat is voor een patiënt met sBCC.  
 In hoofdstuk 3.5 vergelijken we de effectiviteit op lange termijn van gefractioneerd 
20% 5-aminolevulinezuur (ALA)-PDT met voorafgaande debulking versus chirurgische 
excisie voor nBCC. Bovendien hebben we geanalyseerd wat het effect is van nBCC dikte 
op het behandelfalen van ALA-PDT. Patiënten die zich presenteerden op de polikliniek 
Dermatologie van het Maastricht Universitair Medisch Centrum met een primair, histo-
logisch bewezen nBCC werden geïncludeerd en gerandomiseerd naar een behandeling 
met gefractioneerd ALA-PDT (n=85) of chirurgische excisie met een marge van 3 mm 
(n=88). Twee PDT belichtingen werden uitgevoerd met één uur interval. De follow-up 
bedroeg minimaal 5 jaar na behandeling en elk klinisch verdacht behandelfalen werd 
histologisch bevestigd met een 3 mm punch biopt. In de ALA-PDT groep werd de tu-
mordikte retrospectief bepaald op het initiële diagnostische punch biopt door een onaf-
hankelijk onderzoeker . De cumulatieve kans op behandelfalen 5 jaar na behandeling 
was 30.7% voor ALA-PDT en 2.3% voor chirurgische excisie (p<0.0001). Opvallend is 
dat twee tumoren behandeld met ALA-PDT nog recidiveerden 72 en 91 maanden na 
behandeling. De tumordikte van nBCC varieerde van 0.3-1.3 mm. De cumulatieve kans 
op tumorvrije overleving na ALA-PDT was 65.0% voor tumoren met een dikte > 0.7 
mm vergeleken met 94.4% voor tumoren ≤ 0.7 mm. Deze bevindingen bevestigen dat 
chirurgische excisie de gouden standard moet blijven voor behandeling van nBCC. 
ALA-PDT zou daarentegen wel overwogen kunnen worden als aanvaardbare behande-
ling voor een selecte groep patiënten met een inoperabele nBCC met een dikte ≤ 0.7 
mm. Dit betekent dat wanneer er een verdenking op een nBCC bestaat, artsen een di-
agnostisch punch biopt zouden moeten afnemen van het klinisch meest dikke deel van de 
tumor en dat pathologen op verzoek de tumordikte van nBCC zouden moeten bepalen. 
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Hoofdstuk 4 besluit met een discussie en valorisatie waarin wordt besproken welke 
plaats de resultaten van dit proefschrift innemen binnen de bestaande kennis over di-
agnostiek en behandeling van het BCC.  
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List of abbreviations 
5-FU 5-fluorouracil 
aBCC aggressive basal cell carcinoma 
ALA aminolaevulinic acid 
BCC basal cell carcinoma 
BCNS basal cell nevus syndrome 
CI confidence interval 
dUMP deoxyuridine monophosphate 
dTMP deoxythymidine monophosphate 
ESR European Standardized Rate 
FDA Food and Drug Administration 
HH hedgehog 
HR hazard ratio 
IL interleukin 
LED light emitting diode 
MAL methylaminolevulinate  
MC Medical Centre 
MC1R melanocortin 1 receptor 
MMS Mohs’ micrographic surgery 
MUMC Maastricht University Medical Centre 
nBCC nodular basal cell carcinoma 
NMSC non melanoma skin cancer 
OR odds ratio 
PDT photodynamic therapy 
PpIX protoporphyrin IX 
PTCH patched 1 
RCT randomized controlled trial 
sBCC superficial basal cell carcinoma 
SCC squamous cell carcinoma 
SHH sonic hedgehog 
SMO smoothened  
TS thymidylate synthetase 
UV ultraviolet light 
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